

September 26, 2019, 8:30AM
Chancellor's Ballroom, Carolina Inn

OPEN SESSION

1. Convene Meeting
2. Roll Call
3. Consent Agenda
 - a. Approval of July 31-August 1, 2019 Minutes (Regular Meeting)
 - b. Ratification of Mail Ballot dated June 6, 2019
 - c. Ratification of Mail Ballot dated August 13, 2019
 - d. Ratification of Mail Ballot dated September 12, 2019
4. Chair's Remarks
5. Student Body President's Remarks
6. Chancellor's Remarks
7. Environment, Ecology, and Energy Program – Dr. Jaye Cable, Senior Associate Dean for Natural Sciences and Mathematics and Professor, Department of Marine Sciences, & Dr. Paul Leslie, Chair, Environment and Ecology and Pardue Distinguished Professor, Department of Anthropology
8. UNC Policy Collaboratory – Dr. Jeff Warren, Research Director
9. Report of the External Relations Committee
10. Report of the Finance, Infrastructure & Audit Committee
11. Report of the University Affairs Committee

CLOSED SESSION

12. *Report of the University Affairs Committee
13. *Legal Update

OPEN SESSION

14. Report of the University Affairs Committee
15. Adjournment

BOARD OF TRUSTEES MEETING
The University of North Carolina at Chapel Hill
August 1, 2019

The Board of Trustees met in regular session on Thursday, August 1, 2019 at The Carolina Inn, Chancellor's Ballroom. Chair Stevens convened the meeting at 8:32 a.m.

ROLL CALL

Trustee Artis Neal called the roll and the following members were present:

Teresa Artis Neal	Ashton B. Martin
David L. Boliek, Jr.	Allie Ray McCullen
Jefferson W. Brown	Ralph W. Meekins, Sr.
Haywood D. Cochrane, Jr.	John P. Preyer
R. Gene Davis, Jr.	Richard Y. Stevens, Chair
Charles G. Duckett	Dwight D. Stone
Kelly Matthews Hopkins	

Trustee Artis Neal indicated that there was a quorum.

RATIFICATION OF JULY 8 ELECTIONS OF CHAIR AND ASSISTANT SECRETARY

Chairman Stevens asked for a motion to ratify the elections that took place at the July 8, 2019 special meeting. Trustee Stevens was selected as chair, and Clayton Somers, Vice Chancellor for Public Affairs and Secretary of the University was elected Assistant Secretary.

Trustee Cochrane made a motion to ratify the elections. Trustee Davis seconded, and it passed.

ELECTION OF OFFICERS

Chairman Stevens shared that he had spoken with each of the trustees about officer positions. Chair Stevens then asked for approval of Trustee Gene Davis as Vice Chair, and Trustee Teresa Artis Neal as Secretary.

Trustee Stone made a motion to approve the officers. Trustee Hopkins seconded, and it passed.

STATE GOVERNMENT ETHICS ACT

Chair Stevens read the following statement:

As Chair of the Board of Trustees, it is my responsibility to remind all members of the Board of their duty under the State Government Ethics Act to avoid conflicts of interest and appearances of conflict of interest as required by this Act. Each member has received the agenda and related information for this Board of Trustees' meeting. If any Board member knows of any conflict of interest or appearance of conflict with respect to any matter coming before the Board of Trustees at this meeting, the conflict or appearance of conflict should be identified at this time.

Chairman Stevens and Trustee Brown both indicated a potential conflict of interest for the grant of easement item being brought to the board by the Finance, Infrastructure, and Audit Committee.

CONSENT AGENDA

Approval of Minutes

On motion of Chair Stevens and a second by Vice Chair Davis, the minutes of the following meetings were approved as distributed, as well as the other following actions:

- May 29-30, 2019 regular meeting
- June 27, 2019 special meeting
- July 8, 2019 special meeting

Ratification of the mail ballots dated:

- July 11th – confidential naming action
- July 19th – Appointment of Suzanne Barbour as Dean of the Graduate School

Also, approval of the following:

- Petition regarding political activity
- Adoption of Revisions to the Board of Trustee Bylaws
- 2020 BOT Meeting dates

(ATTACHMENTS A-H)

ACC GOVERNING BOARD CERTIFICATION FORM

Chairman Stevens read aloud the ACC Governing Board certification form for academic year 2019-20.

(ATTACHMENT I)

CHAIR'S REMARKS

- Chair Stevens thanked everyone for attending the meeting.
- Chair Stevens then asked Secretary Artis Neal to read a resolution of appreciation for Haywood Cochrane who just ended his second term as chair.

RESOLUTION OF APPRECIATION HAYWOOD D. COCHRANE JR.

WHEREAS, Haywood D. Cochrane Jr. has served as Chair of the Board of Trustees from July 1, 2017 through July 8, 2019, providing strong leadership and focused management to the University throughout his service as a trustee; and

WHEREAS, Mr. Cochrane has helped with the financial stewardship of the University, serving as chair of the Endowment Fund, the UNC Foundation Board and the Real Estate Holdings Board, and as a member of the Investment Fund Board, and Carolina Research Ventures Board providing counsel to the Chancellor and fellow board members on timely issues; and

WHEREAS, Mr. Cochrane provided exceptional counsel to all facets of the University, including guiding work on the University strategic framework and Campus Master Plan, as well as strengthening relations with the University's external constituents; and

WHEREAS, Mr. Cochrane as chair devoted considerable time and attention to ably guiding the Trustees and the University through significant challenges; accomplishing these efforts with humility and unyielding dedication to the mission of the University.

NOW, THEREFORE, BE IT RESOLVED that members of the Board of Trustees of the University of North Carolina at Chapel Hill deeply thank Haywood Cochrane and express their great appreciation for his leadership and devoted service to this Board, the University, and the State of North Carolina.

Vice Chair Davis made a motion to adopt the resolution. Secretary Artis Neal seconded, and it passed.

- The Chair continued and welcomed the five new trustees to the board.
- Chairman Stevens then thanked Interim Chancellor Guskiewicz for his strong and stable leadership in this time of transition.

- The Chair then explained the committee assignments for the coming year.
- Chairman Stevens then shared the names of the twenty individuals who are serving alongside him on the Chancellor Search Committee.
- The Chair concluded his remarks by calling upon Trustee Martin.

[A copy of these remarks is in the Office of the Assistant Secretary and at bot.unc.edu.]

STUDENT BODY PRESIDENT'S REMARKS

- Trustee Martin shared remarks on her administration and their work so far this summer.

[A copy of these remarks is in the Office of the Assistant Secretary and at bot.unc.edu.]

CHANCELLOR'S REMARKS

- Interim Chancellor Guskiewicz began his remarks by thanking Chair Stevens, the board, and his administrative team for their support.
- Interim Chancellor Guskiewicz shared highlights and campus updates since the last meeting.
- Interim Chancellor Guskiewicz concluded by introducing the presentation.

[A copy of these remarks is in the Office of the Assistant Secretary and at bot.unc.edu.]

MILITARY AND VETERANS LAW CLINIC

Interim Chancellor Guskiewicz introduced Dean Martin Brinkley to introduce the presentation. Dean Brinkley introduced John Brooker, Director of the Military and Veterans Law Clinic. Mr. Brooker shared with the board the clinic's work on campus and in the community. In addition, he had law student Isabelle Stevens and client Scott Whitaker join him.

To conclude their presentation, they entertained questions from the board. This presentation can be found on bot.unc.edu and on file in the Office of the Assistant Secretary.

REPORT OF THE EXTERNAL RELATIONS COMMITTEE

Vice Chair Davis presented a review of the External Relations Committee meeting. There were no action items for this committee in open session. Vice Chair Davis then shared the items presented for information:

- Communications update given by Beth Keith, Associate Vice Chancellor for Communications and Tanya Moore, Associate Vice Chancellor for Communications
- Public Affairs update given by Clayton Somers, Vice Chancellor for Public Affairs and Secretary of the University, Amy Auth, Director of State Affairs, and Kelly Dockham, Director of Federal Affairs

A full review of the committee meeting is in the committee minutes in the Office of the Assistant Secretary.

REPORT OF THE FINANCE, INFRASTRUCTURE & AUDIT COMMITTEE

Trustee Preyer presented the report from the Finance, Infrastructure and Audit Committee. The following items were presented to the committee for action:

Transfer to the University of the Endowment's Distribution from the Investment Fund

The Board of Governors requires that the Trustees approve transfer of Endowment principal or income to the useful possession of the institution. The Board of Trustees of the Endowment Fund has already approved, by mail ballot, the proposed transfer for University expenditure during the 2019-2020 fiscal year.

(ATTACHMENT J)

Appointments to the Endowment Fund and UNC-CH Foundation Boards

Mr. Pruitt presented for approval the nominees for the Endowment Board of Trustees and The University of North Carolina at Chapel Hill Foundation, Inc. Board.

(ATTACHMENT K)

Withdrawal from Quasi-Endowment for the Department of Athletics

The Department of Athletics requests to withdraw \$300,000 from principal to support operational needs. The Board of Trustees of the Endowment Fund approved this withdrawal by mail ballot dated July 9, 2019 with the support of the Chancellor and Vice Chancellor for Finance and Operations.

(ATTACHMENT L)

Annual Audit Certification Letter Process

Dean Weber, Chief Audit Officer, presented the Annual Audit Certification Letter for approval and signature. This letter satisfies a UNC Board of Governors requirement for the Finance, Infrastructure and Audit to certify in writing that UNC's internal audit function complies with a defined set of standards regarding communications and meetings, reporting, compliance and organizational structure of the internal audit function.

(ATTACHMENT M)

Internal Audit FY19-20 Work Plan

Mr. Weber presented the FY 2019-20 work plan for review and approval. He detailed aspects of the planning process and identification of proposed engagements.

(ATTACHMENT N)

Anna Wu, Associate Vice Chancellor for Facilities Services, recommended for approval the following designer approval and site approval:

Designer Approval

1. **Koch Memorial Forest Theatre and Coker Arboretum**

This advanced planning project will develop a vision, concept plan, and initial cost estimates for the renovation of the Koch Memorial Forest Theatre and the Cameron Avenue frontage of the Coker Arboretum. These two places are iconic open spaces in the historic campus district and share important ecological connections. The development of a concept plan will support fundraising efforts that will allow the project to move into full design and construction. A University steering committee will have representation from a broad range of stakeholders, including the North Carolina Botanical Garden, Playmakers Repertory Company, Department of Dramatic Art, Arts Everywhere, Office of Admissions, and Facilities Planning and Design.

The estimated project budget is \$6.2 million and will be funded through a combination of gifts, North Carolina Botanical Garden reserves, and the Open Space Trust Fund. The project was advertised on May 23, 2019. Eighteen (18) proposals were received. Six (6) firms were interviewed on July 9, 2019. Members of the Board of Trustees did not participate in the interviews. The committee recommended the selection of the three (3) firms in the following priority order:

- | | | |
|----|---------------------------------------|----------------|
| 1. | Reed Hilderbrand Landscape Architects | Cambridge, MA |
| 2. | Michael Vergason Landscape Architects | Alexandria, VA |
| 3. | Clearscapes | Raleigh, NC |

The firms were selected for their past performance on similar projects, strength of their consultant team and experience with campus projects.

(ATTACHMENT O)

Site Approval

1. UNC Health Care Proton Therapy Unit

UNC Health Care plans to expand the services of its North Carolina Cancer Hospital to include a proton therapy unit, which is proposed to be housed in an addition to the west side of the existing building in the area of the landscape labyrinth. The new construction will be almost entirely below grade, with the landscape labyrinth to be restored over the building's roof.

(ATTACHMENT P)

A motion came from committee to approve the first seven committee actions (above). Trustee McCullen seconded, and they all passed.

Grant of Easement

Gordon Merklein, Associate Vice Chancellor for Real Estate Operations presented a grant of easement to Duke Energy. Duke Energy is requesting a permanent easement on property owned by UNC along Old Mason Farm Road. A portion of this parcel is currently ground leased to the SECU Family House and to the Ronald McDonald House. The proposed easement will allow Duke Energy to install electric lines providing redundant service to these two facilities. Construction is anticipated to begin in August and take approximately 6 weeks to complete.

Chairman Richard Stevens and Trustee Brown both indicated a potential conflict of interest. Vice Chair Davis called for a motion to approve the grant of easement. Trustee Boliek made a motion to approve. Trustee Cochrane seconded, and it passed.

(ATTACHMENT Q)

Trustee Preyer continued and shared the items for information only:

- Arts Everywhere update given by Emil Kang, Executive Director for the Arts
- Internal Audit External Quality Assessment Review given by Dean Weber, Chief Audit Officer
- Development report given by David Routh, Vice Chancellor for University Development
- Semi-Annual Lease Report given by Gordon Merklein, Associate Vice Chancellor for Real Estate Operations (ATTACHMENT R)
- Semi-Annual Capital Report given by Anna Wu, Associate Vice Chancellor for Facilities Services (ATTACHMENT S)
- Budget process update given by Jonathan Pruitt, Vice Chancellor for Finance and Operations

A full review of the committee meeting is in the committee minutes in the Office of the Assistant Secretary.

REPORT OF THE UNIVERSITY AFFAIRS COMMITTEE

Trustee Duckett presented the report from the University Affairs Committee. There were no action items for this committee in open session. Trustee Duckett then shared the items presented for information:

- Provost update, given by Bob Blouin, Executive Vice Chancellor and Provost
- GPSF update given by Chastan Swain, President
- Employee Forum update given by Shayna Hill, Chair
- Faculty retention update given by Ron Strauss, Executive Vice Provost

A full review of the committee meeting is in the committee minutes in the Office of the Assistant Secretary.

MOTION TO CONVENE IN CLOSED SESSION

On motion of Secretary Artis Neal, and seconded by Vice Chair Davis, the Board voted to convene in closed session pursuant to North Carolina General Statutes Section 143-318.11 (a) (1) (to prevent the disclosure of privileged information under Section 126-22 and the following); and also pursuant to Section 143-318.11 (a) (2), (3), (5), (6), (7), and (9).

RECONVENE MEETING IN OPEN SESSION

Secretary Artis Neal made a motion to return to open session. Vice Chair Davis seconded, and it passed.

OPEN SESSION

REPORT OF THE UNIVERSITY AFFAIRS COMMITTEE

Chair Stevens referred the members to the personnel matters submitted for review. Trustee Duckett made a motion from committee to approve; Vice Chair Davis seconded, and it passed.

Chair Stevens stated that the personnel and salary actions voted on in open session had been distributed.

(ATTACHMENTS T-U)

ADJOURNMENT

There being no further business to come before the Board, Chair Stevens called for a motion to adjourn. Vice Chair Davis made the motion; Trustee Cochrane seconded, and it passed. Chair Stevens adjourned the meeting at 12:11 pm.

Clayton Somers, Assistant Secretary



**OFFICE OF
THE CHANCELLOR**

KEVIN M. GUSKIEWICZ
INTERIM CHANCELLOR

chancellor@unc.edu
O 919-962-1365 | F 919-962-1647

THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
OFFICE OF THE CHANCELLOR
South Building | Suite 103 | Campus Box 9100
200 East Cameron Avenue | Chapel Hill, NC 27599-9100
chancellor.unc.edu

MEMORANDUM

TO: Members of the Board of Trustees

FROM: Kevin M. Guskiewicz *K. M. G.*

RE: Mail Ballot

DATE: June 6, 2019

You have authorized me to poll you by mail ballot concerning personnel matters which require the immediate attention of the Board.

I am seeking approval to appoint Dr. Angela Kashuba as Dean of the Eshelman School of Pharmacy. The appointment is effective October 1, 2019. Attached is the formal offer letter and a copy of Dr. Kashuba's CV.

Please complete the attached mail ballot and return to TJ Scott at your earliest convenience.



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

OFFICE OF THE EXECUTIVE
VICE CHANCELLOR AND PROVOST

104 SOUTH BUILDING
CAMPUS BOX 3000
CHAPEL HILL, NC 27599-3000

T 919.962.2198
F 919.962.1593
provost@unc.edu

May 29, 2019

Dr. Angela Kashuba
112 Hogan Woods Circle
Chapel Hill, NC 27516

ROBERT A. BLOUIN, PharmD
Executive Vice Chancellor and Provost
Bryson Distinguished Professor
provost@unc.edu

Dear Dr. Kashuba:

It is with great pleasure that I extend to you a formal offer to become the next Dean of the UNC Eshelman School of Pharmacy and Director of the Eshelman Institute for Innovation at The University of North Carolina at Chapel Hill. This appointment will be subject to approval by the University Board of Trustees. This administrative appointment preserves your status as a Professor with Tenure within the UNC Eshelman School of Pharmacy.

Appointment

103
5/29/19
Your initial twelve-month annual salary will be \$350,000 and you will begin your responsibilities as Dean effective October 1, 2019 on the terms and conditions outlined herein. Your total salary compensation will be broken down as follows: your new base salary will be \$220K, your administrative supplement for the position of Dean will be \$80K, and your administrative supplement for the position of Director of the Eshelman Institute for Innovation will be \$50K. Upon your return to the faculty of the UNC Eshelman School of Pharmacy, your retreat salary will be the average of the top three salaries of pharmacy faculty at the full professor level within the School. Your salary will be reviewed at least annually, subject to the compensation policies of the Board of Trustees and Board of Governors. Your appointed position will report to the Chancellor with administrative assignment to the Executive Vice Chancellor and Provost. This will be an "at will" appointment of indeterminate length with a review every five years and subject to continuation or discontinuation at the discretion of the Chancellor.

This appointment is subject to the "Employment Policies for EHRA Non-Faculty Tier 1 Senior Academic and Administrative Officer Employees of The University of North Carolina at Chapel Hill" as originally adopted and as they may be periodically revised from time to time. According to the Policies, you will be entitled to 26 days of annual leave per year. Sick leave is earned at the rate of 1 day per month or 12 days per year. On December 31, of each year, any annual leave accrued in excess of 30 days will automatically be converted to sick leave. There is no limit to the amount of sick leave you may accrue.

At the end of appointment, EHRA employees are eligible for vacation and bonus leave payout or the transfer of leave, if appropriate. The full Policies are available for reference online at:

<https://hr.unc.edu/employees/policies/ehra-non-faculty-policies/>.

At the end of a deanship, tenured faculty are eligible to retreat to their faculty appointment in accordance with the provision of the "Separation and Retreat Policy for Senior Academic and Administrative Officers (as Amended, 05/02/2010)" available for reference online at <http://hr.unc.edu/policies-procedures-systems/epa-non-faculty-employee-policies/appointment-and-end-of-appointment/separation-and-retreat-policy-for-senior-academic-and-administrative-officers/>.

Start-up Resources

- Individual Research Program: I have discussed the elements you will need to ensure the continued success of your research program while in the position of Dean. It is my commitment to provide you with those resources during this period. These resources include the following:
 - Tenured Faculty Line – This will be an open rank, tenure or tenure track position to assist and support you in maintaining a competitive research program.
 - Start-up - In order to recruit a competitive individual, I will provide you with additional start up resource of \$900K to be spent over a three-year period.
 - Discretionary Funding – In order to facilitate your transition to the leadership role of Dean, I am providing you with \$300K (\$100K per year for three years).
 - I will recommend to the UNC Eshelman Foundation Board that you be offered the John A. and Margaret P. McNeill, Sr. Endowed Professorship in place of your existing professorship.
- Enrichment Resources to Enhance the UNC Eshelman School of Pharmacy
 - Tenured Faculty Lines - I am in support of a cluster hire of five new tenure-track faculty to support the development of a highly competitive neuroscience research initiative. I am asking you to work with Dr. Terry Magnuson, Vice Chancellor for Research and other campus leaders to maximize the potential for collaborative science on the UNC campus. Two of these faculty will be at the assistant professor level (with an average salary commitment from this office not to exceed \$125K), two of these faculty will be at the associate professor level (with an average salary commitment from this office not to exceed \$175K), and one of these faculty will be at the full professor level (with a starting salary commitment from this office not to exceed \$225K). These resources will be called for at the time of each hire.
 - Start-up – A total of \$4.0M will be made available to the UNC Eshelman School of Pharmacy to support these five faculty hires. These resources will be called for at the time of each hire.
- Support of the hiring of Dr. Nathaniel Gray – Consistent with our previous conversations, I am prepared to support the strategic hiring of Dr. Nathaniel

Gray up to a maximum of \$6M to be distributed evenly over a two-year period following his official hiring. \$3.0M *plz*

- Beard Hall Renovation – To assist in the minimization of the School's debt toward the renovation of Beard Hall, I am prepared to provide \$1.5M to defray building infrastructure expenses to include, bathrooms, air handling system, stairway repair, elevator rebuild etc. *plz*
5.29.19

Tickets

You will receive two season tickets to the men's football and men's basketball games. The basketball tickets will be in the Ring Section where the other deans are positioned. Please note that the tickets are considered taxable income.

Angela, I am very excited with the prospects of you leading the UNC Eshelman School of Pharmacy as its next Dean. I believe that you have the potential to be a truly outstanding leader and create a new trajectory for the School. I pledge to you my support and will work tirelessly to assist you in these endeavors. I hope that you share my enthusiasm and recognize the potential that exists for you in this leadership role on this campus. If you have any questions, please don't hesitate to contact me at 919-218-5611. Your immediate attention to the letter of offer is requested.

If you agree to these terms, please sign and return this letter to me at your earliest convenience.

Sincerely,

Robert A. Blouin

Robert A. Blouin
Executive Vice Chancellor and Provost

*I am requesting that the
UNC ESOP be spared any
budget cuts for FY 2019-2020
AKEL 5.29.19*

*plz
5/29/19*

Enclosures: Employment Policies for EHRA Non-Faculty Tier 1 SAAO Employees

Acknowledgement and Acceptance by Appointee:

[Signature]

5.29.19

Name

Date

cc: Academic Personnel Office
EHRA Non-Faculty Personnel Office
Kim Hutter, Human Resources, ESOP

K.M.J. 5-29-19

ANGELA DM KASHUBA, BScPHM, PHARM.D, DABCP, FCP

Eshelman School of Pharmacy
Room 1094, Genetic Medicine Building
CB 7361, 120 Mason Farm Road
The University of North Carolina
Chapel Hill, North Carolina
27599-7361
(919) 966-9998
akashuba@unc.edu

EDUCATION

July 1993 – June 1995 **Doctor of Pharmacy**
State University of New York at Buffalo
Department of Pharmacy Practice
Amherst, New York

September 1986 – June 1990 **Bachelor of Science in Pharmacy**
University of Toronto
Faculty of Pharmacy
Toronto, Ontario, Canada

LICENSURE

Licensed Pharmacist Ontario, Canada #108812
1990 to Present

Diplomat American Board of Clinical Pharmacology
2001 to Present

POST-GRADUATE TRAINING

October 2000 – October 2002 **UNC Faculty Scholar**
Building Interdisciplinary Research Careers in Women's Health
NIH K30 Mentored Research Grant
PI: Eugene Orringer, MD
Mentor: Myron Cohen, MD

July 1995 – July 1997 **Clinical Pharmacology Research Fellow**
Attending, Clinical Pharmacology Consult Service
Bassett Healthcare
Clinical Pharmacology Research Center
Co-Directors: Joseph S. Bertino Jr., Pharm.D.
 Anne N. Nafziger, M.D., M.H.S.

June 1990 – June 1991 **Pharmacy Practice Resident (CSHP Accredited)**
University of Toronto, Faculty of Pharmacy
Women's College Hospital
60 Grenville Street, Toronto, Ontario

PROFESSIONAL EXPERIENCE - PRESENT

<i>July 2015 – Present</i>	Chair Division of Pharmacotherapy and Experimental Therapeutics Eshelman School of Pharmacy The University of North Carolina Chapel Hill, North Carolina
<i>September 2015 – Present</i>	Associate Research Director, Resource Laboratory Network Director K12 Building Interdisciplinary Research Careers in Women's Health The University of North Carolina Chapel Hill, North Carolina
<i>April 2012 – Present</i>	John A. and Deborah S. McNeill Jr Distinguished Professor Eshelman School of Pharmacy The University of North Carolina Chapel Hill, North Carolina
<i>June 2012 – Present</i>	Adjunct Professor Department of Medicine, School of Medicine The University of North Carolina Chapel Hill, North Carolina
<i>November 2011 – Present</i>	Professor of Pharmacy Division of Pharmacotherapy and Experimental Therapeutics Eshelman School of Pharmacy, The University of North Carolina Chapel Hill, North Carolina
<i>July 2004 – Present</i>	Director Clinical Pharmacology and Analytical Chemistry Core UNC Center for AIDS Research (NIAID P30) The University of North Carolina Chapel Hill, North Carolina

PROFESSIONAL EXPERIENCE - PAST

<i>July 2011 – July 2018</i>	Co-Director Clinical Pharmacology Fellowship Program (T32 NIGMS and NICHD) The University of North Carolina and Duke University Chapel Hill and Durham, North Carolina
<i>July 2011 – December 2016</i>	Director Preclinical and Clinical Pharmacology Core Martin Delaney Collaboratory to Eradicate HIV-1 Infection (U19 NIAID) The University of North Carolina Chapel Hill, North Carolina
<i>November 2011 – July 2015</i>	Vice Chair for Research and Graduate Education Division of Pharmacotherapy and Experimental Therapeutics

Eshelman School of Pharmacy
The University of North Carolina
Chapel Hill, North Carolina

July 2003 – November 2011

Associate Professor of Pharmacy

Division of Pharmacotherapy and Experimental Therapeutics
Eshelman School of Pharmacy,
The University of North Carolina
Chapel Hill, North Carolina

January 2006 – July 2008

Director

Verne S Caviness General Clinical Research Center Analytical
Laboratory
University of North Carolina at Chapel Hill
Chapel Hill, NC

April 2004 – July 2006

Director

Cellular Metabolism and Transport Core
School of Pharmacy, UNC-CH

July 2004 – July 2006

Divisional Director of Graduate Studies

Pharmacotherapy and Experimental Therapeutics
School of Pharmacy, UNC-CH

January 2004 – December 2005 **Director**

University of North Carolina ACTG Pharmacology Support
Laboratory

October 1999 – December 2005 **Pharmacologist**

UNC AIDS Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina

July 1999 – July 2004

Associate Director

Pharmacology Core, UNC Center for AIDS Research
The University of North Carolina
Chapel Hill, North Carolina

July 1997 – July 2003

Assistant Professor of Pharmacy

School of Pharmacy, Division of Pharmacotherapy
CB #7360, Beard Hall
The University of North Carolina
Chapel Hill, North Carolina
27599-7360

February 1995 – July 1995

Poison Information Specialist

Western New York Poison Control Center
Children's Hospital of Buffalo
219 Bryant Street, Buffalo, New York, 14222

August 1991 – May 1993

Critical Care Pharmacist

Critical Care Preceptor, Pharmacy Students/Residents
Co-Editor, Hospital Formulary Manual
Department of Pharmacy

Mount Sinai Hospital
600 University Avenue, Toronto, Ontario

July 1990 – June 1991

Oncology Pharmacist
Department of Pharmacy
Mount Sinai Hospital
600 University Avenue, Toronto, Ontario

May 1989 – September 1989

Registered Pharmacy Student
Etobicoke General Hospital
Department of Pharmacy
101 Humber College Boulevard, Etobicoke, Ontario

May 1988 – September 1988

Medical Research Council Scholar
University of Toronto
Faculty of Pharmacy Research Laboratories
19 Russell Street, Toronto, Ontario

HONORS AND AWARDS

- 2019:** 1. *Voices of Discovery Featured Speaker*, Elon University, September 17, 2019
- 2018:** 1. American Society for Clinical Pharmacology and Therapeutics, *Featured Speaker* Annual Meeting, Washington March 22, 2018
- 2017:** 1. American College of Clinical Pharmacology *Honorary Fellowship Award* (FCP), September 2017
2. American College of Clinical Pharmacy *Therapeutic Frontiers Lecture Award*, October 2017
3. Society of Infectious Diseases Pharmacists' *Pharmacotherapy Paper of the Year*, 2016-2017 (*The Journal of Infectious Diseases* 2016; 214:55–64)
4. *Three Minute Thesis Competition*, for Aaron Devanathan, Graduate Student, People's Choice Award
- 2016:** 1. *AFPE Pre-doctoral Fellowship* for Corbin Thompson, Graduate Student
2. *AFPE Pre-doctoral Fellowship* for Nithya Srinivas, Graduate Student
3. *AFPE Gateway Research Scholarship* for Ashlyn Norris, PY1 Pharmacy Student
4. *ASCPT 2017 Presidential Trainee Award* for Corbin Thompson, Graduate Student.
- 2015:** 1. *ASCPT 2016 Presidential Trainee Award*, for Nithya Srinivas, Graduate Student
2. *Young Investigator Scholarship* for Corbin Thompson, PharmD, PhD Candidate, Conference on Retroviruses and Opportunistic Infections, 2016
- 2014:** 1. *AFPE Pre-doctoral Fellowship* for Corbin Thompson, Graduate Student
- 2013:** 1. *UNC Chapel Hill Institute for the Arts and Humanities Academic Leadership Fellow* for 2013-2014
2. *Young Investigator Award* for Melanie Nicol, PharmD, PhD Candidate, Conference on Retroviruses and Opportunistic Infections, 2014
- 2012:** 1. *Conference-Sponsored Investigator Award* for graduate student Melanie Nicol, PharmD. GPEN 2012

- 2011:** 1. 1 of 11 women scientists featured on the "Women in Biomedical Careers" NIH Website (<http://womeninscience.nih.gov/>)
- 2010:** 1. *Young Investigator Award* for Fellow Kevin Brown, PharmD, Conference on Retroviruses and Opportunistic Infections
2. *UNC Summer Undergraduate Research Fellowship Award* to Allison Hastings, BS Candidate
- 2009:** 1. *Leon I. Goldberg Young Investigator Award*, American Society for Clinical Pharmacology and Therapeutics.
2. *F.O. Bowman Award*, for Allison L Pecha, PharmD Candidate, Best UNC Honors Program Paper
- 2008:** 1. *Rho Chi Honors Research Scholarship* for Kevin Brown, Academic Fellow
- 2007:** 1. *Pam Herriott Award* for Outstanding Service, UNC-CH Department of Infectious Diseases
- 2006:** 1. *ACCP Infectious Diseases Fellowship Award* for Julie Dumond, Academic Fellow
2. *ACCP ID PRN Minisabbatical* awarded to ADM Kashuba (Mentor, Alan Forrest)
3. *Young Investigator Award* for Fellow Manoli Vourvahis, Pharm.D., Conference on Retroviruses and Opportunistic Infections
- 2005:** 1. *Young Investigator Award* for Fellows Julie Dumond, PharmD, and Manoli Vourvahis, Pharm.D., Conference on Retroviruses and Opportunistic Infections
2. Paper of the Year, Society of Infectious Diseases Pharmacists, for **Kashuba ADM, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005; 19:145-152**
3. *F.O. Bowman Award*, Carolina Molina Lowe, PharmD Candidate, Best UNC Honors Program Paper
- 2004:** 1. *Annual Bayer Research Fellowship Award* for Rosa Yeh, Research Fellow
2. *Society of Infectious Diseases Pharmacists Fellowship Award* for Rosa Yeh, Research Fellow
3. *F.O. Bowman Award*, Vincent Gaver, PharmD Candidate, Best UNC Honors Program Paper
- 2003:** 1. *AFPE Pre-doctoral Fellowship* for Mary Peace McRae, Graduate Student
2. *F.O. Bowman Award*, Stephanie Burge Hollowell, PharmD Candidate, Best UNC Honors Program Paper
- 2002:** 1. *Hollingsworth Scholar for 2002-2004, School of Pharmacy, UNC-CH*
2. *International AIDS Society Young Investigator Award for Clinical Sciences and Care* for Sherene Min, Infectious Diseases Fellow (Differential penetration of protease inhibitors and non-nucleoside reverse transcriptase inhibitors into the female genital tract. World AIDS Conference Poster)
3. *AFPE Pre-doctoral Fellowship* for Mary Peace McRae, Graduate Student
4. *ACCP Infectious Diseases Fellowship Award* for Amanda Corbett, Academic Fellow

- 2001:** 1. *Young Investigator of the Year*, Society for Infectious Diseases Pharmacists
- 2000:** 1. *UNC Faculty Scholar*, NIH Mentored Research Grant "Building Interdisciplinary Research Careers in Women's Health"
2. *UNC Nominee*, George H. Hitchings New Investigator Award in Health Research and Training
- 1997:** 1. E. Donnell Thomas Award for Research Excellence, Bassett Healthcare
- 1996:** 1. ASM Sustaining Member Student Travel Grant, ICAAC 1996
- 1995:** 1. Rho Chi Award for Academic Excellence
- 1994:** 1. Ciba-Geigy Award for Excellence in Pharmacotherapeutics
- 1990:** 1. First Class Honors, Bachelor of Science in Pharmacy
- 1988:** 1. Southerton Wadhams Scholarship for Academic Excellence
2. Medical Research Council Scholarship
- 1987:** 1. Rokeah Centennial Scholarship for Academic Excellence

BIBLIOGRAPHY AND PRODUCTS OF SCHOLARSHIP:

PEER REVIEWED BOOK EDITOR (1):

1. A Practical Approach to Pharmacogenomics, McGraw Hill. Bertino JS Jr, **Kashuba ADM**, Fuhr U, Devane L, Ma J, eds. June 2012.

PEER REVIEWED BOOK CHAPTERS (18):

1. Andrews E and **Kashuba ADM**. Pharmacology of Antimicrobial Drug Resistance. *In* Antimicrobial Drug Resistance (2nd edition) Mechanisms of Drug Resistance, Volume 1. Mayer D (ed). Springer International Publishing AG, 2017.
2. Pai MP, Cottrell ML, **Kashuba ADM**, Bertino JS Jr. Pharmacokinetics and Pharmacodynamics of Antiinfective Agents. Chapter 19. Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett (eds). Churchill Livingstone, 2013.
3. Heinene W, **Kashuba ADM**. HIV Prevention by Oral Pre-Exposure Prophylaxis. *In*, Human Immunodeficiency Virus, from Cold Spring Harbor Laboratory Press. Bushman F, Nabel G, Swanstrom R, editors. Copyright January 2012.
4. Adams J, Corbett AH, Dumond J, **Kashuba ADM**. Human Immunodeficiency Virus Infection. *In*, Pharmacotherapy Principles and Practices, McGraw-Hill. DiPiro and Rotschafer, eds. Copyright January 2012.
5. Adams J, Dumond J, **Kashuba ADM**. Human Immunodeficiency Virus Infection. *In Applied Therapeutics, The Clinical Use of Drugs*. Koda-Kimble and Young (eds), Lippincott, Williams, and Wilkins, copyright 2011.
6. Brown K, **Kashuba ADM**. Mechanisms of Drug Interactions, *in Drug Interactions in Infectious Diseases*, Third Edition. Piscitelli S and Rodvold K, (eds), Humana Press 2011.
7. Corbett AH, Yeh RF, Dumond J, **Kashuba ADM**. Human Immunodeficiency Virus Infection. *In*, Pharmacotherapy Principles and Practices, McGraw-Hill. DiPiro and Rotschafer, eds. Jan 2009.
8. Gay C, **Kashuba ADM**, Cohen MS. Using Antiretroviral Therapy for Prevention. *In*, HIV Prevention: A Comprehensive Approach. HF Pizer and KH Mayer, eds. Nov 2008.
9. Dumond J, **Kashuba ADM**. Human Immunodeficiency Virus Infection. *In Applied Therapeutics, The Clinical Use of Drugs*. Koda-Kimble and Young (eds), Lippincott, Williams, and Wilkins, 2008.
10. Corbett AH, Yeh RF, Dumond J, **Kashuba ADM**. Human Immunodeficiency Virus Infection. *In*, Pharmacotherapy Principles and Practices, McGraw-Hill. DiPiro and Rotschafer, eds. Jan 2007.
**Winner, 2008 American Medical Writers Association Award
Medical Book Healthcare Professionals Category**
11. **Kashuba ADM**, Bertino JS Jr. Mechanisms of Drug Interactions, *in Drug Interactions in Infectious Diseases*, Second Edition. Piscitelli S and Rodvold K, (eds), Humana Press 2004.
12. **Kashuba ADM**, Park JJ, Persky AM, Brouwer KR. Drug Metabolism, Transport and the Influence of Hepatic Disease, *in Applied Pharmacokinetics, Principles of Therapeutic*

Drug Monitoring. Fourth Edition. Evans WE, Schentag JJ, Jusko WJ (eds), Applied Therapeutics, Inc. Vancouver, WA 2004.

13. Catanzaro L, **Kashuba A**, Corbett A, Shafer R, Hewitt RG, Acosta E, and Morse GD. HIV-1 Protease Inhibitors, in *Antimicrobial Therapy and Vaccines*, Vol. II. Yu VL, et al. (eds), New York: Apple Trees Production, 2004.
14. Amsden G, Ballow C, Bertino Jr J, **Kashuba ADM**. Pharmacokinetics and Pharmacodynamics of Antiinfective Agents. In *Principles and Practices of Infectious Diseases*. Mandell, Bennett, Dolin (eds). Churchill Livingstone, 2004.
15. **Kashuba ADM** and Robinson M. Opportunistic Infections in HIV Patients. In *Applied Therapeutics, The Clinical Use of Drugs*. Koda-Kimble and Young (eds), Lippincott, Williams, and Wilkins, 2004.
16. Cohen MS, Hosseinipour M, **Kashuba ADM**, Butera S. Use of Antiretroviral Drugs to Prevent Transmission of HIV. In *Current Clinical Topics in Infectious Disease*, Remington JS and Swartz M (eds), Blackwell Science, Incorporated 2001.
17. Ozdemir V, **Kashuba ADM**, Basile VS, Kennedy JL. Pharmacogenetics of psychotropic drug metabolism: Clinical Relevance, Gene-Environment interactions and Future Research Directions. in *Pharmacogenetics Of Psychotropic Drugs*, Lerer B (ed), Cambridge University Press 2001.
18. **Kashuba ADM**, Bertino JS Jr. Mechanisms of Drug Interactions, in *Drug Interactions in Infectious Diseases*, Piscitelli S and Rodvold K, (eds), Humana Press 2000.

REFEREED MANUSCRIPTS (241):

1. Cottrell ML, Prince HMA, Schauer AP, Sykes C, Maffuid K, Polisen A, Chun TW, Huiting E, Stanczyk FZ, Peery AF, Dellon ES, Adams JL, Gay C, **Kashuba ADM**. Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for HIV pre-exposure prophylaxis (PrEP). *Clin Infect Dis*. 2019 Apr 9. pii: ciz290. doi: 10.1093/cid/ciz290. [Epub ahead of print] PMID: 30963179
2. Devanathan AS, Anderson DJC, Cottrell ML, Burgunder EM, Saunders AC, **Kashuba ADM**. Contemporary Drug-Drug Interactions in HIV Treatment. *Clin Pharmacol Ther*. 2019 Feb 10. doi: 10.1002/cpt.1393. [Epub ahead of print] PMID: 30739315
3. Srinivas N, Joseph SB, Robertson K, Kincer LP, Menezes P, Adamson L, Schauer AP, Blake KH, White N, Sykes C, Luciw P, Eron JJ, Forrest A, Price R, Spudich S, Swanstrom R, **Kashuba AD**. Predicting efavirenz concentrations in the brain tissue of HIV-infected individuals and exploring their relationship to neurocognitive impairment. *Clin Transl Sci*. 2019 Jan 24. doi: 10.1111/cts.12620. [Epub ahead of print] PMID: 30675981
4. Rudolph JE, Cole SR, Eron JJ, **Kashuba AD**, Adimora AA. Estimating human immunodeficiency virus (HIV) prevention effects in low-incidence settings. *Epidemiology*. 2019 Jan 10. doi: 10.1097/EDE.0000000000000966. [Epub ahead of print] PMID: 30640216
5. Pack AP, Golin CE, Hill LM, Carda-Auten J, Wallace DD, Cherkur S, Farel CE, Rosen EP, Gandhi M, Asher Prince HM, **Kashuba ADM**. Patient and clinician perspectives on optimizing graphical displays of longitudinal medication adherence data. *Patient Educ Couns*. 2019 Jan 2. pii: S0738-3991(18)30396-3. doi: 10.1016/j.pec.2018.12.029. [Epub ahead of print] PMID: 30626550
6. Medina-Moreno S, Zapata JC, Cottrell ML, Le NM, Tao S, Bryant J, Sausville E, Schinazi RF, **Kashuba AD**, Redfield RR, Heredia A. Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients. *Antivir Ther*. 2018 Dec 21. doi: 10.3851/IMP3285. [Epub ahead of print] PMID: 30574873
7. Imaz A, Niubó J, Cottrell ML, Perez E, **Kashuba ADM**, Tiraboschi JM, Morenilla S, Garcia B, Podzamczek D. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40). *Clin Infect Dis*. 2018 Dec 18. doi: 10.1093/cid/ciy1074. [Epub ahead of print] PMID: 30561517
8. Dumond JB, Greene SA, Prince HM, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JA, Gay CL, **Kashuba AD**, Cohen MS. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. *Antivir Ther*. 2018 Oct 30. doi: 10.3851/IMP3277. PMID: 30375984.
9. Srinivas N, Rosen EP, Gilliland WM Jr, Kovarova M, Remling-Mulder L, De La Cruz G, White N, Adamson L, Schauer AP, Sykes C, Luciw P, Garcia JV, Akkina R, **Kashuba ADM**. Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species. *Xenobiotica*. 2018 Dec 17:1-10. doi: 10.1080/00498254.2018.1539278. PMID: 30346892.
10. Ekelöf M, Garrard KP, Judd R, Rosen EP, Xie DY, **Kashuba ADM**, Muddiman DC. Evaluation of Digital Image Recognition Methods for Mass Spectrometry Imaging Data Analysis. *J Am Soc Mass Spectrom*. 2018 Dec;29(12):2467-2470. doi:

10.1007/s13361-018-2073-0. Epub 2018 Oct 15. PMID: 30324263; PMCID: PMC6250575.

11. Krovi SA, Gallovic MD, Keller AM, Bhat M, Tiet P, Chen N, Collier MA, Gurysh EG, Pino EN, Johnson MM, Shamim Hasan Zahid M, Cottrell ML, Pirone JR, **Kashuba AD**, Kwiek JJ, Bachelder EM, Ainslie KM. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles. *Int J Pharm*. 2018 Dec 1;552(1-2):371-377. doi: 10.1016/j.ijpharm.2018.10.017. Epub 2018 Oct 8. PMID: 30308272.
12. Kovarova M, Benhabbour SR, Massud I, Spagnuolo RA, Skinner B, Baker CE, Sykes C, Mollan KR, **Kashuba ADM**, García-Lerma JG, Mumper RJ, Garcia JV. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. *Nat Commun*. 2018 Oct 8;9(1):4156. doi: 10.1038/s41467-018-06490-w. PMID: 30297889.
13. Sykes C, Blake K, White N, Schauer AP, Guzman BB, Cottrell ML, Tamraz B, **Kashuba ADM**. Development and validation of an LC-MS/MS assay for the quantification of dolutegravir extracted from human hair. *Anal Bioanal Chem*. 2018 Nov;410(29):7773-7781. doi: 10.1007/s00216-018-1394-y. Epub 2018 Oct 2. PMID: 30280227.
14. Thurman AR, Schwartz JL, Brache V, Chen BA, Chandra N, **Kashuba ADM**, Weiner DH, Mauck C, Doncel GF. Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users. *J Acquir Immune Defic Syndr*. 2019 Jan 1;80(1):79-88. doi: 10.1097/QAI.0000000000001864. PMID: 30212395.
15. Mitchell JT, LeGrand S, Hightow-Weidman LB, McKellar MS, **Kashuba AD**, Cottrell M, McLaurin T, Satapathy G, McClernon FJ. Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial. *JMIR Mhealth Uhealth*. 2018 Sep 10;6(9):e10456. doi: 10.2196/10456. PMID: 30201601; PMCID: PMC6231728.
16. Dong OM, Howard RM, Church R, Cottrell M, Forrest A, Innocenti F, Mosedale M, **Kashuba A**, Gonzalez D, Wiltshire T. Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine. *Am J Pharm Educ*. 2018 Aug;82(6):6652. doi: 10.5688/ajpe6652. PMID: 30181675; PMCID: PMC6116878.
17. Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, **Kashuba A**, Amblard F, Schinazi RF, Jean S, Cohen J, McGary C, Paiardini M, Wood MP, Sodora DL, Silvestri G, Estes J, Chahroudi A. Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques. *J Virol*. 2018 Aug 29;92(18). pii: e00562-18. doi: 10.1128/JVI.00562-18. Print 2018 Sep 15. Erratum in: *J Virol*. 2019 Jan 17;93(3). PMID: 29997216; PMCID: PMC6146711.
18. Brocca-Cofano E, Xu C, Wetzel KS, Cottrell ML, Policicchio BB, Raehtz KD, Ma D, Dunsmore T, Haret-Richter GS, Musaitif K, Keele BF, **Kashuba AD**, Collman RG, Pandrea I, Apetrei C. Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques. *J Virol*. 2018 Aug 16;92(17). pii: e00576-18. doi: 10.1128/JVI.00576-18. Print 2018 Sep 1. PMID: 29925666; PMCID: PMC6096825.
19. Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD, Dellon ES, De Paris K, Nelson JA, Gay CL, **Kashuba AD**. Virological and immunological responses to raltegravir and dolutegravir in the gut-associated

lymphoid tissue of HIV-infected men and women. *Antivir Ther.* 2018 May 1. [Epub ahead of print] PMID: 29714167

20. Eke AC, Chakhtoura N, **Kashuba A**, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S, Capparelli EV, Mirochnick M; IMPAACT P1026s Protocol Team. Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. *J Acquir Immune Defic Syndr.* 2018 Jul 1;78(3):308-313. doi: 10.1097/QAI.0000000000001677. PMID: 29528944; PMCID: PMC6002878.
21. McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivo A, Nagelkerke N, Garcia Lerma JG, **Kashuba AD**, Masson L, Mansoor LE, Karim QA, Karim SSA, Passmore JS. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. *Nat Med.* 2018 May;24(4):491-496. doi: 10.1038/nm.4506. Epub 2018 Feb 26. PMID: 29480895; PMCID: PMC5893390.
22. Srinivas N, Maffuid K, **Kashuba ADM**. Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System. *Clin Pharmacokinet.* 2018 Sep;57(9):1059-1074. doi: 10.1007/s40262-018-0632-y. Review. PMID: 29464550; PMCID: PMC6062484.
23. Thurman AR, Chandra N, Yousefieh N, Kimble T, Anderson SM, Cottrell M, Sykes C, **Kashuba A**, Schwartz JL, Doncel GF. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel. *J Acquir Immune Defic Syndr.* 2018 May 1;78(1):82-92. doi: 10.1097/QAI.0000000000001648. PMID: 29424790; PMCID: PMC5902131.
24. Nicol MR, Brewers LM, **Kashuba ADM**, Sykes C. The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. *AIDS.* 2018 Jan 2;32(1):11-15. doi: 10.1097/QAD.0000000000001678. PMID: 29112071.
25. Schauer AP, Sykes C, Cottrell ML, Prince H, **Kashuba ADM**. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots. *J Pharm Biomed Anal.* 2018 Feb 5;149:40-45. doi: 10.1016/j.jpba.2017.10.030. Epub 2017 Oct 31. PMID: 29100029; PMCID: PMC5741486.
26. Shen Z, Rodriguez-Garcia M, Patel MV, Bodwell J, **Kashuba ADM**, Wira CR. Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells. *Sci Rep.* 2017 Dec 18;7(1):17697. PMID: 29255206.
27. Pope R Jr, **Kashuba A**. Darunavir for use in pregnant women with HIV. *Expert Rev Clin Pharmacol.* 2017 Dec;10(12):1317-1327. doi: 10.1080/17512433.2017.1390428. Epub 2017 Nov 14. Review. PMID: 28988509.
28. Asmuth DM, Thompson CG, Chun TW, Ma ZM, Mann S, Sainz T, Serrano-Villar S, Utay NS, Garcia JC, Troia-Cancio P, Pollard RB, Miller CJ, Landay A, **Kashuba AD**. Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. *J Infect Dis.* 2017 Oct 17;216(7):813-818. doi: 10.1093/infdis/jix418. PMID: 28968888; PMCID: PMC6279130.
29. Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, **Kashuba ADM**, Lee CR, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell JR. Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. *Clin Transl*

Sci. 2017 Nov;10(6):443-454. doi: 10.1111/cts.12490. Epub 2017 Aug 10. Review. PMID: 28875519; PMCID: PMC5698804.

30. Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, **Kashuba AD**, Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. *J Clin Invest*. 2017 Aug 1;127(8):3126-3135. doi: 10.1172/JCI92684. Epub 2017 Jul 17. PMID: 28714868; PMCID: PMC5531421.
31. Thompson CG, Fallon JK, Mathews M, Charlins P, Remling-Mulder L, Kovarova M, Adamson L, Srinivas N, Schauer A, Sykes C, Luciw P, Garcia JV, Akkina R, Smith PC, **Kashuba ADM**. Multimodal analysis of drug transporter expression in gastrointestinal tissue. *AIDS*. 2017 Jul 31;31(12):1669-1678. PMCID: PMC5546623, NIHMSID: NIHMS882592, PMID: 28590331
32. Cottrell ML, Garrett KL, Prince HMA, Sykes C, Schauer A, Emerson CW, Peery A, Rooney JF, McCallister S, Gay C, **Kashuba ADM**. Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. *J Antimicrob Chemother*. 2017 Jun 1;72(6):1731-1740. PMID: 28369415
33. Thompson CG, Gay CL, **Kashuba ADM**. HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities. *AIDS Res Hum Retroviruses*. 2017 Jun;33(6):513-523. doi: 10.1089/AID.2016.0253. Epub 2017 May 16. Review. PMID: 28398774; PMCID: PMC5467125.
34. Feder AF, Kline C, Polacino P, Cottrell M, **Kashuba ADM**, Keele BF, Hu SL, Petrov DA, Pennings PS, Ambrose Z. A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. *PLoS Pathog*. 2017 May 25;13(5):e1006358. PMID: 28542550.
35. Wahl A, Ho PT, Denton PW, Garrett KL, Hudgens MG, Swartz G, O'Neill C, Veronese F, **Kashuba AD**, Garcia JV. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. *Sci Rep*. 2017 Feb 1;7:41098. PMID: 28145472.
36. Imaz A, Niubó J, **Kashuba AD**, Ferrer E, Sykes C, Rozas N, Acerete L, Vila A, Podzamczar D. Elvitegravir concentrations in seminal plasma in HIV-1-infected men. *HIV Med*. 2017 Mar;18(3):225-230. doi: 10.1111/hiv.12417. Epub 2016 Aug 1. PMID: 27477062.
37. Asher GN, Xie Y, Moaddel R, Sanghvi M, Dossou KS, **Kashuba AD**, Sandler RS, Hawke RL. Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers. *J Clin Pharmacol*. 2017 Feb;57(2):185-193. doi: 10.1002/jcph.806. Epub 2016 Sep 6. PMID: 27503249; PMCID: PMC5233601.
38. Khandelwal, P, Fukuda T, Mizuno K, Teusink-Cross A, Mehta PA, Marsh RA, **Kashuba ADM**, Vinks AA, Davies SM. A pharmacokinetic and pharmacodynamic study of maraviroc as acute graft versus host disease prophylaxis in pediatric allogeneic stem cell transplant recipients with non-malignant diagnoses. *Biology of Blood and Marrow Transplantation*, 2016 Oct;22(10):1829-35.
39. Imaz A, Martinez-Picado J, Niubo J, **Kashuba ADM**, Ferrer E, Rozas N, Acerete L, Vila A, Ouchi D, Sykes C, Podzamczar D. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen. *Journal of Infectious Diseases* 2016; Nov 15;214(10): 1512-1519.

40. Clutton G, Xu Y, Baldoni PL, Mollan KR, Kirchnerr J, Kurac J, **Kashuba A**, Barnard R, Archin N, Hudgens M, Gay C, Margolis D, Goonetilleke N. The differential short- and long-term effects of HIV-1 latency reversing agents on T cell function. *Nature Scientific Reports*. 2016 Aug 2;6:30749.
41. Slaven JE, Decker BS, **Kashuba AD**, Atta MG, Wyatt CM, Gupta SK. Plasma and Intracellular Concentrations in HIV-infected Patients Requiring Hemodialysis Dosed with Tenofovir Disoproxil Fumarate and Emtricitabine: TDF and FTC in HD. *J Acquir Immune Defic Syndr*. 2016 Sep 1;73(1):e8-e10.
42. Collier MA, Gallovic MD, Bachelder EM, Sykes CD, **Kashuba ADM**, Ainslie KM. Saquinavir loaded acetalated dextran microconfetti – a long acting protease inhibitor injectable. *Pharmaceutical Research*. 2016 Aug;33(8):1998-2009.
43. Stalter RM, Moench TR, MacQueen KM, Tolley EE, Owen DH; **Consortium for Ring Adherence**. Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings. *J Int AIDS Soc*. 2016;19(1):20746.
44. Oramasionwu CU, **Kashuba AD**, Napravnik S, Wohl DA, Mao L, Adimora AA. Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection. *World J Hepatol*. 2016 Mar 8;8(7):368-75.
45. Cottrell ML, Prince HMA, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, **Kashuba ADM**. Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. *J Infect Dis*. 2016 Jul 1;214(1):55-64.
46. Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JAE, **Kashuba ADM**. A Translational Pharmacology Approach to Predicting HIV Pre-Exposure Prophylaxis Outcomes in Men and Women Using Tenofovir Disoproxil Fumarate ± Emtricitabine. *J Infect Dis*. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077.
**J Infect Dis. 2016/17 Pharmacotherapy Paper of the Year
Society of Infectious Diseases Pharmacists**
47. Chang A, Bertino Jr J, Nafziger A, **Kashuba ADM**, Turpault S, Lewis L, Ma JD. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and Following Induction. *Ther Drug Monit*. 2016 Jun;38(3):383-7.
48. Veselinovic M, Yang KH, Sykes C, Remling-Mulder L, **Kashuba A**, Akkina R. Mucosal Tissue Pharmacokinetics of Integrase Inhibitor Raltegravir in a Humanized Mouse Model: Implications for HIV Pre-Exposure Prophylaxis. *Virology*. 2016 Feb;489:173-8.
49. Rosen EP, Thompson CG, Bokhart MT, Prince HM, Sykes C, Muddiman DC, **Kashuba AD**. Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging. *Anal Chem*. 2016 Jan 19;88(2):1336-44.
50. Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, **Kashuba AD**, Sieve B, Albanese A, Troia-Cancio P, Sinclair E, Pollard RB, Miller CJ, Somasunderam A, Yotter T, Deeks SG, Moreno S, Asmuth DM. Effects of Combined CCR5/Integrase Inhibitors-based Regimen on Mucosal Immunity in HIV-infected

Patients Naïve to Antiretroviral Therapy: a Pilot Randomized Trial. PLoS Pathog. 2016 Jan 21;12(1):e1005381.

51. Melody K, McBeth S, Kline C, **Kashuba AD**, Mellors JW, Ambrose Z. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. *Antimicrob Agents Chemother*. 2015 Dec;59(12):7762-70. doi: 10.1128/AAC.01937-15. Epub 2015 Oct 5. PMID: 26438501; PMCID: PMC4649225.
52. Dumond JB, Yang KH, Kendrick R, Reddy YS, **Kashuba AD**, Troiani L, Bridges AS, Fiscus SA, Forrest A, Cohen MS. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. *Antimicrob Agents Chemother*. 2015 Oct;59(10):6395-401. doi: 10.1128/AAC.01148-15. Epub 2015 Aug 3. PMID: 26239974.
53. Hendrix CW, Andrade A, Bumpus NN, **Kashuba AD**, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). *AIDS Res Hum Retroviruses*. 2016 Jan;32(1):32-43. PMID: 26414912.
54. Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, **Kashuba AD**, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ. Antiretroviral activity and safety of once-daily etravirine in treatment-naïve HIV-infected adults: 48-week results. *Antivir Ther*. 2016;21(1):55-64.
55. Dumond JB, Rigdon J, Mollan K, Tierney C, **Kashuba ADM**, Aweeka F, Collier AC. Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Co-administration: ACTG Protocol A5143/A5147s Results. *J Acquir Immune Defic Syndr*. 2015 Jul 30. [Epub ahead of print].
56. **Kashuba ADM**, Gengiah TN, Werner L, Yang KH, White NR, Abdool Karim Q, Abdool Karim S. Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial: Importance of adherence for microbicide effectiveness. *JAIDS* 2015 Jul 1;69(3):264-9.
57. Abdool Karim SS, Abdool Karim Q, Bharsany ABM, Baxter C, Grobler AC, Werner L, **Kashuba ADM**, Mansoor LE, Samsunder N, Mindel A, Gengiah TN on behalf of the CAPRISA 004 Trial Group. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type-2 Infection. *N Engl J Med*. 2015 Aug 6;373(6):530-9.
58. Cottrell ML, Patterson KB, Prince HM, Jones A, White N, Wang R, **Kashuba AD**. Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract. *Antivir Ther*. 2015;20(8):795-803. doi: 10.3851/IMP2968. Epub 2015 Jun 3. PMID: 26040011; PMCID: PMC5242325.
59. Joseph SB, Swanstrom R, **Kashuba AD**, Cohen MS. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. *Nat Rev Microbiol*. 2015 Jul;13(7):414-25. Epub 2015 Jun 8. Review. PMID: 26052661.
60. Maher JR, Chuchuen O, Henderson MH, Kim S, Rinehart MT, **Kashuba ADM**, Way A, Katz DF. Katz Co-localized confocal Raman spectroscopy and optical coherence tomography (CRS-OCT) for characterizing analytes in biological tissues. *Biomedical Optics Express*. In press, 2015.

61. Peterson CW, Haworth KG, Polacino P, Huang ML, Sykes C, Obenza WM, Repetto AC, **Kashuba ADM**, Bumgarner R, DeRosa SC, Woolfrey AE, Jerome KR, Mullins JI, Hu SL, Kiem HP. Lack of viral control and development of cART escape mutations in macaques after bone marrow transplantation. *AIDS*. 2015 Aug 24;29(13):1597-606. PMID: 26372270.
62. Smith NM, Micochova P, Watters SA, Aasa-Chapman MM, Rabin N, Moore S, Edwards SG, Garson JA, Grant PR, Ferns RB, **Kashuba A**, Mayor NP, Schellekens J, Marsh SG, McMichael AJ, Perelson AS, Pillay D, Goonetilleke N, Gupta RK. Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. *Clin Infect Dis*. 2015 Jul 1;61(1):120-8. doi: 10.1093/cid/civ219. Epub 2015 Mar 16. PMID: 25778749; PMCID: PMC4463006.
63. Widen EM, Bentley ME, Chasela CS, Kayira D, Flax VL, Kourtis AP, Ellington SR, Kacheche Z, Tegha G, Jamieson DJ, van der Horst CM, Allen LH, Shahab-Ferdows S, Adair LS; **BAN Study Team**. Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding. *J Acquir Immune Defic Syndr*. 2015 Jul 1;69(3):319-28. Erratum in: *J Acquir Immune Defic Syndr*. 2015 Aug 15;69(5):e184.
64. Thompson CG, Bokhart MT, Sykes C, Adamson L, Fedoriw Y, Luciw PA, Muddiman DC, **Kashuba AD**, Rosen EP. Mass Spectrometry Imaging Reveals Heterogeneous Efavirenz Distribution within Putative HIV Reservoirs. *Antimicrob Agents Chemother*. 2015 May;59(5):2944-8. Epub 2015 Mar 2. PMID: 25733502.
65. Cottrell ML, Srinivas N, **Kashuba AD**. Pharmacokinetics of antiretrovirals in mucosal tissue. *Expert Opin Drug Metab Toxicol*. 2015 Jun;11(6):893-905.
66. Sellers CJ, Lee H, Chasela C, Kayira D, Soko A, Mofolo I, Ellington S, Hudgens MG, Kourtis AP, King CC, Jamieson DJ, van der Horst C; **BAN Study Team**. Reducing lost to follow-up in a large clinical trial of prevention of mother-to-child transmission of HIV: the Breastfeeding, Antiretrovirals and Nutrition study experience. *Clin Trials*. 2015 Apr;12(2):156-65. doi: 10.1177/1740774514562031. Epub 2014 Dec 17. PMID: 25518956; PMCID: PMC4355163.
67. Grant RM, Liegler T, Defechereux P, **Kashuba AD**, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. *AIDS*. 2015 Jan 28;29(3):331-7. PMID: 25503265.
68. Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, Geller EJ, Patterson KB, Cohen MS, **Kashuba AD**. Models for Predicting Effective HIV Chemoprevention in Women. *J Acquir Immune Defic Syndr*. 2015 Apr 1;68(4):369-76.
69. Sabo JP, Kort J, Ballow C, **Kashuba AD**, Haschke M, Battegay M, Girlich B, Ting N, Lang B, Zhang W, Cooper C, O'Brien D, Seibert E, Chan TS, Tweedie D, Li Y. Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. *J Clin Pharmacol*. 2015 Apr;55(4):467-77. doi: 10.1002/jcph.436. Epub 2015 Jan 14. PMID: 25449227.
70. Rahangdale L, De Paris K, **Kashuba AD**, Nelson JA, Cottrell M, Sykes C, Emerson C, Young SL, Stevens T, Patterson KB, Cohen MS. Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected

women. *J Acquir Immune Defic Syndr*. 2015 Apr 1;68(4):420-4. doi: 10.1097/QAI.0000000000000480. PMID: 25501615; PMCID: PMC4334681.

71. Jacot TA, Nelson A, Thurman A, **Kashuba AD**, Archer DF, Doncel GF. Development of a Composite Measure of Product Adherence, Protocol Compliance, and Semen Exposure Using DNA and Protein Biomarkers for Topical HIV Prevention Studies. *PLoS One*. 2014 Dec 9;9(12):e114368. PMID: 25489736.
72. Richardson-Harman N, Hendrix CW, Bumpus NN, Mauck C, Cranston RD, Yang K, Elliott J, Tanner K, McGowan I, **Kashuba A**, Anton PA. Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study. *PLoS One*. 2014 Oct 28;9(10):e111507. PMID: 25350130.
73. Yang KH, Hendrix C, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, **Kashuba AD**. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. *PLoS One*. 2014 Oct 28;9(10):e106196. PMID: 25350119.
74. Bokhart MT, Rosen E, Thompson C, Sykes C, **Kashuba AD**, Muddiman DC. Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization. *Anal Bioanal Chem*. 2015 Mar;407(8):2073-84. doi: 10.1007/s00216-014-8220-y. Epub 2014 Oct 16. PMID: 25318460; PMCID: PMC4495968.
75. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Manongi R, Kapiga S, **Kashuba A**, Van Damme L; for the FEM-PrEP Study Group. FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis. *J Acquir Immune Defic Syndr*. 2014 Jul 1;66(3):324-331. PMID: 25157647.
76. Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, **Kashuba AD**, Akkina R. HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. *Virology*. 2014 Aug 5;464-465C:253-263. PMID: 25105490.
77. Agot K, Taylor D, Corneli AL, Wang M, Ambia J, **Kashuba AD**, Parker C, Lemons A, Malahleha M, Lombaard J, Van Damme L. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. *AIDS Behav*. 2015 May;19(5):743-51. PMID: 25100053.
78. Shen Z, Fahey JV, Bodwell JE, Rodriguez-Garcia M, **Kashuba ADM**, et al. (2014) Sex Hormones Regulate Tenofovir-Diphosphate in Female Reproductive Tract Cells in Culture. *PLoS ONE* 9(6). PMID: 24978212.
79. Trezza C, **Kashuba ADM**. Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention. *Clinical Clin Pharmacokinet*. 2014 Jul;53(7):611-24. PMID: 24859035; PMCID: PMC4094112.
80. Barry JA, Robichaud G, Bokhart MT, Thompson C, Sykes C, **Kashuba AD**, Muddiman DC. Mapping Antiretroviral Drugs in Tissue by IR-MALDESI MSI Coupled to the Q Exactive and Comparison with LC-MS/MS SRM Assay. *J Am Soc Mass Spectrom*. 2014 Dec;25(12):2038-47. PMID: 24744212; PMCID: PMC4201889.

81. Cottrell ML, **Kashuba AD**. Topical microbicides and HIV prevention in the female genital tract. *J Clin Pharmacol*. 2014 Jun;54(6):603-15. doi: 10.1002/jcph.292. Epub 2014 Mar 28. Review. PMID: 24664786; PMCID: PMC4144014.
Featured in Wiley's News Round-Up, May 2014
Biweekly mailing to journalists of most newsworthy research published in Wiley journals
82. Gengiah TN, Mansoor LE, Upfold M, Naidoo A, Yende-Zuma N, **Kashuba AD**, Karim QA, Karim SS. Measuring Adherence by Visual Inspection of Returned Empty Gel Applicators in the CAPRISA 004 Microbicide Trial. *AIDS Behav*. 2014 May;18(5):820-5. PMID: 24623069.
83. Archin NM, Bateson R, Tripathy M, Crooks AM, Yang KH, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, **Kashuba AD**, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM. HIV-1 Expression within Resting CD4 T-Cells Following Multiple Doses of Vorinostat. *J Infect Dis*. 2014 Sep 1;210(5):728-35. PMID: 24620025.
84. Thompson CG, Sedykh A, Nicol MR, Muratov E, Fourches D, Tropsha A, **Kashuba AD**. Short communication: cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tract. *AIDS Res Hum Retroviruses*. 2014 Nov;30(11):1058-64. doi: 10.1089/AID.2013.0254. Epub 2014 Mar 13. PMID: 24512359; PMCID: PMC4208595.
85. Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C, Martinson F, Phiri G, Musisi B, Kamwendo D, Hudgens MG, Hosseinipour MC, Nelson JA, Ellington SR, Jamieson DJ, van der Horst C, **Kashuba A**; the BAN Study Team. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN Study. *Antivir Ther*. 2014;19(6):587-95. PMCID: PMC4110187.
86. Kahle EM, **Kashuba A**, Baeten JM, Fife KH, Celum C, Mujugira A, Essex M, De Bruyn G, Wald A, Donnell D, John-Stewart G, Delany-Moretlwe S, Mugo NR, Farquhar C, Lingappa JR. Unreported Antiretroviral Use by HIV-1-Infected Participants Enrolling in a Prospective Research Study. Partners in Prevention HSVHIV Transmission Study Team. *J Acquir Immune Defic Syndr*. 2014 Feb 1;65(2):e90-4. PMCID: PMC3898592.
87. Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, **Kashuba AD**. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. *J Clin Pharmacol*. 2014 May;54(5):574-83. PMID: 24343710; PMCID: PMC4061289.
88. Wei X, Hunt G, Karim SS, Naranbhai V, Sibeko S, Karim QA, Li JF, **Kashuba AD**, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA. Sensitive Tenofovir Resistance Screening of HIV-1 from the Genital and Blood Compartments of Women with Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. *J Infect Dis*. 2014 Jun 15;209(12):1916-20. PMID: 24436453
89. Denton PW, Long JM, Wietgreffe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, **Kashuba AD**, Berger EA, Margolis DM, Garcia JV. Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. *PLoS Pathog*. Epub 2014 Jan 9. PMCID: PMC3887103.
90. Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, Dumond JB, **Kashuba AD**. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women. *Antivir Ther*. 2014;18(8):1005-13. PMCID: PMC4038682.

91. Sampson MR, Bloom BT, Lenfestey RW, Harper B, **Kashuba AD**, Anand R, Benjamin DK Jr, Capparelli E, Cohen-Wolkowicz M, Smith PB; Best Pharmaceuticals for Children Act–Pediatric Trials Network. Population pharmacokinetics of intravenous acyclovir in preterm and term infants. *Pediatr Infect Dis J*. 2014 Jan;33(1):42-9. PMID: PMC3904301.
92. Nicol MR, Adams JL, **Kashuba AD**. HIV PrEP Trials: The Road to Success. *Clin Investig (Lond)*. 2013 Mar;3(3). PMID: PMC3882078.
93. Chuchuen O, Henderson MH, Sykes C, Kim MS, **Kashuba AD**, Katz DF. Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy. *PLoS One*. 2013 Dec 30;8(12):e85124. PMID: PMC3875564.
94. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, **Kashuba A**, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. *PLoS Pathog*. Epub 2013 Dec 26. PMID: PMC3873446.
95. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, **Kashuba AD**. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? *Lancet*. 2013 Nov 2;382(9903):1515-24. PMID: PMC3880570.
96. Marshall L, Cummins J, Spiegel H, Turpin J, Veronese F, **Kashuba A**. Critical Need for Appropriate Mucosal Sample Collection to determine Relational Animal Pharmacokinetic-Pharmacodynamic Models in HIV Prevention. *AIDS Res Hum Retroviruses*. 2013 Nov;29(11):1398-400. PMID: PMC3809943.
97. Thompson CG, Cohen MS, **Kashuba AD**. Antiretroviral pharmacology in mucosal tissues. *J Acquir Immune Defic Syndr*. 2013 Jul;63 Suppl 2:S240-7. PMID: PMC3951793.
98. Greener, B, Patterson, K, Prince, H, Sykes, C, Adams, J, Dumond, JB, Shaheen, NJ, Madanick, RD, Dellon, ES, Cohen MS, **Kashuba ADM**. Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV Negative Men After Single and Multiple Dosing. *J Acquir Immune Defic Syndr*. 2013 Sep 1;64(1):39-44. PMID: PMC3804901.
99. Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, Jennings S, Cohen MS, **Kashuba ADM**. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. *AIDS*. 27(9):1413-1419, June 1, 2013. PMID: PMC4016763.
100. Cottrell ML, Hadzic T, **Kashuba AD**. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. *Clin Pharmacokinet*. 2013 Nov;52(11):981-94. PMID: PMC3805712.
101. Romano J, **Kashuba A**, Becker S, Cummins J, Turpin J, Veronese On Behalf Of The Antiretroviral Pharmacology In HIV Prevention Think Tank Participants F. Pharmacokinetics and Pharmacodynamics in HIV Prevention: Current Status and Future Directions: A Summary of the DAIDS and BMGF Sponsored Think Tank on Pharmacokinetics (PK)/Pharmacodynamics (PD) in HIV Prevention. *AIDS Res Hum Retroviruses*. 2013 Nov;29(11):1418-27. PMID: PMC3809377.

102. Dumond J, Adams J, Prince H, Kendrick R, Wang R, Jennings S, Malone S, White N, Sykes C, Corbett A, Patterson K, Forrest A, **Kashuba A**. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. *HIV Med*. 2013 Aug;14(7):401-9. PMID: PMC3664258.
103. Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, **Kashuba AD**, Stewart PW, Lindley CM, Chen ML. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. *Drug Metab Dispos*. 2013 Mar;41(3):575-81. doi: 10.1124/dmd.112.048108. Epub 2012 Dec 13. PMID: 23238783; PMCID: PMC4162003.
104. Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, **Kashuba A**. Protein Binding of Lopinavir and Ritonavir During Four Phases of Pregnancy: Implications for Treatment Guidelines. *J Acquir Immune Defic Syndr*. 2013 May 1;63(1):51-8. PMID: PMC3625477.
105. Wohl DA, Dumond JB, Blevins S, Pittard D, Ragan D, Wang R, Massengale K, Walsh K, Floris-Moore M, Eron JJ Jr, Richardson A, Hudgens MG, **Kashuba AD**. Raltegravir Pharmacokinetics in Treatment-Naive Patients is not influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study. *Antimicrob Agents Chemother*. 2013 Feb;57(2):784-8. PMID: PMC3553727.
106. Adams JL, Sykes C, Menezes P, Prince HM, Patterson KB, Fransen K, Crucitti T, Baetselier ID, Damme LV, **Kashuba AD**. Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in Blood Cells Compared with Isolated Peripheral Blood Mononuclear Cells: A New Measure of Antiretroviral Adherence? *J Acquir Immune Defic Syndr*. 2013 Mar 1;62(3):260-6. PMID: PMC4042836.
107. Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, **Kashuba AD**. Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women. *Clin Pharmacokinet*. 2012 Dec;51(12):809-22. PMID: PMC3508718.
108. Anton PA, Cranston RD, **Kashuba A**, Hendrix CW, Bumpus NN, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis R, Cumberland WG, Ju C, Carballo-Diéguez A, Mauck C, McGowan I. RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate. *AIDS Res Hum Retroviruses*. 2012 Nov;28(11):1412-21.
109. Archin NM, Liberty AL, **Kashuba AD**, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. *Nature*. 2012 Jul 25;487(7408):482-5.

Selected by Faculty of 1000
(top 2% of published articles in biology and medicine)

110. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, **Kashuba A**, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2012 Aug 2;367(5):411-22. Epub 2012 Jul 11.

Selected by Faculty of 1000
(top 2% of published articles in biology and medicine)

111. Adams JL, Greener BN, **Kashuba AD**. Pharmacology of HIV integrase inhibitors. *Curr Opin HIV AIDS*. 2012 Sep;7(5):390-400.
112. Chasela CS, Wall P, Drobeniuc J, King CC, Teshale E, Hosseinipour MC, Ellington SR, Codd M, Jamieson DJ, Knight RJ, Fitzpatrick P, Kourtis AP, Hoffman IF, Kayira D, Mumba N, Kamwendo DD, Martinson F, Powderly W, van der Horst C, Kamili S; **BAN team**. Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: the BAN study. *J Clin Virol*. 2012 Aug;54(4):318-20. Epub 2012 Jun 2.
113. Brown KC, Patterson KB, Jennings SH, Malone SA, Shaheen NJ, Asher Prince HM, Spacek M, Cohen MS, **Kashuba ADM**. Single and Multiple Dose Pharmacokinetics of Darunavir plus Ritonavir and Etravirine in Semen and Rectal Tissue of HIV-Negative Men. *J Acquir Immune Defic Syndr*. 2012 Oct 1;61(2):138-44.
114. Cohen-Wolkowicz M, Benjamin DK Jr, Ross A, James LP, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, **Kashuba AD**, Ouellet D. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. *Ther Drug Monit*. 2012 Jun;34(3):312-9.
115. Cohen MS, Muessig KE, Smith MK, Powers KA, **Kashuba AD**. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. *AIDS*. 2012 Aug 24;26(13):1585-98.
116. Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, Hosseinipour MC, Kamwendo DD, Ellington SR, Wiener JB, Fiscus SA, Tegha G, Mofolo IA, Sichali DS, Adair LS, Knight RJ, Martinson F, Kacheche Z, Soko A, Hoffman I, van der Horst C; **BAN study team**. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. *Lancet*. 2012 Jun 30;379(9835):2449-58. Epub 2012 Apr 26.
117. Heneine W, **Kashuba A**. HIV Prevention by Oral Preexposure Prophylaxis. *Cold Spring Harb Perspect Med*. 2012 Mar;2(3):a007419.
118. Adams J, **Kashuba ADM**. Formulation, pharmacokinetics and pharmacodynamics of topical Microbicides. *Best Practice & Research Clinical Obstetrics & Gynaecology*. *Best Pract Res Clin Obstet Gynaecol*. 2012 Aug;26(4):451-62
119. Cohen-Wolkowicz M, Ouellet D, Smith PB, James LP, Ross A, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, **Kashuba AD**, Benjamin DK Jr. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. *Antimicrob Agents Chemother*. 2012 Apr;56(4):1828-37. Epub 2012 Jan 17.
120. **Kashuba ADM**, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. *The Lancet*, Early Online Publication, 7 December 2011. doi:10.1016/S0140-6736(11)61852-7.
121. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, **Kashuba ADM**. Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission. *Sci Transl Med* 7 December 2011: Vol. 3, Issue 112, p. 112re4.

**Selected by Faculty of 1000
(top 2% of published articles in biology and medicine)**

122. Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, Tauzie J, Shumba I, Lamba JK, Schuetz EG, McLeod HL, **Kashuba AD**, Corbett AH.

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. *Pharmacogenomics*. 2012 Jan;13(1):113-21. doi: 10.2217/pgs.11.132. Epub 2011 Nov 23.

123. Cohen-Wolkowicz M, Smith PB, Piper L, Cheifetz I, Moran C, Liu P, Aram J, **Kashuba ADM**, Capparelli E, Walsh TJ, Hope WW, Benjamin DK. Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates *Clin Pharmacol Ther*. 2011 May;89(5):702-7. doi: 10.1038/clpt.2011.26. Epub 2011 Mar 16.
124. Nuttall J, **Kashuba A**, Wang R, White N, Allen P, Roberts J, Romano J. The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques. *Antimicrob Agents Chemother*. 2012 Jan;56(1):103-9. doi: 10.1128/AAC.00597-11. Epub 2011 Oct 10.
125. Cohen-Wolkowicz M, White NR, Bridges A, Benjamin DK Jr, **Kashuba AD**. Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2011 Nov 15;879(30):3497-506. Epub 2011 Sep 22.
126. Stuart GS, Moses A, Corbet A, Phiri G, Kimwenda W, Mkandawire N, Chintedze J, Malunga G, Hosseinipour M, Cohen MS, Stanczyk FZ, **Kashuba ADM**. Pharmacokinetics and Pharmacodynamics of a Combined Oral Contraceptive and a Generic Combined Formulation Antiretroviral in Malawi. *JAIDS* 2011 Oct 1;58(2):e40-3.
127. Schwartz JL, Rountree RW, **Kashuba ADM**, Brache V, Creinin MD, Poindexter A, Kearney BP. A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel. *PLoS ONE* 2011;6(10):e25974. Epub 2011 Oct 19.

**Top 10% of most cited articles in PLoS One
(10th Anniversary Metrics, June 2017)**

128. Abdool-Karim S, **Kashuba ADM**, Werner L, Abdool-Karim Q. Drug concentrations following topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. *Lancet*. 2011 Jul 16;378(9787):279-81.
129. Wang X, Boffito M, Zhang J, Chung E, Zhu L, Wu Y, Patterson K, **Kashuba A**, Tebas P, Child M, Mahnke L, Bertz R. Effects of the H₂ Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients. *AIDS Patient Care STDS*. 2011 Sep;25(9):509-15. Epub 2011 Jul 19.
130. Kwara A, Tashima KT, Dumond JB, Poethke P, Kurpewski J, **Kashuba AD**, Court MH, Greenblatt DJ. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. *Antimicrob Agents Chemother*. 2011 Jul;55(7):3527-33. Epub 2011 Apr 25.
131. Smith K, Powers KA, **Kashuba AD**, Cohen MS. HIV-1 treatment as prevention: the good, the bad, and the challenges. *Curr Opin HIV AIDS*. 2011 Jul;6(4):315-25.
132. Dillingham R, Leger P, Beauharnais C-A, Miller E, **Kashuba A**, Jennings S, Dupnik K, Samie A, Eyma E, Guerrant R, Pape J, Fitzgerald D. AIDS Diarrhea and Antiretroviral Drug Concentrations; A Matched-Pair Cohort Study in Port au Prince, Haiti. *Am J Trop Med Hyg* 2011;84(6):878-882.

133. Patterson KB, Jennings S, Falcon R, Mrus J, **Kashuba ADM**. Darunavir, Ritonavir and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-infected Women. *Antimicrob Agents Chemother*. 2011;55(3):1120-1122.
134. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Asher Prince HM, Dumond JB, Spacek MB, Heidt PE, Cohen MS, **Kashuba ADM**. Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men. *Journal of Infectious Diseases* 2011 203: 1484-1490.
135. Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwierski S, Burns D; Workshop Organizing Committee. Implications of HIV PrEP trials results. *AIDS Res Hum Retroviruses*. 2011 Jan;27(1):81-90.
136. Cates Jr W, **Kashuba ADM**. The North Carolina Contribution to the CAPRISA 004 Study: The Global Health Initiative in Action. *N C Med J*. September/October 2010;71(5):490-491.
137. Nicol MR, **Kashuba AD**. Pharmacologic opportunities for HIV prevention. *Clin Pharmacol Ther*. 2010 Nov;88(5):598-609. Epub 2010 Sep 29.
138. Winters MA, Van Rompay KK, **Kashuba AD**, Shulman NS, Holodniy M. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. *Antimicrob Agents Chemother*. 2010 Oct;54(10):4059-63. Epub 2010 Aug 9.
139. Ngo N, Brantley SJ, Carrizosa DR, **Kashuba AD**, Dees EC, Kroll DJ, Oberlies NH, Paine MF. The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation. *J Exp Pharmacol*. 2010 Jul;2010(2):83-91.
140. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, Martinson F, Tegha G, Knight RJ, Ahmed YI, Kamwendo DD, Hoffman IF, Ellington SR, Kacheche Z, Soko A, Wiener JB, Fiscus SA, Kazembe P, Mofolo IA, Chigwenembe M, Sichali DS, van der Horst CM; **BAN Study Group**. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. *N Engl J Med*. 2010 Jun 17;362(24):2271-81.
141. Farr SL, Nelson JAE, Thokozani JN, Kourtis AP, Chasela C, Johnson JA, **Kashuba ADM**, Tegha GL, Wiener J, Eron JJ, Banda HN, Mpaso M, Lipscomb J, Matiki C, Fiscus SA, Jamieson DJ, van der Horst C. Addition of 7 Days of Zidovudine plus Lamivudine to Peripartum Single-Dose Nevirapine Effectively Reduces Nevirapine Resistance Postpartum in HIV-Infected Mothers in Malawi. *J Acquir Immune Defic Syndr*. 2010 Aug 15;54(5):515-23.
142. Twigg HL, S Schnizlein-Bick CT, Weiden M, Valentine F, Wheat J, Day RB, Rominger H, Zheng L, Collman RG, Coombs RW, Bucy RP, Rezk NL, **Kashuba ADM**. Measurement of antiretroviral drugs in the lungs of HIV-infected patients. *HIV Ther*. 2010 Mar 1;4(2):247-251.
143. Choi SO, Rezk N, Kim JS, **Kashuba AD**. Development of an LC-MS method for measuring tenofovir in human vaginal tissue. *J Chromatogr Sci*. 2010;48(3):219-23.
144. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, **Kashuba AD**. Variability in Drug Metabolizing Enzyme Activity in HIV-Infected Patients. *Eur J Clin Pharmacol*. 2010 May;66(5):475-85. Epub 2010 Jan 19.
145. Corbett AH, Hosseinipour MC, Nyirenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, **Kashuba AD**, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics of

generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. *Antivir Ther.* 2010;15(1):83-90.

146. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La I, Drulak M, Sabo JP, Castles MA, MacGregor TR, **Kashuba ADM**. A Phenotype-Genotype Approach to Predicting CYP450 and P-glycoprotein Drug Interactions with the Mixed Inhibitor/Inducer Tipranavir/ritonavir. *Clin Pharm Ther* advanced online publication 10 Feb 2010 doi 10.1038/clpt.2010.253
147. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, **Kashuba ADM**, Rosenkranz SL, Kmack A, Ferguson F, Dehlinger M, Mildvan D. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naïve patients: results of aids clinical trials group (ACTG) a5073, a 48-week randomized controlled trial. *Clin Infect Dis* 2010; 50:1041–1052.
148. McRae MP, Rezk NL, Bridges AS, Corbett AH, Tien HS, Brouwer KLR, **Kashuba ADM**. Plasma Bile Acid Concentrations in HIV Infected Subjects Taking Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity. *Pharmacotherapy* 2010; 30 (1): 17-24.
149. Talameh JA, Rezk NL, **Kashuba AD**. Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2010 Jan 1;878(1):92-6. doi: 10.1016/j.jchromb.2009.11.015. PMID: 19942487; PMCID: PMC2852126.
150. Brown KC, Paul S, **Kashuba AD**. Drug Interactions with New and Investigational Antiretrovirals. *Clin Pharmacokinet* 2009;48(4):211-41.
151. Leger P, Dillingham R, Beauharnais CA, **Kashuba AD**, Rezk NL, Fitzgerald DW, Pape JW, Haas DW. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. *J Infect Dis.* 2009 Sep 15;200(6):955-64. doi: 10.1086/605126. PMID: 19659438; PMCID: PMC2754599.
152. Rezk, NL, White NR, Jennings S, **Kashuba ADM**. A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. *Talanta*, Oct 15 2009;79(5):1372-8. Epub 2009 Jun 9.
153. Choudhary SK, Rezk NL, Ince WL, Cheema M, Zhang L, Su L, Swanstrom R, **Kashuba ADM**, Margolis DM. Suppression of HIV-1 viremia with reverse transcriptase and integrase inhibitors, CD4+ T cell recovery, and viral rebound upon therapy interruption in a new model for HIV treatment in the humanized Rag2^{-/-} γc^{-/-} mice. *Journal of Virology* 2009 Aug;83(16):8254-8. Epub 2009 Jun 3.
154. Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, **Kashuba ADM**. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women. *J AIDS* 2009 Aug 15;51(5):546-53.
155. Ferguson YO, Eng E, Bentley M, Sandelowski M, Steckler A, Randall-David E, Piwoz EG, Zulu C, Chasela C, Soko A, Tembo M, Martinson F, Tohill BC, Ahmed Y, Kazembe P, Jamieson DJ, van der Horst C; UNC Project BAN Study Team, Adair L, Ahmed Y, Ait-Khaled M, Albrecht S, Bangdiwala S, Bayer R, Bentley M, Bramson B, Bobrow E, Boyle N, Butera S, Chasela C, Chavula C, Chimerang'ambe J, Chigwenembe M, Chikasema M, Chikhungu N, Chilongozi D, Chiudzu G, Chome L, Cole A, Corbett A, Corneli A, Duerr A, Eliya H, Ellington S, Eron J, Farr S, Ferguson YO, Fiscus S, Galvin S, Guay L, Heilig C, Hoffman I, Hooten E, Hosseinipour M, Hudgens M, Hurst S, Hyde

- L, Jamieson D, Joaki G, Jones D, Kacheche Z, Kamanga E, Kamanga G, Kampani C, Kamthunzi P, Kamwendo D, Kanyama C, **Kashuba A**, Kathyola D, Kayira D, Kazembe P, Knight R, Kourtis A, Krysiak R, Kumwenda J, Loeliger E, Luhanga M, Madhlopa V, Majawa M, Maida A, Marcus C, Martinson F, Thoofer N, Matika C, Mayers D, Mayuni I, McDonough M, Meme J, Merry C, Mita K, Mkomawanthu C, Mndala G, Mndala I, Moses A, Msika A, Msungama W, Mtimuni B, Muita J, Mumba N, Musis B, Mwansambo C, Mwapasa G, Nkhoma J, Pendame R, Piwoz E, Raines B, Ramdas Z, Rublein J, Ryan M, Sanne I, Sellers C, Shugars D, Sichali D, Snowden W, Soko A, Spensley A, Steens JM, Tegha G, Tembo M, Thomas R, Tien HC, Tohill B, van der Horst C, Waalberg E, Wiener J, Wilfert C, Wiyo P, Zgambo O, Zimba C. Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. *AIDS Educ Prev*. 2009 Apr;21(2):141-55.
156. Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, **Kashuba AD**, Court MH. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. *J Clin Pharmacol*. 2009 Sep;49(9):1079-90. doi: 10.1177/0091270009338482. Epub 2009 Jul 23. PMID: 19628728; PMCID: PMC2749505.
 157. Yeh RF, Rezk NL, **Kashuba AD**, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB. Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs During and After Pregnancy in HIV-1 Infected Women. *Antimicrob Agents Chemother*. Jun;53(6):2367-74. Epub 2009 Mar 23.
 158. Ngo N, Yan Z, Graf TN, Carrizosa DR, **Kashuba AD**, Dees EC, Oberlies NH, Paine MF. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. *Drug Metab Dispos*. 2009 Mar;37(3):514-22. Epub 2008 Dec 29.
 159. Rezk NL, White N, **Kashuba AD**. An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. *Anal Chim Acta*. 2008 Nov 3;628(2):204-13. Epub 2008 Sep 11.
 160. Rezk NL, White N, Bridges AS, Abdel-Megeed MF, Mohamed TM, Moselhy SS, **Kashuba AD**. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. *Ther Drug Monit*. 2008 Oct;30(5):611-9. doi: 10.1097/FTD.0b013e318186e08e. PMID: 18758393; PMCID: PMC2901847.
 161. Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, **Kashuba AD**, Hawke RL. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. *Drug Metab Dispos*. 2008 Sep;36(9):1909-16. doi: 10.1124/dmd.107.019604. Epub 2008 Jun 19. PubMed PMID: 18566043.
 162. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, **Kashuba A**, Anton P, McGowan I, Shattock R. Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel. *PLoS Medicine* 2008; 5 (8):1-13.

Selected by Faculty of 1000
(top 2% of published articles in biology and medicine)

163. Roberts PJ, Rollins KD, **Kashuba ADM**, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG, Hawke RL The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans Published May 19, 2008; doi: 10.1124/dmd.107.020065
164. Collier AC, Tierney C, Downey GF, Eshleman SH, **Kashuba A**, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW; the AIDS Clinical Trials Group Protocol A5143 Team. Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV. *HIV Clin Trials*. 2008 Jan 1;9(2):91-102.
165. Cao YJ, Flexner CW, Dunaway S, Park JG, Klingman K, Wiggins I, Conley J, Radebaugh C, **Kashuba AD**, MacFarland R, Becker S, Hendrix CW. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. *Antimicrob Agents Chemother*. 2008 May;52(5):1630-4. doi: 10.1128/AAC.01460-07. Epub 2008 Feb 19. PMID: 18285477; PMCID: PMC2346642.
166. Cohen MS, **Kashuba AD**. Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. *PLoS Med*. 2008 Feb;5(2):e30.
167. Dumond JB, Reddy YS, Troiani L, Rodriguez JF, Bridges AS, Fiscus SA, Cohen MS, **Kashuba ADM**. Differential Extracellular and Intracellular Concentrations of Zidovudine and Lamivudine in Semen and Plasma of HIV-1 Infected Men. *JAIDS* 2008;48(2):156-162.
168. Tappouni HL, Rublein JC, Donovan BJ, Hollowell SB, Tien HC, Min SS, Theodore D, Rezk NL, Smith PC, Tallman MN, Raasch RH, **Kashuba AD**. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. *Am J Health Syst Pharm*. 2008 Mar 1;65(5):422-8.
169. Kwara A, DeLong A, Rezk NL, Hogan J, Burtwell H, Champan S, Moreira C, Kurpewski J, Ingersoll J, Caliendo A, **Kashuba A**, Susan Cu-Uvin, Antiretroviral Drug Concentrations and Virologic Rebound in the Genital Tract of HIV-Infected Women, *Clin Infect Dis* 2008 Mar 1;46(5):719-25.
170. Vourvahis M, Tappouni HL, Patterson KB, Chen YC, Rezk NL, Fiscus SA, Kearney BP, Rooney JF, Hui J, Cohen MS, **Kashuba ADM**. The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital Tract. *J Acquir Immune Defic Syndr*. 2008 Mar 1;47(3):329-33.
171. Vourvahis M and **Kashuba ADM**. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. *Pharmacotherapy*. 2007 Jun;27(6):888-909.
172. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, **Kashuba ADM**. Antiretroviral Drug Exposure in the Female Genital Tract: Implications for Oral Pre- and Post-Exposure Prophylaxis. *AIDS*. 2007 Sep 12;21(14):1899-907

**Selected by Faculty of 1000
(top 2% of published articles in biology and medicine)**

173. Rezk NL, Abdel-Megeed MF, **Kashuba ADM**. Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk. *Therapeutic Drug Monitoring*. 2007 Aug;29(4):429-36.

174. Jung BH, Rezk NL, Bridges AS, **Kashuba ADM**. Simultaneous determination of 16 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. *Biomed Chromatogr*. 2007 Oct;21(10):1095-104.
175. Cohen MS, Gay C, **Kashuba ADM**, Blower S, Paxton L. Narrative Review: Antiretroviral Therapy for Prevention of the Sexual Transmission of HIV-1. *Annals of Internal Medicine* 2007;146:591-601.
176. Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, Van der Horst C, **Kashuba ADM**. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian subjects. *AIDS*. 2007 Jan 2;21(1):59-64.
177. Choi SO, Rezk NL, **Kashuba ADM**. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. *J Pharm Biomed Anal*. 2007 Mar 12;43(4):1562-7.
178. Hogeland GW, Swindells S, McNabb J, **Kashuba ADM**, Yee GC, Lindley CL. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. *Clinical Pharmacol Ther* 2007 Jan;81(1):69-75.

Selected by Faculty of 1000
(top 2% of published articles in biology and medicine)

179. la Porte CJL, Back D, Blaschke T, Boucher CAB, Fletcher CV, Flexner C, Gerber JG, **Kashuba ADM**, Schapiro J, Burger DM. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. *Rev Antivir Ther* 2006;13:4-14.
180. Kim MJ, Nafziger AN, **Kashuba ADM**, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS Jr. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. *Eur J Clin Pharm* 2006;62:431-436.
181. Corbett AH, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, **Kashuba ADM**. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. *Antimicrob Agents Chemother*. 2006 Aug;50(8):2756-61.

Selected by Faculty of 1000
(top 2% of published articles in biology and medicine)

182. Rezk NL, Brown K, **Kashuba, ADM**. A simple and sensitive bioanalytical assay for simultaneous quantitative determination of omeprazole and its three metabolites in human blood plasma using RP- HPLC after an optimized liquid-liquid extraction procedure. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2006 Dec 5;844(2):314-21.
183. McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BT, Kim RB, Brouwer KLR, **Kashuba ADM**. Ritonavir, Saquinavir and Efavirenz, but not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes. *J Pharmacol Exp Ther*. 2006 Sep;318(3):1068-75.
184. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Klein C, Rublein J, **Kashuba ADM**. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes (CYP) 2C9, CYP2C19, and CYP1A2, but Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. *JAIDS* 2006;42:52-60.

185. Rezk N, Crutchley R, Yeh RF, **Kashuba ADM**. Full Validation of An Analytical Method For The HIV Protease Inhibitor Atazanavir In Combination With 8 Other Antiretroviral Agents and Its Applicability to Therapeutic Drug Monitoring. *Ther Drug Monit*. 2006 Aug;28(4):517-25.
186. Chen YC, Gotzkowsky SK, Nafziger AN, Kulawy RW, Rocci ML, Bertino JS Jr, **Kashuba, ADM**. Poor correlation between 6 β -hydroxycortisol: cortisol molar ratios and clearance as measures of hepatic CYP3A activity. *British Journal of Clinical Pharmacology* 2006;62(2):187-195.
187. Cohen MS, **Kashuba AD**, Gay C. HIV antiretroviral postexposure prophylaxis: a cautionary note. *Clin Infect Dis*. 2005 Nov 15;41(10):1514-6. Epub 2005 Oct 13.
188. Shelepova T, Nafziger AN, Victory J, **Kashuba ADM**, Rowland E, Zhang YH, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 Cocktail. *J Clin Pharmacol* 2005;45(12):1412-1421.
189. **Kashuba AD**. Drug-drug interactions and the pharmacotherapy of HIV infection. *Top HIV Med*. 2005 Jun-Jul;13(2):64-9.
190. Rezk NL, Crutchley RD, **Kashuba ADM**. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. *Journal of Chromatography B* 2005;822:201-208.
191. **Kashuba ADM**, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. *AIDS* 2005;19:145-152.
192. Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, **Kashuba ADM**. Protease inhibitor and Nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1 infected women. *J AIDS* 2004;37(5):1577-1580.
193. Sunman JA, Hawke RL, LeCluyse EL, **Kashuba AD**. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. *Drug Metab Dispos*. 2004 Mar;32(3):359-63.
194. Wohl DA, Pilcher CD, Evans S, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, **Kashuba A**, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL; Adult AIDS Clinical Trials Group A5129 Team. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. *J AIDS* 2004;35(3):274-8.
195. Kennedy MP, Abdel-Rahman SM, **Kashuba ADM**, Leeder JS. Comparison of Various Urine Collection Intervals for Caffeine and Dextromethorphan Phenotyping in Children. *J Clin Pharmacol* 2004;44:708-714.
196. Ma JD, Nafziger AN, **Kashuba ADM**, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS Jr. Limited Sampling Strategy of S-Warfarin Concentrations, but Not Warfarin S/R Ratios, Accurately Predicts S-Warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers. *J Clin Pharmacol* 2004;44:570-576.
197. Rezk NL, Tidwell RR, **Kashuba ADM**. High-Performance Liquid Chromatography Assay For The Quantification Of HIV Protease Inhibitors And Non-Nucleoside Reverse

Transcriptase Inhibitors In Human Plasma J Chromatography B Analyt Technol Biomed Life Sci 2004;805(2):241-247.

198. Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, **Kashuba ADM**. Co-Administration of Lopinavir/Ritonavir and Phenytoin Results in A Two-Way Drug Interaction Through Cytochrome P-450 Induction. J Acquir Immune Defic Syndr 2004;36:1034–1040.
199. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, **Kashuba ADM**. The Pharmacokinetics, Safety, and Initial Virologic Response of A Triple-Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir. J Acquir Immune Defic Syndr 2004;36:921–928.
200. Kennedy MJ, Scripture CD, **Kashuba ADM**, Scott CS, Gotschall RR, Gaedigk A, Kearns GL. Activities of CYP1A2, NAT-2, XO, and CYP2D6 are Unaltered in Children with Cystic Fibrosis. Clinical Pharmacol Ther 2004;75(3):163-71.
201. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, **Kashuba AD**, Rowland E, Bertino JS Jr. Combined Phenotypic Assessment Of Cytochrome P450 1A2, 2C9, 2C19, 2D6, And 3A, N-Acetyltransferase-2, And Xanthine Oxidase Activities With The "Cooperstown 5+1 Cocktail". Clin Pharmacol Ther. 2003;74(5):437-47.
202. Reddy YS, **Kashuba ADM**, Gerber JG, Miller V. Importance of Antiretroviral Drug Concentrations in Sanctuary Sites and Viral Reservoirs. AIDS Research and Human Retroviruses 2003;19(3):167-176.
203. Rezk NL, Tidwell RR, **Kashuba ADM**. Simultaneous Determination Of Six HIV Nucleoside Analogue Reverse Transcriptase Inhibitors And Nevirapine By Liquid Chromatography With Ultraviolet Detection After Solid-Phase Extraction. J Chromatography B 2003;791:137–147.
204. Lowry JA, Kearns GL, Abdel-Rahman AM, Nafziger AN, Khan IS, **Kashuba ADM**, Schuetz EG, Bertino Jr JS, van den Anker JN Leeder JS. Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther 2003;73:209-22.
205. McRae MP, Brouwer KLR, **Kashuba ADM**. Cytokine regulation of P-glycoprotein. Drug Metabolism Reviews 2003;35(1):19-33.
206. Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, Petch L, Cohen MS, **Kashuba ADM**. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of HIV-1 infected men. J Infectious Diseases 2002;186:1339–43.
207. Rogers JF, Nafziger AN, **Kashuba ADM**, Streetman DS, Rocci ML, Choo EF, Wilkinson GR, Bertino JS Jr. Single Plasma Concentrations of 1 α -Hydroxymidazolam or the Ratio of 1 β -Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects. J Clinical Pharmacology 2002;42:1079-7082.
208. Acosta EP, Gerber JG, and the **Adult Pharmacology Committee Of The AIDS Clinical Trials Group**. Position Paper on Therapeutic Drug Monitoring of Antiretroviral Agents. AIDS Research and Human Retroviruses 2002;18(12):825–834.
209. Chaudry, NI. Eron JJ, Naderer OJ, Pereira AS, Fiscus SA, Wire MB, **Kashuba ADM**. Effects of Formulation and Dosing Strategy on Amprenavir (APV) Concentrations in the

Seminal Plasma (SP) of HIV-1 Infected Males. *Clinical Infectious Diseases* 2002;35:760-762.

210. Cohen MS, Hosseinipour M, **Kashuba A**, Butera S. Use of antiretroviral drugs to prevent sexual transmission of HIV. *Current Clinical Topics in Infectious Diseases*. 2002;22:214-5.
211. Rezk NL, Tidwell RR, **Kashuba ADM**. Simple and rapid quantification of the nonnucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet detection. *J Chromatography B* 2002;774 (1);79-88.
212. Corbett AH, Lim ML, **Kashuba ADM**. Kaletra. *Annals of Pharmacother* 2002;36:1193-203.
213. Corbett AH, **Kashuba ADM**. Fosamprenavir. *Current Opinion in Investigational Drugs*. 2002;3(3):384-390.
214. Hosseinipour M, Cohen MS, Vernazza PL, **Kashuba ADM**. Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? *Clinical Infectious Diseases* 2002; 34:1391–5.
215. Kim JS, Nafziger AN, Tsunoda SM, Choo EF, Streetman DS, **Kashuba ADM**, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. *J Clin Pharmacol* 2002;42:1-7.
216. Stephen Becker; Alvan Fisher; Charles Flexner; John G. Gerber; Richard Haubrich; **Angela D. M. Kashuba**; Andrew D. Luber; Stephen C. Piscitelli. Pharmacokinetic Parameters of Protease Inhibitors and the Cmin/IC50 Ratio: Call for Consensus. *J AIDS* 2001;27:210.
217. Jordan HL, Pereira AS, Cohen MS, **Kashuba ADM**. Domestic Cats as Models for Predicting Human Nucleoside Analogue Pharmacokinetics in Blood and Seminal Plasma. *Antimicrobial Agents and Chemotherapy*, 2001;45:2173-2176.
218. Vernazza PL, **Kashuba ADM**, Cohen MS. Biological correlates of sexual transmission of HIV: Practical consequences and potential targets for public health. *Reviews in Medical Microbiology* 2001;12:131-142.
219. Streetman DS, **Kashuba ADM**, Bertino JS Jr., Kulawy R, Rocci, ML Jr., Nafziger AN. Use of Midazolam Urinary Metabolic Ratios for Cytochrome P450 3A (CYP3A) Phenotyping. *Pharmacogenetics* 2001;11(4):349-355.
220. Nafziger AN, Bertino JS, Goss-Bley AI, **Kashuba, ADM**. Sexual dysfunction and fluvoxamine therapy. *Journal of Clinical Psychiatry* 2001;62(2):127-128.
221. Ozdemir V, Kalow W, Tang B-K, Paterson AD, Walker SE, Endrenyi L, **Kashuba ADM**. Evaluation of the genetic component of variability in CYP3A4 activity: a repeat drug administration (RDA) method. *Pharmacogenetics* 2000;10(5):373-388.
222. Nafziger AN, Bertino JS, Goss-Bley AI, **Kashuba, ADM**. Sexual dysfunction on fluvoxamine therapy. *Journal of Clinical Psychiatry* 2000;61(1):62-63.
223. Pereira AS, **Kashuba ADM**, Fiscus SA, Hall JE, Tidwell RR, Troiani L, Dunn JA, Eron JJ Jr., Cohen MS. Nucleoside analogues achieve high concentrations in seminal

plasma: relationship between drug concentration and viral burden. *Journal of Infectious Diseases* 1999;180:2039-2043.

224. **Kashuba ADM**, Dyer J, Eron JJ, Kramer LM, Raasch RH, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. *Antimicrob Agents Chemother* 1999;43:1817-1826.
225. Nafziger AN, Bertino JS, Goss-Bley AI, **Kashuba, ADM**. Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction. *Journal of Clinical Psychiatry* 1999;60(12):867-868.
226. **Kashuba A.D.M.**, Nafziger A.N., Kearns G.L., Leeder J.S., Gotschall R, Rocci M.L., Kulawy R.W., Beck D.J., Bertino J.S., Jr. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. *Pharmacogenetics* 1999;9:453-462.
227. **Kashuba A.D.M.**, Nafziger A.N., Drusano G.L., Bertino Jr. J.S. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. *Antimicrob Agents Chemother* 1999;43:623-629.
228. **Kashuba ADM**, Bertino JS, Rocci ML et al. Quantification of intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP3A as measured by phenotyping with intravenous midazolam. *Clin Pharmacol Ther* 1998;64:269-77.
229. **Kashuba ADM**, Nafziger AN, Kearns, GL et al. Quantification of intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP2D6 as measured by dextromethorphan phenotyping. *Pharmacogenetics* 1998;8:403-410.
230. **Kashuba ADM**, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS Jr. Effect of fluvoxamine on the activities of CYP1A2, CYP2D6, and CYP3A, as determined by phenotyping. *Clin Pharmacol Ther* 1998;64:257-68.
231. **Kashuba ADM**, Bertino JS Jr, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response using individualized pharmacokinetic monitoring in gram-negative pneumonia. *Antimicrobial Agents and Chemotherapy* 1998;42(7):1842-45.
232. Nafziger AN, Bertino JS, GossBley AI; **Kashuba, ADM**. Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. *Journal of Clinical Psychiatry* 1999;60:187.
233. **Kashuba AD**, Bertino JS, Kearns GL, Leeder JS, James AW, Gotschall R, Nafziger AN. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. *Clin Pharmacol Ther.* 1998;63(5):540-551.
234. **Kashuba AD**, Bertino JS, Rocci ML, Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. *Clin Pharmacol Ther.* 1998;64(3):269-277.
235. **Kashuba ADM**, Bertino JS, Kearns, GL, et al. Quantification of long-term intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activities as determined by caffeine phenotyping. *Clin Pharmacol Ther* 1998;63:540-51.

236. Trepanier EF, Nafziger AN, Kearns GL, **Kashuba ADM**, Amsden GW. Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase. *J Clin Pharmacol* 1998;28:424-428.
237. **Kashuba ADM**, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. *Clinical Pharmacokinetics* 1998;34(3):203-218.
238. **Kashuba A.D.M.**, Amsden G., Bronchopulmonary Pharmacokinetics of Clarithromycin and Azithromycin. *Antimicrobial Agents and Chemotherapy* 1998;42(2):481-482.
239. **Kashuba A.D.M.**, Ballow C., Forrest A., Development of a Population Pharmacokinetic Model and Optimal Sampling Strategies for Intravenous Ceftazidime in the Critically Ill. *Antimicrobial Agents and Chemotherapy* 1996;40(8):1860-1865.
240. **Kashuba A.D.M.**, Ballow C., Legionella Urinary Antigen Testing: Potential Impact on Diagnosis and Antibiotic Therapy. *Diagnostic Microbiology and Infectious Disease* 1996;24(4):129-139.
241. **Kashuba A.D.M.**, Gee S., Lane G., Moy D. Inflammatory Bowel Disease: Advances in Therapy, *On Continuing Practice* 1992;19(4):21-26.

NON-REFEREED MANUSCRIPTS:

Dumond JB, Roland M, **Kashuba ADM**. Understanding Primary and Secondary HIV Prophylaxis – Part I: Non-occupational Post-Exposure Prophylaxis and Antiretroviral Pharmacokinetics in the Male and Female Genital Tract. *The PRN Notebook* 2006; 11(2):10-16.

WEB PAGES/ELECTRONIC MEDIA (CME/CPE Credit):

Garrett K, Pope R, **Kashuba A**. Hangouts with HIVE: **Pharmacokinetics of HIV Pre-exposure Prophylaxis**. HIVE (Bay Area Perinatal AIDS Center). University of California at San Francisco, National Webcast, April 12, 2016

Kashuba ADM. Clinical Pearl: Managing Drug-Drug Interactions in Aging HIV-Infected Patients. **Stay Tuned: Evolving Concepts in Antiretroviral Therapy Edition 6. Feb 2009.** <http://www.clinicaloptions.com/HIV/Treatment%20Updates/Stay%20Tuned/Volume%201%20Edition%206.aspx>

Kashuba, ADM. DHHS Guidelines for the Use of Antiretroviral Agents in Patients with HIV Infection. *in* Boosting Adherence and Managing Antiretroviral Drug Adverse Events: The Role of the Community Pharmacist. University of Tennessee Advanced Studies in Pharmacy. June 2008. (CPE Credit Program)
([http://www.utasip.com/template.cfm?TEMPLATE=include_programinfo.cfm&ID=85&ZoneID=8&TYPE=text&pageName=Volume%205,%20\(4\)%20Content](http://www.utasip.com/template.cfm?TEMPLATE=include_programinfo.cfm&ID=85&ZoneID=8&TYPE=text&pageName=Volume%205,%20(4)%20Content))

Kashuba, ADM. Use of Pharmacokinetic Enhancement in Antiretroviral Treatment-Experienced HIV Patients. Enduring CME Program from ICAAC 2005, Management of Treatment-Experienced Patients (<http://www.medscape.com/viewprogram/5036>)

Yeh R, Tappouni H, **Kashuba ADM**. Drug information: Delavirdine, Amprenavir, Atazanavir, Indinavir, Nelfinavir, Ritonavir, Didanosine, Zalcitabine, Zidovudine 2004-2005
(<http://clinicaloptions.com/hiv/drugs/>)

Park J and **Kashuba ADM**. Drug information: Abacavir, Tenofovir, Lopinavir/ritonavir. 2004
(<http://clinicaloptions.com/hiv/drugs/drugs.asp>)

Cohen MS and **Kashuba ADM**. Antiretroviral Drugs and the Prevention of Sexual Transmission of HIV. Medscape CME 2003.
(<http://www.medscape.com/viewprogram/2671?mpid=19123>)

Park J and **Kashuba ADM**. Drug information: Stavudine, Nevirapine, Saquinavir. 2003
(<http://clinicaloptions.com/hiv/drugs/drugs.asp>)

Lim M and **Kashuba ADM**. Ask the Experts on...Heroin-Antiretroviral Drug interactions
(<http://www.medscape.com/medscape/HIV/AskExperts/2001/12/AIDS-ae152.html>)

Corbett A and **Kashuba ADM**. Ask the Experts on...Treatment of Nelfinavir-Associated Diarrhea? 2001. (<http://www.medscape.com/medscape/HIV/AskExperts/2001/12/AIDS-ae152.html>)

Kashuba ADM. Ask the Experts on . . .Protocol for Routine Therapeutic Drug Monitoring? 2001. (<http://www.medscape.com/medscape/HIV/AskExperts/2001/06/AIDS-ae129.html>)

Kashuba ADM. Ask the Experts on . . . Interactions Between Bupropion and Antiretrovirals?
2001. (<http://www.medscape.com/medscape/HIV/AskExperts/2001/06/AIDS-ae128.html>)

Kashuba ADM. Ask the Experts on . . . Food Effects on Protease Inhibitor Bioavailability?
2001. (<http://www.medscape.com/medscape/HIV/AskExperts/2001/10/AIDS-ae142.html>)

SELECTED INVITED ORAL PRESENTATIONS (118 of 196):

1. *Are YOU on the pill? Developing prevention strategies for HIV infection.*
Invited Lecture, Voices of Discovery Series
Elon University
Elon, NC
September 17, 2019
2. *Pharmacologic Measures of Adherence: Pitfalls and Promises*
Invited Lecture, Antiretrovirals for Prevention Conference
Emory Center for AIDS Research
Atlanta, GA
January 28-30, 2019
3. *Pharmacokinetics/Pharmacodynamics in Drug Development and Implications for Adolescents*
Invited Lecture, 2nd International Workshop on HIV Adolescence: Challenges and Solutions
Cape Town, South Africa
October 10, 2018
4. *The Impact of Clinical Pharmacology In HIV Cure Research*
Invited Lecture, American Society of Clinical Pharmacology and Therapeutics
Orlando, FL
March 22, 2018
5. *The Evolution of Precision Medicine in HIV Infection*
School of Pharmacy, Annual Pharmacy Practice Seminar
Madison, WI
February 9, 2018
6. *The Power of Clinical Pharmacology to Influence a Field*
American College of Clinical Pharmacology Honorary Fellowship Lecture
San Diego, CA
September 19, 2017
7. *The Evolution of Precision Medicine in HIV Infection*
American College of Clinical Pharmacy Therapeutic Frontiers Lecture
Phoenix, AZ
October 8, 2017
8. *Does Pharmacology Support Topical PrEP?*
International AIDS Society Conference
Paris, France
July 23-26, 2017
9. *Does Pharmacology Support On Demand PrEP?*

International AIDS Society Conference
Paris, France
July 23-26, 2017

10. *Do Tissue Concentrations Matter in HIV Prevention and Eradication?*
3rd Coast Center for AIDS Research Seminar Series
Chicago, IL
February 23, 2017
11. *The Pharmacology of PrEP*
HIV Endgame Annual Conference
Toronto, Ontario, Canada
October 24, 2016
12. *Location, Location, Location: Antiretroviral Pharmacology and Tissue Delivery of Antiretrovirals*
HIV Research for Prevention Annual Meeting
Chicago, IL
October 18, 2016
13. *Target Drug Concentrations in Tissue: What Do We Know?*
International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy
Baltimore, MD
June 8-10, 2016
14. *Should Tissues be Targeted for Developing HIV Prevention Strategies?*
HIV Scientific Input Engagement Program
Merck and Company
May 26, 2016
15. *Clinical Research: Developing a Successful and Funded Program*
Annual Infectious Diseases Pharmacotherapy Fellowship Forum.
Aspen, CO
May 19-22, 2016
16. *Hangouts with HIVE: Pharmacokinetics of HIV Pre-exposure Prophylaxis.*
HIVE (Bay Area Perinatal AIDS Center)
University of California at San Francisco
National Webcast
April 12, 2016
17. *Getting The Drug To Where It Needs To Be: Pharmacokinetic/Pharmacodynamic Evidence for Pre-Exposure Prophylaxis*
Office of AIDS Research Advisory Council
National Institutes of Health Office of AIDS Research
Rockville, MD
April 7, 2016
18. *Assessing Pre-Exposure Prophylaxis Evidence*
Consultation on Alternative Drug Options for Pre-Exposure Prophylaxis
World Health Organization/UNAIDS
Geneva, Switzerland
March 21-22, 2016

19. *Worlds Colliding: When Preparation Meets Opportunity*
Inaugural Address, 1st Research in Education and Practice Symposium
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, NC
May 16, 2014
20. *Did We Put the Cart Before the Horse? Clinical Pharmacology Insights into HIV Prevention Trial Outcomes.*
27th International Conference on Antiviral research (ICAR)
Raleigh, NC
May 14, 2014
21. *Current and Future Approaches to Quantifying the Relationship Between Pharmacology and HIV Persistence*
6th International Workshop on HIV Persistence During Therapy
Miami, FL
December 5, 2013
22. *The Pharmacology of HIV Prevention: Where do we go next?*
CASE Seminar
Center for Drug Evaluation and Research, Food and Drug Administration:
Silver Spring, MD
November 20, 2013
23. *Antiretroviral Pharmacology in the Female Genital Tract*
Women's Interagency HIV Study Annual Meeting
Miami, FL
October 29, 2013
24. *The Pharmacology of HIV Prevention: Lessons Learned AND Reflections on training the next generation of translational scientists*
Department of Experimental and Clinical Pharmacology
College of Pharmacy, University of Minnesota
Minneapolis, MN
May 15, 2013
25. *Developing a Platform for Collaboration: The Influence of Clinical Pharmacology on HIV Prevention and Cure*
MD/PhD Program Seminar Series
UNC School of Medicine, Chapel Hill, NC
March 18, 2013
26. *Characterizing Mucosal Tissue Drug Penetration: Implications for HIV Prevention and Eradication*
GlaxoSmithKline HIV Discovery Performance Unit "HIV Day"
Research Triangle Park, NC
February 27, 2013
27. *Characterizing Drug Penetration into Tissues: Implications for HIV Eradication*
Martin Delaney Collaboratory for the Eradication of HIV Annual Meeting
NIAID, NIH
Washington, DC
November 30, 2012

28. *Development of a Mucosal Biopsy Challenge Model*
 Biopsy Challenge as a Clinical Pharmacodynamic Biomarker for Clinical Efficacy of
 HIV Prevention: Practical Applications
 NIH, NIAID, DAIDS, PSP, and The Bill and Melinda Gates Foundation
 November 29, 2012

29. *Clinical Pharmacology of Antiretrovirals at Mucosal Surfaces*
 NIH DAIDS Clinical Pharmacology Quality Assurance Program
 Cross Network Scientific Laboratory Group
 September 20, 2012

30. *Preclinical and Clinical Pharmacology of Antiretrovirals in HIV Prevention*
 Aaron Diamond AIDS Research Center
 New York, NY
 September 19, 2012

31. *Drug Exposure and Correlates of Oral and Topical ARV Protection*
 Microbicides and PrEP: Back to Basics Plenary
 International AIDS Conference
 Washington, DC
 July 22-27, 2012

32. *Penetration of Antiretrovirals into Tissue Compartments*
 HIV Eradication Think Tank
 AIDS Clinical Trials Group Annual Meeting
 Washington, DC
 July 18, 2012

33. *Pharmacologic Insights into HIV Prevention*
 HIV Global Therapeutic Expert Forum
 Philadelphia, PA
 May 1-2, 2012

34. *Pre-exposure Prophylaxis for HIV Prevention: Where Does the Field Currently Stand?*
 13th International Workshop on the Pharmacology of HIV Therapy
 Barcelona, Spain
 April 16-18, 2012

35. *HIV Prevention with Antiretrovirals: how to predict success?*
 Physician's Research Network
 New York, NY
 March 27, 2012

36. *Animal and Human Studies of PrEP and Vaginal Rings*
 Discussant, CROI Themed Discussion #32
 19th Conference on Retroviruses and Opportunistic Infections.
 Seattle, WA
 March 5-8 2012

37. *Sex Differences in HIV/AIDS: Biologic Perspectives*
 Emerging Issues AIDS 20/20: amfAR Consultation Meeting: Sex Differences in
 HIV/AIDS
 Bethesda, MD
 January 11, 2012

38. *A World Without AIDS: How UNC is Changing A Field*
UNC Eshelman School of Pharmacy Alumni Board
Chapel Hill, NC
January 7, 2012
39. *Protecting Women from HIV: How BIRCWH Transformed a Field*
Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Scholars Meeting, Office of Research on Women's Health, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD
November 16, 2011
40. *UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry (Major Program Initiatives Update)*
UNC Eshelman School of Pharmacy Board of Visitors Meeting
Chapel Hill, NC
November 17-18, 2011
41. *The Pharmacology of Mucosal Compartments: Current and Planned PK/PD Studies*
WHO NIH Working Group Meeting
ART as HIV Prevention for MSM:What Additional Evidence is Required?
Geneva, Switzerland
October 26-27, 2011
42. *Pharmacokinetics and Pharmacodynamics of Antiretrovirals in HIV Prevention*
NIH Think Tank on Clinical Pharmacology of HIV Prevention
Washington, DC
August 8, 2011
43. *PrEP: Does formulation impact drug concentrations in different compartments? Implications for preventing HIV infection*
HIV Prevention Trials Network Annual Meeting Plenary
Washington, DC
June 8, 2011
44. *Genetic Barriers in Sanctuary Sites*
HIV Genetic Barrier Expert Consultation
Dallas, TX
June 6, 2011
45. *CAPRISA 004, iPrEX, and FEM PrEP: What have they taught us about antiretrovirals?*
HIV Care 2011: Trends in Clinical Care, Caring for Vulnerable Populations
Chapel Hill, NC
May 2, 2011
46. *Antiretroviral Pharmacokinetics and Pharmacodynamics in HIV Prevention*
Europrise International Prevention Meeting: Understanding How Adherence and Biology Influence Effectiveness
London, England
May 3-4, 2011
47. *HIV and Sanctuary Sites*
Collaborative Institute of Virology, Clinical Pharmacology Panel

Miami, FL
April 12, 2011

48. *Pharmacokinetics of Oral HIV Prevention Strategies*
Gilead Sciences HIV Medical Affairs Advisory Program on PrEP
Foster City, CA
March 24-25, 2011
49. *The Pharmacology of HIV Prevention: What Have We Learned in 2010?*
Grand Rounds
National Institutes of Allergy and Infectious Diseases
National Institute of Health Clinical Center
January 14, 2011
50. *Drug Exposure in Women: What's Important?*
1st International Workshop on HIV In Women: From Adolescence through
Menopause
Washington, DC
January 10-11, 2011
51. *Pharmacokinetic Evaluations in Humans*
Workshop on Optimization of Preclinical Methods for Improved Prioritization and
Advancement of Lead Microbicide Candidates
Division of AIDS, National Institute of Allergy and Infectious Diseases
National Institute of Health, Bethesda, MD
December 11-12, 2010
52. *CAPRISA 004 The First Successful HIV Microbicide: Why it Worked (and iPrEX too!)*
World AIDS Day Scientific Session
UNC Chapel Hill School of Medicine
December 1, 2010
53. *The Pharmacology of HIV Prevention: What Have We Learned from CAPRISA 004?*
Grand Rounds
Division of AIDS, National Institute of Allergy and Infectious Diseases
National Institute of Health, Bethesda, MD
November 12, 2010
54. *Role of Antiretroviral Medications in HIV Prevention*
Regional Child and Adolescent Health Meeting
Durham, NC
November 5, 2010
55. *Semen and Cervicovaginal Fluid Studies*
Penetration of Anti-Infective Agents
55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Boston, MA
September 12-15, 2010
56. *ARV Prevention of HIV: Compartment-Specific Pharmacokinetics of Oral and Topical Antiretrovirals*
5th International Workshop on HIV Transmission – Principles of Intervention
Vienna, Austria
July 15-16, 2010

57. *A Tale of 2 Compartments: Pharmacology of Antiretrovirals in Cervical, Vaginal, and Rectal Tissue*
Microbicides 2010
Pittsburgh, PA
May 23-26, 2010
58. *Meet the Experts*
American Society for Clinical Pharmacology and Therapeutics
111th Annual Meeting
Atlanta, GA
March 17-20, 2010
59. *Compartmental Pharmacokinetics of Antiretrovirals for HIV Prevention*
Consultation on the Implications of PrEP Trial Results
NIH – NIAID, NIH Campus
Bethesda, MD
January 29, 2010
60. *Pharmacokinetic-Pharmacodynamic Relationships in Human and Animal PrEP Models*
Beyond 2010: “Gaps, Challenges, and Priorities for the Future of Preclinical PrEP
Meeting (NIH, NIAID, DAIDS)
Bethesda, MD
October 21-22, 2009
61. *Surrogate Markers for PrEP: Bridging Between Animal and Human Studies*
PrEP Science Discussion
AVAC: Global Advocacy for HIV Prevention
Arlington, VA
September 9, 2009
62. *Pharmacokinetics-Pharmacodynamics of Antiretroviral Agents*
Meet the Experts
49th Interscience Conference on Antimicrobial Agents and Chemotherapy
San Francisco, CA
September 13, 2009
63. *The Pharmacology of Aging*
UNC Annual Regional HIV Update
Friday Center, UNC-CH
Chapel Hill, NC
May 4, 2009
64. *Drug Interactions of HIV Therapy*
HIV Update 2009
Oslo, Norway
April 20, 2009
65. *HIV Prevention in Women: Will Drugs Work?*
World AIDS Day Conference
UNC Chapel Hill
Chapel Hill, NC
December 1, 2008

66. *Antiretroviral Pharmacology in the Genital Tract*
Expert Consultation on the Effect of Antiretroviral Therapy on the Risk of Sexual
Transmission of HIV Infection and Superinfection
Centers for Disease Control and Prevention
Atlanta, GA
October 23, 2008
67. *The Pharmacology of HIV Prevention: What Drugs Will Work?*
Infectious Diseases Conference
Center for Infectious Diseases
UNC-CH
Chapel Hill, NC
September 12, 2008
68. *Clinical Pharmacology of Antiretroviral Therapy in Women: How Much Do We Know?*
Invited Presentation, International AIDS Society Industry Liaison Forum
15th Conference on Retroviruses and Opportunistic Infections
Boston, MA
February 2008
69. *Genital Compartmentalization of Orally and Topically Administered Antiretrovirals*
Invited Presentation, 15th Conference on Retroviruses and Opportunistic Infections
(Abstr 95)
Boston, MA
February 2008
70. *Pharmacokinetics of Antiretroviral Drugs in the Female Genital Tract: Implications for
HIV PrEP and PEP*
Invited Presentation
South Africa CAPRISA
Durban, South Africa
October 2007
71. *Optimal Design of Drug Interaction Studies*
Invited Roundtable Discussant, 8th Annual International Workshop on Clinical
Pharmacology in HIV Therapy
Budapest, Hungary
April 2007
72. *Phenotyping for Drug Interactions: Cocktails Anyone?*
Invited Presentation, 14th Conference on Retroviruses and Opportunistic Infections
(Abstr 50)
Los Angeles, CA
Feb 2007
73. *"Genital Tract Pharmacokinetics of Antiretroviral Drugs: Implications for HIV Pre- and
Post-Exposure Prophylaxis".*
Grand Rounds
Albany Medical Center, Albany, NY
May 2006
74. *"The Drugs, The Doses, The Interactions"*
UNC Annual Regional HIV Update
Friday Center, UNC-CH

Chapel Hill, NC
May 1, 2006

75. *"Genital Tract Pharmacokinetics of Antiretroviral Drugs: Implications for HIV Pre- and Post-Exposure Prophylaxis"*.
HIV Physician's Research Network (PRN)
New York, NY
March 2006
76. *"The Role of Antiretroviral Pharmacology in Preventing the Sexual Transmission of HIV"*
Infectious Diseases Conference
Center for Infectious Diseases
UNC-CH
Chapel Hill, NC
March 17, 2007
77. *"Antiretroviral Pharmacology for Pre-exposure Prophylaxis"*
International AIDS Society Industry Liaison Forum
Denver, CO
February 2006
78. *"Use of Pharmacokinetic Enhancement in Treatment Experienced Patients"*
Management of Treatment-Experienced HIV-Infected Patients
CME Satellite Symposium
Interscience Conference on Antimicrobial Agents and Chemotherapy
December 2005
79. *"Pharmacologic Complexities in the Treatment of HIV"*
Management of HIV Disease, International AIDS Society
Los Angeles, CA, and New York, NY
April and October 2005
80. *"Drug Interactions"*
Treatment and Management of HIV Infection in the United States
US HIV Conference
Atlanta, GA
September 2005
81. *"Navigating the Concentration Curves: Pharmacologic Considerations in the Treatment of HIV"*
Continuing Education Program for HIV Practitioners
Teleconference Program 2005
On-Site Program Boston MA
Atlanta GA, Dallas TX
2005
82. *"Pharmacokinetics of Systemically Administered Antiretroviral Drugs in Compartments Relevant to Sexual Transmission:"*
Novel Pharmacokinetic Methods for Developing HIV Chemoprevention Strategies
Symposium
American Society of Clinical Pharmacology and Therapeutics Annual Meeting
Orlando, FL
March 2005
83. *"Clinically Important Antiretroviral Drug Interactions"*
HIV CARE 2004

UNC – CH Infectious Diseases Symposium
May 2004

84. *"The Genital Tract as a Sanctuary Site for HIV"*
First International Workshop on HIV Persistence During Therapy
St. Martin, FWI
2003
85. *"Pharmacogenomics: The New Frontier of Pharmacy".*
Pennsylvania Society of Health Systems Pharmacists Annual Assembly
Champion, PA
2003
86. *"AIDS Blunts Treatments and Laughs at Vaccines": The Future of HIV Prevention Research*
Grand Rounds, Bassett Healthcare,
Cooperstown, NY
2003
87. *How Should Phenotyping Biomarkers Be Validated?*
INVITOX 2002 Annual Meeting
Formia, Italy
2002
88. *Understanding and Predicting Antiviral Drug Interactions*
Infectious Diseases Society of America, Annual Meeting
Chicago, IL
2002
89. *Can Antiretroviral Therapy Be Used to Prevent Sexual Transmission of HIV-1?*
GlaxoSmithKline Seminar Series
RTP, NC
June 2002
90. *Pharmacokinetics of Antiretroviral Therapy in Genital Secretions*
HAART and Prevention of HIV Transmission
Atlanta, GA
June 2002
91. *Virology and Pharmacology in the Male and Female Genital Tract*
The Importance of Antiretroviral Drugs to Penetrate Viral Reservoirs, Forum for
Collaborative HIV Research, George Washington University
Washington, DC
April 2002.
92. *Antiretroviral Pharmacology in the Genital Tract: Can We Affect HIV Transmission?*
Women's Health Research Day
UNC Chapel Hill
March 2002

93. *Beneficial Antimicrobial Drug Interactions: Taking Advantage of New Insights into Clinical Pharmacology. Metabolism interactions to improve systemic exposure.*
41st Interscience Conference on Antimicrobial Agents and Chemotherapy
Chicago, IL
December 2001
94. *How Should Phenotyping Biomarkers Be Validated?*
International Society for the Study of Xenobiotics, 6th International Meeting
Munich, Germany
October 2001
95. *Romancing the Genome: Clinical Pharmacogenetics*
Annual Meeting, New York State Chapter, American College of Clinical Pharmacy,
Syracuse, NY
June 2001
96. *Romancing the Genome: How Genes Can Tailor Your Drugs*
UNC Chapel Hill School of Medicine "Mini-Med School"
Chapel Hill, NC
March 2001
97. *The Effect of Cytokines and Endotoxins on Drug Metabolism and the Relevance to HIV Infected Patients*
American Society for Clinical Pharmacology and Therapeutics Annual Meeting
Orlando, FL
March 2001
98. *Pharmacotherapy of Influenza Virus*
American College of Clinical Pharmacy Annual Meeting
Los Angeles, CA
November 2000
99. *Understanding And Predicting Drug-Cytokine Interactions*
"Drug-Drug Interactions" Conference, Barnett International
October 2000
100. *Intra- and Interindividual Variability in Cytochrome P450 Activity: The Influence of Cytokines On Antiretroviral Pharmacokinetics and Possible Failure In HIV-1 Infection*
University of Toronto Department of Pharmacology Seminar Series
Toronto, Ontario, Canada
May 2000
101. *Pharmacogenetics and HIV: Special Considerations in Women*
Emerging Treatment Strategies for Patients with Human Immunodeficiency Virus Infection, State University of New York at Buffalo HIV Symposium
Buffalo, NY
February 2000
102. *CYP3A and P-glycoprotein: Implications for Absorption and Viral Reservoir Distribution of Protease Inhibitors*
UNC Center for AIDS Research Clinical Core Collaborative Research Seminar
Chapel Hill, NC
April 2000

103. *Understanding and Predicting Drug Interactions of the Cytochrome P450 Enzyme System*
Anesthesiology Conference. School of Medicine. UNC-Chapel Hill
Chapel Hill, NC
November 1999
- UNC Center for Infectious Diseases Conference. UNC-Chapel Hill
Chapel Hill, NC
November 1999
104. *Pharmacogenetics of Antiretroviral Therapy*
UNC School of Pharmacy Division of Drug Delivery and Disposition Seminar Series,
September 1999
- New York State Society of Infectious Diseases Pharmacists Annual Meeting,
Syracuse, NY, September 1999.
105. *Pharmacokinetics and Pharmacodynamics of Antiretroviral Agents.*
Infectious Diseases Conference, School of Medicine, UNC-Chapel Hill
Chapel Hill, NC
June 1999
106. *Advances in the Treatment of HIV.* Session Moderator,
American Society of Health Systems Pharmacists, Annual Meeting
Reno, NV
1999
107. *Inflammation, Cytokine Networks, and Drug Metabolism: Experimental and Clinical Findings.*
Breaking Issues Symposium Presentation, American Society of Health Systems
Pharmacists Annual Midyear Clinical Meeting
Las Vegas, NV
1998
108. *HIV: Review of New Guidelines.*
Making a Difference: Trends in Infectious Diseases Pharmacotherapy,
Annual Conference.
Orlando, FL
May 1998
109. *The New Macrolides: Are the Differences Real?*
Scientific Exhibits. Sponsored by Pfizer.
American College of Physicians, Annual Meeting 1997 - 1999
American Society of Health Systems Pharmacists, Midyear Clinical Meeting 1998 -
Present
American Society of Health Systems Pharmacists, Annual Meeting 1998 - Present
110. *Drug Interactions and the Cytochrome P450 Enzyme System,*
Departments of Pharmacy and Infectious Diseases, Audey Murphy VA Hospital
San Antonio, TX
1997
111. *Genetics, Environment, Drug Efficacy, and Side Effects: You Can't Pick Your Parents.*

Medical Grand Rounds, Bassett Healthcare, Cooperstown, New York, 1996.

New York State Council of Health-System Pharmacists: Leatherstocking Chapter
Continuing Education Seminar, 1996

112. *Development of a Population Pharmacokinetic Model and Optimal Sampling Strategies for Intravenous Ceftazidime in the Critically Ill*

Platform Presentation, New York State Clinical Pharmacists Infectious Diseases
Group Annual Meeting, Syracuse, NY, 1995.

Research Defense, Department of Pharmacy Practice, State University of New York
at Buffalo, Amherst, NY, 1995.

113. *Chronic Obstructive Pulmonary Disease*,
Fourth Year Pharmacy Student Lecture, Department of Pharmacy Practice
State University of New York at Buffalo
Amherst, NY
1995

114. *The Use of Itraconazole in the Treatment of Aspergillosis*,
Doctor of Pharmacy Seminar, Department of Pharmacy Practice
State University of New York at Buffalo
Amherst, NY
1994

115. *Overcoming Drug Resistance in Oncology*,
Doctor of Pharmacy Seminar, Department of Pharmacy Practice
State University of New York at Buffalo
Amherst, NY
1994

116. *Inflammatory Bowel Disease: Advances in Therapy*,
Toronto Intra-City Hospital Rounds, Mount Sinai Hospital
Toronto, Ontario
1992

117. *Ethics and Biotechnology*, Fourth Year Pharmacy Student Lecture,
University of Toronto, Faculty of Pharmacy
Toronto, Ontario
1992

118. *Comparison of Two Vancomycin Dosing Guidelines for Use in the Neonatal Intensive
Care Unit: A Focus on Serum Concentrations and Cost Effectiveness*,
Ontario Pharmacy Residency Meeting, Mount Sinai Hospital
Toronto, Ontario
1991

REFEREED SCIENTIFIC ABTRACTS (227):

1. Anderson DJC, Prince HMA, Polisen A, Moody K, Saunders A, Sykes C, Schauer AP, Van Horne B, Mollan KR, Hudgens MG, **Kashuba ADM**. An Exploration of Adherence Measures to Detect Recent Changes in Truvada® Dosing Patterns. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. Oral abstract presentation. May 14-16, 2019. Noordwijk, NL.
2. Devanathan AS, Fallon JK, White N, Schauer AP, Blake K, Sykes C, Adamson L, Luciw P, Garcia JV, Akkina R, Pirone JR, Smith PC, **Kashuba ADM**. Antiretroviral penetration and drug transporter concentrations in the spleens of three preclinical animal models and humans. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, NL.
3. Schauer A, Sykes C, **Kashuba ADM**. When a Dried Sample Isn't Dry: How Different Sample Handling Procedures Between the Clinic and the Analytical Laboratory Can Impact Drug Quantification. 71st Annual Meeting, American Association for Clinical Chemistry. August 4-8, 2019, Anaheim, CA.
4. Handy K, Pirone J, Schauer A, Bryan H, Sykes C, Prince H, Polisen A, **Kashuba ADM**. Comparison of Human Whole Blood Dolutegravir Concentrations Collected on Dried Blood Spot Cards versus Mitra® Microsampling Devices. 71st Annual Meeting, American Association for Clinical Chemistry. August 4-8, 2019, Anaheim, CA.
5. Schauer A, Sykes C, Pirone J, White N, Bryan H, Prince H, Polisen A, **Kashuba ADM**. A Comparison of Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations Collected in Whole Blood by a Microsampler or Dried Blood Spot. ASMS Conference on Mass Spectrometry and Allied Topics, June 2 - 6, 2019, Atlanta, GA.
6. Garrard KP, Ekelöf M, Khodjanizyazova S, Bagley MC, Rosen EP, Gilliland WM, **Kashuba AD**, Muddiman DC. RastirX: A versatile platform for imaging arbitrary spatial patterns. Abstract ID number: 297204. ASMS Conference on Mass Spectrometry and Allied Topics, June 2 - 6, 2019, Atlanta, GA.
7. Mitchell, J. T., McLaurin, T., Frye, J., McKellar, M. S., Satapathy, G., Cottrell, M., **Kashuba, ADM**, LeGrand, S, McClernon, FJ, Parker, S, and Okeke, NL. Development of a mobile contingency management intervention for PrEP adherence among young black men who have sex with men. National HIV Prevention Conference, March 2019, Atlanta, GA.
8. Schauer A, Sykes C, Pirone JR, Blake K, Bryan H, **Kashuba ADM**. Comparison of Human Whole Blood Maraviroc Concentrations Collected on Dried Blood Spot Cards versus Mitra® Microsampling Devices. Poster 35A. MSACL. Mass Spectrometry: Applications to the Clinical Lab 2019. Palm Springs, CA.
9. Pirone JR, Akkina RK, Garcia-Martinez JV, Luciw P, Adamson L, Sykes C, White N, Schauer A, Blake KH, Burgunder EM, Devanathan AS, Srinivas N, Rosen E, **Kashuba ADM**. 2019 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle, WA.
10. Rosen E, Deleage C, Fedoriw Y, Estes JD, **Kashuba ADM**. A Quantitative Approach to Evaluate ARV Proximity to Virus and Cells in Lymph Nodes. Poster ID 2395. 2019 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle, WA.

11. Mitchel JT, McLaurin T, Frye J, McKellar MS, Satapathy G, Cottrell M, **Kashuba ADM**, LeGrand S, McClernon FJ, Parker S, Okeke NL. Development of a Mobile Contingency Management Intervention for PrEP Adherence among Young Black Men who have Sex with Men. Abstract ID 5854, Oral Presentation. 2019 National HIV Prevention Conference (NHPC). March 18-21, 2019 Atlanta, GA.
12. Gilliland WM, Jr., Asher Prince H, Poliseno A, Gandhi M, **Kashuba ADM**, Rosen EP. IR-MALDESI Mass Spectrometry Imaging of Maraviroc in Hair for Long-Term Adherence Monitoring. Imaging Mass Spectrometry Society II & OURCON VI Joint Meeting. November 11-14, 2018 Charleston, SC.
13. Hill, LM, Golin CE, Pack A, Carda-Auten J, Wallace DD, Cherjur S, Farel CE, Rosen EP, Gandhi M, Asher Prince HM, **Kashuba ADM**. Using real-time adherence feedback to enhance communication about adherence to antiretroviral therapy; Patient and provider perspectives. Poster 144. 13th International Conference on HIV Treatment and Prevention Adherence. June 8-10, 2018.
Selected as one of the Top 15 Meeting Posters, and Featured on TheBody.com
14. Ekelöf M, Garrard KP, Rosen EP, **Kashuba ADM**, Muddiman DC. Evaluation of Digital Image Recognition Methods for Mass Spectrometry Imaging Data Analysis. ASMS Conference on Mass Spectrometry and Allied Topics. June 3-7, 2018. San Diego, CA.
15. Schauer A, Sykes C, Benhabbour R, Cottrell ML, **Kashuba ADM**. An LC-MS/MS Method for the Quantification of the Endogenous Steroid Progesterone in Mouse Plasma Using the Surrogate Analyte Approach. ASMS Conference on Mass Spectrometry and Allied Topics. June 3-7, 2018. San Diego, CA.
16. Gilliland, WM Jr., Moody K, Poliseno A, Prince HA, Gandhi M, Muddiman DC, **Kashuba ADM**, Rosen EP. Developing IR-MALDESI Mass Spectrometry Imaging of HIV Medications in Hair as a Clinical Tool for Measuring Patient Adherence ASMS Conference on Mass Spectrometry and Allied Topics. June 3-7, 2018. San Diego, CA.
17. Srinivas N, Cottrell M, White N, Sykes C, Prince H, Gonzalez D, **Kashuba AD**. Development and Application of a Population Pharmacokinetic Model of Maraviroc to Predict HIV Pre-Exposure Prophylaxis Efficacy in Mucosal Tissues. ASCPT 2018 Annual Meeting, March 21-24, 2018. Orlando, FL.
18. Srinivas N, Rosen E, Cruz GD, Sykes C, Schauer A, Adamson L, Luciw P, **Kashuba A**. Mapping the Distribution of Efavirenz with Brain Tissue Cells. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7 2018, Boston, MA
19. Melody K, Kline C, Cottrell M, Keele B, **Kashuba A**, Bility M. RPV LA Does not Inhibit Resistant HIV Transmission or Select Significant Resistance. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7 2018, Boston, MA
20. Imaz A, Niubo J, Cottrell M, Perez E, **Kashuba A**, Tiraboschi J, Morenilla S, Garcia B, Podzamczar D. Seminal Tenofovir Concentrations, Viral Suppression and Semen Quality with TAF VS TDF. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7 2018, Boston, MA
21. Price J, Vwalika B, Winston J, Kasaro M, Mwape H, Chi B, Stringer E, Freeman B, Gravett C, Rittenhouse K, Njobvu L, Nelson J, **Kashuba A**, Stringer J. Preconceptional ART and Spontaneous Preterm Birth in an Urban Zambian Cohort. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7 2018, Boston, MA

22. Rosen E, Deleage C, White N, Sykes C, Adamson L, Fedoriw Y, Estes JD, Luciw P, **Kashuba ADM**. Mass Spec Imaging Reveals Associations Between ARVs, Virus and Cells in Lymph Nodes. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7 2018, Boston, MA
23. Burgunder E, Fallon J, White N, Schauer A, Sykes C, Adamson L, Pirone J, Luciw P, Smith P, **Kashuba A**. Effect of Sex, SHIV, and Drug Transporters on Lymph Node Antiretroviral Penetration. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7 2018, Boston, MA
24. Aguirre A, Mehta C, Hussen SA, Ofotokun I, Greenblatt R, Merenstein D, **Kashuba A**, Anastos K, Kempf MC, Golub ET, DeHovitz J, Cohen MH, Weiser S, Sheth AN. Persistent Low-Level Viremia is Associated with Low Protease Inhibitor Levels in Hair. 2018 Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7 2018, Boston, MA
25. Bokhart MT, Garrard K, Rosen E, Thompson C, Sykes S, **Kashuba ADM**, Manni J, Muddiman DC. A Quantitative Mass Spectrometry Imaging Workflow using IR-MALDESI and MSiReader. Eastern Analytical Symposium. Princeton NJ November 13-15 2017.
26. Pack A, Golin C, Carda-Auten J, Cherkur S, Farel C, Rosen E, Gandhi M, Prince H, Barley K, **Kashuba A**. Patient acceptability of obtaining near real-time feedback on antiretroviral (ART) adherence using mass spectrometry imaging of hair samples: A formative sub-study for the ENLIGHTEN (Establishing Novel antiretroviral ImaginG for Hair to Elucidate Nonadherence) Project. Oral presentation. American Public Health Association Annual Meeting & Expo. Atlanta, GA. November 4-8, 2017.
27. Greene SA, Garrett K, Prince H, Chen J, Maas B, Maffuid K, Sykes C, Schauer A, Gay C, **Kashuba ADM**, Cohen M, Dumond J. Population Pharmacokinetics of Tenofovir (TFV) and Tenofovir Diphosphate (TFVdp) in the Blood, Semen, and Mononuclear Cells of HIV-Negative and Positive Men Receiving Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF). American Conference on Pharmacometrics, October 15-18, 2017. Ft. Lauderdale, FL.
28. Garrett K, Maas B, Cottrell M, Prince H, Sykes C, Schauer A, White N, Dumond J, **Kashuba ADM**. Tenofovir Alafenamide (TAF) for HIV Prevention in IV Drug Users. American Conference on Pharmacometrics, October 15-18, 2017. Ft. Lauderdale, FL.
29. Pack A, Golin C, Carda-Auten J, Cherkur S, Farel C, Rosen E, Gandhi M, Prince H, Barley K, **Kashuba ADM**. Patient perspectives: Preliminary results from the formative sub-study of the Establishing Novel Antiretroviral ImaginG for Hair to Elucidate Nonadherence (ENLIGHTEN) Project. 12th International Conference on HIV Treatment and Prevention Adherence. June 4-6, 2017. Miami Beach, FL.
30. Cherkur S, Golin C, Carda-Auten J, Pack A, Farel C, Rosen E, Gandhi M, Prince H, Barley K, **Kashuba ADM**. Provider perceptions of using mass spectrometry imaging of hair to manage antiretroviral adherence: a formative sub-study for the Establishing Novel Antiretroviral ImaginG for Hair to Elucidate Nonadherence (ENLIGHTEN) Project. 12th International Conference on HIV Treatment and Prevention Adherence. June 4-6, 2017. Miami Beach, FL.
31. Srinivas N, Fallon J, Sykes C, White N, Schauer A, Matthews M, Adamson L, Luciw P, Smith P, **Kashuba ADM**. SHIV infection and drug transporters influence brain tissue concentrations of efavirenz. *Platform Presentation* 9th International AIDS Society Conference on HIV Science. July 23-26, 2017, Paris, France.

Winner: IAS/ANRS Lange-van Tongeren Young Investigator Prize

32. Thompson CG, Prince HA, Rosen E, Sykes C, Mathews M, Arora S, Dellon E, Peery A, Shaheen N, Gay C, Luciw PA, Akkina R, Garcia JV, Smith PC, **Kashuba ADM**. Differential Antiretroviral Localization and Drug Transporter Expression Within Gut-Associated Lymphoid Tissue of HIV+ Subjects: Comparison to Pre-Clinical Species. 9th International AIDS Society Conference on HIV Science. July 23-26, 2017, Paris, France.
33. Garrett K, Mann S, Sainz Costa T, Serrano Villa S, Garcia J-C, Troia-Cancio P, Li X-D, Pollard R, **Kashuba A**, Asmuth D. Exposure of Darunavir (DRV), Ritonavir (RTV), Emtricitabine (FTC), and Tenofovir (TFV) in Duodenal Tissue: Implications for Gastrointestinal (GI) Immune Reconstitution Among HIV-infected Patients Undergoing Antiretroviral Treatment. 9th International AIDS Society Conference on HIV Science. July 23-26, 2017, Paris, France.
34. Rosen E, White N, Sykes C, Adamson L, Mathews M, Fedoriw Y, Luciw P, **Kashuba ADM**. Panobinostat Distribution in Rhesus Macaque Lymph Nodes Following Anti-latency Therapy. 9th International AIDS Society Conference on HIV Science. July 23-26, 2017, Paris, France.
35. Rosen E, Deleage C, White N, Sykes C, Mathews M, Fedoriw G, Estes J, Luciw P, **Kashuba ADM**. Imaging Modalities to Evaluate the Spatial Distributions of SHIV and Antiretroviral Therapies in Putative Viral Reservoirs. 65th American Society for Mass Spectrometry Conference, June 4-8, 2017, Indianapolis, Indiana.
36. Sykes C, Schauer, A, Prince, H, Cottrell, M, **Kashuba, AD**. Validation of an LC-MS/MS Assay to Monitor Adherence of Subjects on Antiretroviral Therapy Using Dried Blood Spots. 65th American Society for Mass Spectrometry Conference, June 4-8, 2017, Indianapolis, Indiana.
37. Thompson CG, Rosen EP, Matthews M, White N, Sykes C, Fedoriw Y, Charlins P, Mulder L, Kovorova M, Adamson L, Muddiman DC, Akkina R, Garcia V, Luciw P, **Kashuba ADM**. Imaging antiretroviral distribution within gastrointestinal tissues across pre-clinical species: implications for HIV eradication. Poster and Young Investigator Award; American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 15-18 2017, Washington DC.
38. Sulggi L, Hatano H, **Kashuba ADM**, Cottrell ML, Liegler T, Stephenson S, Somsouk M, Hunt PW, Deeks SG, Savic RM. Integrase and protease inhibitor concentrations in lymphoid vs GI tissues. Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, Washington.
39. McKinnon L, Leibenberg L, Yende N, Masson L, **Kashuba ADM**, Archary D, Abdool Karim Q, Abdool Karim S, Passmore JA. Mucosal inflammation abrogates tenofovir gel-mediated protection from HIV infection. Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, Washington.
40. Dumond JB, Greene SA, Asher Prince HM, Chen J, Mass B, Sykes C, Schauer A, Gay CL, **Kashuba ADM**, Cohen MS. Extra/intracellular nucleoside/tide semen pharmacology; implications for eradication. Themed Discussion. Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, Washington.
41. Sykes C, Schauer A, Cottrell ML, **Kashuba ADM**. Method Validation for the Simultaneous Quantification of Three Antiretroviral Drugs in Human Plasma Using LC-

MS/MS Over a 10,000 Fold Calibration Range. Mass Spectrometry: Applications to the Clinical Lab 9th Annual Meeting. Jan 22-26 2017, Palm Springs CA.

42. Rosen E, Thompson C, White C, Sykes C, Adamson L, Mathews M, Fedoriw Y, Luciw P, Kashuba ADM. Biodistribution of Antiretroviral Therapies within the Ovaries and Testes of Rhesus Macaques. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
43. Cottrell ML, Chen J, Maas BM, Prince HMA, Sykes C, White N, **Kashuba ADM**, Dumond JL. A PK/PD Model to Predict Effective HIV PrEP Dosing Strategies for IV Drug Users. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
44. Leal L, Guardo AC, Bedoya LM, Climent N, Llach J, Plana M, Alcamí J, **Kashuba ADM**, Gatell JM, Garcia F. PK, Ex-vivo Efficacy on HIV Infectivity and Effect on Immune System of Maraviroc, raltegravir and Ritonavir-boosted Lopinavir in MSM on PEP. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
45. Melody K, Kline C, Cottrell M, Bility M, **Kashuba A**, Ambrose Z. Vaginal Transmission of WT or Resistant HIV-1 Was Not Inhibited by Long Acting Rilpivirine at High Plasma and Genital Concentrations in BLT Mice. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
46. Schwartz J, Justman J, van der Straten A, Smith-McCune K, Littlefield S, Sykes C, Linton K, Kashuba A, Doncel G. In Vivo Drug-drug Interactions Between Tenofovir Gel and Three Commonly Used Vaginal Products. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
47. Nicol M, Brewster L, **Kashuba A**, Sykes C. Role of Menopause in Tenofovir and Emtricitabine Disposition and Efficacy in Cervicovaginal Explants with Ex Vivo HIV Challenge. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
48. Massud I, Sykes DC, Cong ME, Ellis S, Kelley K, Heneine W, **Kashuba ADM**, Garcia-Lerma JG. Pharmacokinetic Profile of Lamivudine (3TC) in Macaques and Relative Drug Exposure in Rectal and Vaginal Tissues. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
49. Corbin G, Thompson, Elias P, Rosen, Michelle Mathews, Nicole White, Craig Sykes, Yuri Fedoriw, Paige Charlins, Leila Mulder, Martina Kovarova, Lourdes Adamson, David C Muddiman, Ramesh Akkina, Victor Garcia, Paul Luciw, Angela DM Kashuba Massud I, Sykes C, Cong M, Ellis S, Kelley K, Heneine W, **Kashuba ADM**, Garcia-Lerma JG. Pharmacokinetic profile of lamivudine (3TC) in macaques and relative drug exposure in rectal and vaginal tissues. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.
50. Norris AM, Emerson CW, Thompson CG, Fallon JK, Charlins P, Mulder L, Kovarova M, Adamson L, Luciw P, Garcia JV, Akkina R, Smith PC, **Kashuba ADM**. Differential Drug Transporter Expression in the Female Genital Tract of Animal Models for HIV

Prevention. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago, IL, October 17-20 2016.

51. Thurman AR, Kimble T, Yousefieh N, Anderson S, **Kashuba ADM**, Sykes C, Linton K, Schwartz J, Doncel GF. Pharmacokinetic analysis of tenofovir gel use in pre versus postmenopausal women. HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Chicago IL, October 17-20. 2016
52. Garrett KL, Cottrell ML, Prince HMA, Sykes C, Schauer A, Peery A, Rooney JF, McCallister S, Gay C, **Kashuba ADM**. Concentrations of TFV and TFVdp in Female Mucosal Tissues After a Single Dose of TAF. Oral Presentation; Late Breaker; 16LB-3063 Conference on Retroviruses and Opportunistic Infections. February 22-25 2016. Boston, MA.
53. Nicol MR, Brewers L, **Kashuba ADM**, Sykes C. Reduced activation of emtricitabine and tenofovir in cervical and vaginal explants from post-menopausal donors. Abst#O_05. Oral Presentation. 6th International Workshop on HIV & Women. 21 – 22 February 2015, Seattle, WA, USA.
54. Khandelwal P, Fukuda T, **Kashuba ADM**, Teusink A, Vourvahis M, Bleesing J. Phase 1 Study of Maraviroc As Acute Graft-Versus-Host Disease Prophylaxis in Pediatrics. American Society for Blood and Marrow Transplantation. BMT Tandem Meetings, 2/18/16-2/22/16. Honolulu, Hawaii.
55. Joseph SB, Kincer L, Bowman NM, Yosief S, **Kashuba AD**, Robertson KR, Spudich S, Eron JJ, Price RW, Swanstrom R. Persistent HIV-1 in the CNS during therapy: evidence of a viral reservoir in the CNS. Conference on Retroviruses and Opportunistic Infections. February 22-25 2016. Boston, MA.
56. Gay CL, Willis S, Duruc JD, Mcgee KS, McKellar M, Hickey CB, **Kashuba ADM**, Eron J, Margolis DM, Robertson K. Neurocognitive improvement with NRTI-Sparing Treatment in Acute HIV-Infection. Conference on Retroviruses and Opportunistic Infections. February 22-25 2016. Boston, MA.
57. Mirochnick M, Best B, **Kashuba A**, Sykes C, Schauer A, Wang J, Steck A, Smith E, Chakhtoura N, Capparelli E. Rilpivirine Female Genital Tract Concentrations in Pregnant and Postpartum Women. Conference on Retroviruses and Opportunistic Infections. February 22-25 2016. Boston, MA.
58. Thompson CG, Rosen EP, Charlins P, Mulder L, Kovarova M, Fedoriw Y, Luciw P, Garcia JV, Akkina R, **Kashuba ADM**. Multispecies Differences in Drug Transporter Expression and Localization in GI Tissue. Conference on Retroviruses and Opportunistic Infections. February 22-25 2016. Boston, MA.
59. Rosen E, Thompson CG, Sykes C, Adamson L, Matthews M, Fedoriw Y, Luciw P, Garcia JV, Akkina R, **Kashuba ADM**. Multispecies ARV Distribution in Intestinal Tissue by Mass Spectrometry Imaging. Conference on Retroviruses and Opportunistic Infections. February 22-25 2016. Boston, MA.
60. Srinivas N, Yang KH, Collins JW, Sykes C, Joseph SB, Robertson KR, Eron JJ, Swanstrom R, **Kashuba ADM**. Antiretroviral Drug Exposure in Cerebrospinal Fluid as a Predictor of Neurocognitive Outcomes in HIV Infected Patients. Selected for Poster Tour and Presidential Trainee Award. American Society of Clinical Pharmacology and Therapeutics, March 8-12, 2016 San Diego, CA.

61. Rosen E, Thompson C, Bokhart M, Prince H, Sykes C, **Kashuba ADM**, Muddiman DC. Small molecule analysis in single hair strands for evaluation of drug adherence with IR-MALDESI MSI. Poster 1418. ASMS2015 St Louis, MO, May 31-June 4 2015.
62. Bokhart M, Rosen E, Thompson C, Sykes C, Kashuba ADM, Muddiman DC. Absolute Quantification of Antiretroviral Drugs in Tissue using IR-MALDESI Mass Spectrometry Imaging. Poster 1439. ASMS2015 St Louis, MO, May 31-June 4 2015.
63. Mauck C, Thurman A, Keller M, Archer DF, Kimble T, **Kashuba ADM**, Sykes C, Friend D, Schwartz J, Doncel GF. Pharmacokinetics of Tenofovir and Emtricitabine Delivered by Vaginal Tablets. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2015. Vancouver, Canada.
64. Dumond JB, Chen J, Ali I, Malone S, Prince HMA, **Kashuba ADM**, Patterson KB. Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2015. Vancouver, Canada.
65. Dumond JB, Francis O, Trezza CR, Messer J, Lee C, Cottrell M, Prince HMA, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Forrest A, Hudgens MG, Sharpless NE, **Kashuba ADM**. Association of a Senescence Biomarker with Intracellular Nucleotide Metabolite and Endogenous Nucleotide Exposures in HIV+ Subjects Receiving Tenofovir/Emtricitabine. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 26-28 May 2015, Washington DC, USA.
66. Collins JW, Trezza CR, Prince HMA, Cottrell ML, Sykes C, White N, Malone S, Wang R, Torrice C, Sharpless NE, Patterson KB, Forrest A, **Kashuba ADM**, Dumond JB. Aging Effects as Covariates in the Population Pharmacokinetics (PK) of Emtricitabine (FTC) and Its Intracellular Metabolite in HIV+ Subjects. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 26-28 May 2015, Washington DC, USA
67. Cottrell, ML, Prince HMA, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen N, Mollan K, Patterson KB, **Kashuba ADM**. Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. 5th International Workshop on HIV & Women: From Adolescence through Menopause. February 21-22 2015, Seattle WA.
68. Aguirre AJ, Mehta C, Ofotokun I, Gandhi M, Hussien SA, Merenstein D, **Kashuba AD**, Anastos K, Kempf MC, Golub ET, Greenblatt RM, Dehovitz JA, Milam J, Cohen MH, Sheth AN. The prevalence of persistent low-level viremia and virologic failure among a cohort of HIV-infected women on antiretroviral therapy. Inter-CFAR Symposium on HIV Research in Women. Dec 7-8 2015. New Rochelle, NY.
69. Thompson C, Chun TW, Sykes C, Ma ZM, Miller C, Mann S, Pollard R, **Kashuba ADM** Asmuth D. Maraviroc-Dependent Pharmacologic Effects on Viral Decay and Immune Recovery in GALT. Poster PJ1. Conference for Retroviruses and Opportunistic Infections. February 23-26 2015. Seattle, WA.
70. Rosen E, Thompson C, Bokhart M, Sykes C, Fedoriw Y, Luciw P, Muddiman D, **Kashuba ADM**. Imaging the Spatial Distribution of Efavirenz in Intact HIV Tissue Reservoirs. Poster PH5, and Themed Discussion TDH. Conference for Retroviruses and Opportunistic Infections. February 23-26 2015. Seattle, WA.
71. Fallon JK, Thompson CG, **Kashuba ADM**, Smith PC. Targeted Quantitative Proteomic Analysis of UGTs and CYP450s in Rectal, Cervical and Vaginal Tissues and

Implications for Xenobiotic Disposition and Treatment of Disease. Abstract #34419. 19th North American Regional ISSX Meeting and 29th JSSX Annual Meeting. October 19-23, 2014, San Francisco, CA.

72. Yang KH, Cottrell M, Sykes C, Prince HA, Patterson KB, **Kashuba ADM**. Multi-Compartment Population PK Model of Tenofovir (TFV) and Emtricitabine (FTC). American Conference on Pharmacometrics, October 10-17, 2014, Las Vegas, NV.
73. Yang KH, Schwartz JL, Sykes C, Doncel G, **Kashuba ADM**. Population Pharmacokinetic Model of Vaginal Tenofovir 1% Gel in the Cervicovaginal Fluid. Oral Presentation. HIV Research for Prevention 2014. October 28-31, 2014. Cape Town, SA
74. Nicol MR, Prince HMA, Emerson CW, Nelson JAE, Patterson KB, Geller EJ, Cohen MS, **Kashuba ADM**. Oral Maraviroc and Tenofovir for HIV Prevention in Women: An Ex Vivo and Translational Approach. Oral Presentation. HIV Research for Prevention 2014. October 28-31, 2014. Cape Town, SA
75. ML Cottrell, KH Yang, HMA Prince, **ADM Kashuba**. Predicting Effective Truvada PrEP Dosing Strategies With a Novel PK-PD Model Incorporating Tissue Active Metabolites and Endogenous Nucleotides (EN). HIV Research for Prevention (HIV R4P). Cape Town, South Africa, October 28-31, 2014. Abstract OA22.06 LB
76. Thompson Corbin, Rosen Elias, Bokhart Mark, Prince Heather, Sykes Craig, Muddiman David C., and **Kashuba Angela D.M**. Mass Spectrometry Imaging of Hair Strands Allows for Evaluation of Long Term Antiretroviral Adherence. AIDS Research and Human Retroviruses. October 2014, 30(S1): A69-A69.
77. Herrera C, Veazey R, **Kashuba ADM**, García Pérez J, Alcamí J, Malcolm K, Shattock R. Mucosal tissue explants as surrogates for in vivo efficacy of microbicides. Oral Presentation. HIV Research for Prevention 2014. October 28-31, 2014. Cape Town, SA.
78. Chuchuen O, Henderson MH, Sandros MG, **Kashuba ADM**, Katz DF. Transport and Transport Properties of Tenofovir from Microbicide Gels into Vaginal Tissue: Analysis using Raman Spectroscopy. Oral Presentation. HIV Research for Prevention 2014. October 28-31, 2014. Cape Town, SA
79. Shen Z, Fahey JV, Rodriguez-Garcia M, Bodwell JE, **Kashuba ADM**, Wira CR. Female Sex Hormone Regulation of Tenofovir-Diphosphate in Human Female Reproductive Tract (FRT) Cells in Culture. Oral Presentation. HIV Research for Prevention 2014. October 28-31, 2014. Cape Town, SA
80. Schwartz JL, Weiner D, **Kashuba ADM**, Archer D, Brache V, Schreiber CA, Chen BA, Poindexter A, Thurman A, Lai JJ Yang KH, Sykes C, Mauck C, Herold B, Dezzutti C, Doncel GF. Multicompartmental Pharmacokinetics of Tenofovir 1% Gel Using the BAT 24 Regimen Versus Daily and Single Pericoital Dosing. Oral Presentation. HIV Research for Prevention 2014. October 28-31, 2014. Cape Town, SA
81. Cottrell ML, Prince HMA, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, **Kashuba ADM**. Mucosal Tissues In Women Exhibit Different Concentrations of Endogenous Nucleotides and Intracellular and Extracellular Antiretroviral (ARV) Concentrations: Implications for Pre-exposure Prophylaxis (PrEP) Development. A-641-0044-09080. 20th International AIDS Conference (AIDS 2014). 20-25 July 2014, Melbourne, Australia

82. Dumond JB, Trezza CR, Francis O, Prince HMA, Mollan K, Cottrell M, Sykes C, Torrice C, White N, Malone S, Want R, Patterson KB, Forrest A, Hudgens MG, Sharpless NE, **Kashuba ADM**. Tenofovir (TFV), Emtricitabine (FTC), Intracellular Metabolite, and Endogenous Nucleotide (EN) Concentrations as a Function of Aging in HIV+ Adults. Oral Poster Discussion A-641-0127-06497. International AIDS Conference (AIDS 2014), Melbourne, Australia, 20-25 July 2014.
83. Thompson CG, Fallon JK, Smith PC, **Kashuba ADM**. Quantification of Drug Transporters in Vaginal and Cervical Tissue Using a Novel Targeted Proteomics Approach: Implications for Small Molecule Disposition in Viral Reservoirs. A-641-0038-0999620th International AIDS Conference (AIDS 2014), 20-25 July 2014, Melbourne, Australia.
84. Cottrell ML, Prince HMA, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, **Kashuba ADM**. Mucosal Tissue Pharmacokinetics of Maraviroc and Raltegravir in Women: Implications for Chemoprophylaxis. Abstract O-08. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 19-21 May 2014. Washington DC.
85. Thompson CG, Rosen E, Sykes C, Fedoriw Y, Luciw P, Muddiman DC, **Kashuba ADM**. Characterizing Antiretroviral Distribution Within Active Viral Reservoirs Using Mass Spectrometry Imaging 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 19 – 21 May 2014, Washington DC, USA.
86. Dumond JB, Trezza CR, Prince HMA, Cottrell M, Sykes C, White N, Malone S, Wang R, Patterson KB, Forrest A, **Kashuba ADM**. Population Pharmacokinetic (PK) Modeling of Tenofovir (TFV), Emtricitabine (FTC), and Their Intracellular Metabolites in HIV+ Subjects. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 19 – 21 May 2014, Washington DC, USA.
87. Nazari M, Rosen E, Bokhart MT, Thompson C, Sykes C, **Kashuba ADM**, Muddiman DC. Comparison of UV-MALDI and IR-MALDESI Mass Spectrometry Imaging of Biological Tissue Sections. American Society for Mass Spectrometry 62nd Conference on Mass Spectrometry and Allied Topics. June 15 - 19, 2014, Baltimore, MD
88. Muddiman DC, Barry J, Robichaud G, Bokhart M, Thompson C, Sykes C, **Kashuba ADM**. Mapping HIV Drugs in Tissue using IR-MALDESI MSI Coupled to the Q Exactive with Several Acquisition Modes. American Society for Mass Spectrometry 62nd Conference on Mass Spectrometry and Allied Topics. June 15 - 19, 2014, Baltimore, MD
89. Bokhart M, Robichaud G, Barry J, **Kashuba ADM**, Sykes C, Muddiman DC. Toward Quantitative Infrared Matrix Assisted Laser Desorption Electrospray Ionization (IR-MALDESI) mass spectrometry imaging of biological tissue. American Society for Mass Spectrometry 62nd Conference on Mass Spectrometry and Allied Topics. June 15 - 19, 2014, Baltimore, MD
90. Robertson S, Barry J, Robichaud G, Muthusamy N, Sykes C, Thompson C, Ghashghaei T, **Kashuba ADM**, Muddiman DC. Investigating the use of heat stabilization during sample preparation of tissues for mass spectrometry imaging. American Society for Mass Spectrometry 62nd Conference on Mass Spectrometry and Allied Topics. June 15 - 19, 2014, Baltimore, MD
91. Shen Z, Bodwell JE, Fahey JV, Rodriguez-Garcia M, **Kashuba ADM**, Wlra CR. Hormone regulation of tenofovir-diphosphate concentrations in human female

reproductive tract cells in culture. 34th Annual Meeting, American Society for Reproductive Immunology, Long Beach, NY. June 2-5, 2014.

92. Hendrix CW, Andrade A, **Kashuba AD**, Marzinke M, Anderson PL, Moore A, Elharrar V, Wang L, Mayer K, Patterson KB. Tenofovir-Emtricitabine Directly Observed Dosing: 100% Adherence Concentrations (HPTN 066). Conference on Retroviruses and Opportunistic Infections. March 3-6, 2014. Boston, MA. Oral presentation.
93. Nicol MR, Emerson CW, Nelson JAE, Sykes S, Asher Prince H, Patterson KB, **Kashuba ADM**. Tenofovir Diphosphate Concentration Response Relationship for HIV Prevention in Vaginal Tissue. Conference on Retroviruses and Opportunistic Infections. March 3-6, 2014. Boston, MA. Poster 1462.
94. Asmuth DM, **Kashuba AD**, Acosta AP, Albanese A, Li X-D, Troia-Cancio P, Pollard R. Efavirenz, Tenofovir, and Emtricitabine Levels in Colonic Tissue. Poster # MOPE-027. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 1-June 30- July 3 2013, Kuala Lumpur, Malaysia.
95. Akkina R, Veselinovic M, Neff CP, Lecureux J, Mulder L, **Kashuba A**. Modelling HIV PrEP in humanized mice: pharmacokinetic studies on antiretroviral drugs raltegravir, tenofovir and maraviroc MOPE134 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 1-June 30- July 3 2013, Kuala Lumpur, Malaysia.
96. P.W. Denton, J. Long, N. Archin, S. Wietgreffe, S. Choudahry, C. Sykes, K. Yang, M.G. Hudgens, I. Pastan, E.A. Berger, A. Haase, **A. Kashuba**, D.M. Margolis, J.V. Garcia. Destruction of the residual active HIV-1 reservoir by Env-specific immunotoxin TUAA0101 - Oral Abstract Session 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 1-June 30- July 3 2013, Kuala Lumpur, Malaysia.
97. Paul Denton, Julie Long, Steven Wietgreffe, Craig Sykes, Rae Ann Spagnuolo, Olivia Snyder, Orrin Thayer, Katherine Perkey, Nancie Archin, Shailesh Choudhary, Kuo Yang, Michael Hudgens, Ira Pastan, Ashley Haase, **Angela Kashuba**, Edward Berger, David Margolis and J. Victor Garcia. Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells during ART. Oral Abstract S05-4. 4th international workshop on humanized mice. Seoul, Korea Sept 30-Oct 2 2013
98. Greener BN, Adams JL, Patterson KB, Prince HMA, Sykes C, Wai M, Dumond JB, Shaheen NJ, Cohen MS, **Kashuba ADM**. Single and Multiple Dose Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV Negative Men and Women. Abstract J-138. Conference on Retroviruses and Opportunistic Infections. Atlanta, GA. March 3-6, 2013.
99. Thompson CG, Sedykh A, Nicol MR, Muratov D, Fourches D, Tropsha A, **Kashuba ADM**. Prediction of antiretroviral drug penetration into the female genital tract using a novel QSAR model Abstract: O_03 14th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands 22 - 24 April 2013 in Reviews in Antiviral Therapy & Infectious Diseases 2013;3:5
100. Nicol M, Fedoriw Y, Mathews M, Micheli J, Kroetz D, **Kashuba ADM**. Gene and Protein Expression of Drug Transporters in Vaginal, Cervical, and Rectal Tissues: Implications for Drug Disposition in HIV Prevention. Abstract Number J-146. Conference on Retroviruses and Opportunistic Infections. Atlanta, GA. March 3-6, 2013.

101. Katz DF, Gao Y, Chuchuen O, Henderson MH, Matthews T, Sykes C, **Kashuba ADM**, Wax A. Measurement and Prediction of Microbicide Drug Delivery. CONRAD Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies. Arlington, VA February 2013.
102. Nicol M, Fedoriw Y, Nelson J, Malone S, Sykes C, White N, Emerson C, **Kashuba ADM**. Development of a mucosal tissue culture model as a preclinical tool to evaluate antiretroviral (ARV) candidates for HIV pre-exposure prophylaxis (PrEP) Oral Presentation O-S-06. GPEN: Globalization of Pharmaceuticals Education Network. November 28-December 2, 2012. Melbourne, Australia.
103. Sabo J, **Kashuba ADM**, Ballow C, Haschke M, Yong C, Macgregor T, Li Y, Kort J. Cytochrome P450 (CYP) Interactions with the HCV Protease Inhibitor BI 201335 in Healthy Volunteers. 52nd ICAAC. Poster A-1248. San Francisco, CA. September 9-12, 2012.
104. Liegler T, Abdel-Mohsen M, Defechereux P, Atchison R, Bentley LG, Taylor D, **Kashuba ADM**, Ahmed K, Agot K, Rammutla E, Lombaard E, Crucitti T, Fransen K, De Baetselier I, Van Damme L, Grant RM, and the FEM-PrEP Study Group Drug Resistance Among HIV-1 Seroconverters in the FEM-PrEP Study. Oral Presentation. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Sitges, Spain. June 5-8, 2012.
105. Patterson K, Stevens T, Prince H, Jennings S, Shaheen N, Madanick R, Dellon E, Cohen M, **Kashuba A**. Antiretrovirals for prevention: pharmacokinetics of raltegravir in gut-associated lymphoid tissue (GALT) of healthy male volunteers. Oral Presentation O-11. 13th International Workshop on the Pharmacology of HIV Therapy. Barcelona, Spain. April 16-18, 2012.
106. Adams JL, Sykes C, Menezes P, Prince HA, Patterson KB, Fransen K, Crucitti T, De Baetselier I, Van Damme L, **Kashuba ADM**. Can Tenofovir diphosphate and Emtricitabine triphosphate concentrations in total blood cells be used to measure adherence? Oral Presentation O-10. 13th International Workshop on the Pharmacology of HIV Therapy. Barcelona, Spain. April 16-18, 2012.
107. Dumond JB, Adams JL, Prince HMA, Kendrick R, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, **Kashuba ADM**. Tenofovir diphosphate (TFV-DP) and Emtricitabine triphosphate (FTC-TP) pharmacokinetics (PK) in older HIV+ patients. Poster Presentation. 13th International Workshop on the Pharmacology of HIV Therapy. Barcelona, Spain. April 16-18, 2012.
108. Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, **Kashuba ADM**. Pharmacokinetic modeling of Efavirenz (EFV), Atazanavir (ATV), Lamivudine (3TC), and Tenofovir (TFV) in the female genital tract of HIV-infected women. Oral Presentation O-14. 13th International Workshop on the Pharmacology of HIV Therapy. Barcelona, Spain. April 16-18, 2012.
109. Heneine W, Wei, X, Morris L, Naranbhai V, Sibeko S, Abdool Karim Q, **Kashuba ADM**, Passmore JA, Hunt G, Johnson JA. Sensitive tenofovir resistance testing of HIV-1 from the genital tract of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. Late Breaker Oral Presentation. Abstract 888.00. 2012 International Microbicides Conference. Sydney, Australia. 15-18 April 2012
110. Kahle E, **Kashuba ADM**, Baeten J, Delany S, Donnell D, John-Steward G, Mujugaria A, Mugo N, Celum C, Lingappa J. Unreported antiretroviral use by HIV-1 infected members of HIV-1 serodiscordant couples enrolling in an HIV-1 prevention clinical trial.

Oral Presentation. Abstract 347.00. 2012 International Microbicides Conference. Sydney, Australia.15-18 April 2012

111. Chuchuen O, Henderson MH, Sykes C, **Kashuba ADM**, Katz DF. Confocal Raman Spectroscopic Measurement of Microbicide Active Pharmaceutical Ingredient (API) Concentration Distributions in Fluids, Gels and Tissues. Oral Presentation. 2012 International Microbicides Conference. Sydney, Australia.15-18 April 2012
112. Wei, X, Morris L, Naranbhai V, Sibeko S, Abdool Karim Q, **Kashuba ADM**, Passmore JA, Hunt G, Heneine W, Johnson JA. Sensitive Tenofovir Resistance Screening of HIV-1 from the Genital Tract of Women with Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. Oral Presentation Abstract #U-115. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington March 5-8 2012
113. Archin NM, Liberty AL, **Kashuba AD**, Choudhary SK, Kuruc JD, Hudgens MG, Kearney MF, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Oral Presentation Abstract #D-1003. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington March 5-8 2012
114. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Grant R, **Kashuba ADM**, Crucitti T, Taylor D. The FEM-PrEP Trial of FTC/TDF (Truvada TN) among African Women. Oral Presentation Abstract #Y-1008. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington March 5-8 2012
115. Bliven-Sizemore E, **Kashuba ADM**, Malone A, Weiner M, Nuermberger E, Burman W, Dorman S, Dooley KE. CYP3A induction by rifampin and rifapentine: Which drug and dose does it best? Oral Presentation. 4th International Workshop on Clinical Pharmacology of TB Drugs. 16 September 2011, Chicago, USA
116. Anton P, Cranston R, Carball-Dieguez A, **Kashuba ADM**, Elliott J, Cumberland W, Mauck C, McGowan I. RMP-02/MTN-006: A Phase 1 Placebo Controlled Trial of Rectally Applied 1% Vaginal Tenofovir Gel with Comparison to Oral Tenofovir Disoproxil Fumarate. Oral Presentation. 18th Annual Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 27-March 2, 2011
117. Stuart G, Moses A, Corbett A, Phini G, Kumwenda W, Mkandwire N, Chintedze J, Hosseinipour M, Stanczyk F, **Kashuba ADM**. Pharmacokinetic and Pharmacodynamic Activity of the Combined Oral Contraceptive LoFemenal (Norgestrel 300ug/Ethinyl Estradiol 30ug) in HIV+ Women in Lilongwe, Malawi. Poster Presentation. 18th Annual Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 27-March 2, 2011
118. Brown KC, Patterson KB, Jennings SH, Shaheen NJ, Prince HMA, Spacek M, Cohen MS, **Kashuba ADM**. Antiretrovirals for HIV Prevention: Darunavir + low dose Ritonavir and Etravirine Exposure in the Rectal Tissue and Seminal Plasma of Healthy Male Volunteers after Single and Multiple Dosing. Poster Presentation. 18th Annual Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 27-March 2, 2011
119. Patterson KB, Dumond JB, Prince HA, Jenkins A, Scarsci K, Wang R, Malone S, Hudgens MG, **Kashuba ADM**. Pharmacokinetics of the Lopinavir/Ritonavir Tablet in HIV-infected Pregnant Women: A Longitudinal Investigation of Protein Bound and Unbound Drug Exposure With Empiric Dosage Adjustment. Poster Presentation. 18th

Annual Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 27-March 2, 2011

120. Patterson KB, Prince HA, Dumond JB, Kraft E, Eron J, **Kashuba ADM**. Pharmacokinetics of Tenofovir Disoproxil Fumarate in Blood Plasma and Cervicovaginal Fluid of HIV-infected Post-menopausal Women Compared with Pre-menopausal Women. Oral Presentation. 18th Annual Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 27-March 2, 2011
121. **Kashuba, ADM**. Drug Penetration into the Male and Female Genital Tract. Invited Presentation. #1906. ICAAC, Boston, MA, Sept 2010.
122. M. Cohen-Wolkowicz, D. K. Benjamin Jr. , L. Piper, C. Moran, P. Liu, J. Aram, **A. Kashuba**, E. Capparelli, T. Walsh, W. Hope, P. Smith. Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Neonates. Poster Presentation. A1-034. ICAAC, Boston, MA, Sept 2010.
123. A Corbett, D Kayira, **A Kashuba**, N White, A Kourtis, C Chasela, F Martinson, G Phiri, B Musisi, D Kamwendo, M Hudgens, M Hosseinipour, C Van Der Horst For The Ban Study Team. Pharmacokinetics (PK) of HAART in Mothers and Breastfeeding Infants From 6-24 Weeks Post-partum. Poster Presentation. A1-2017. ICAAC, Boston, MA, Sept 2010.
124. Kendrick R, Dumond J, Forrest A, Cohen MS, **Kashuba ADM**. Pharmacokinetic Modeling of Antiretrovirals and their Intracellular Metabolites in Blood and Seminal Plasma. Poster Presentation A1-2016. ICAAC, Boston, MA, Sept 2010.
125. **Kashuba ADM**, S.S. Abdool Karim, E. Kraft, N. White, S. Sibeko, L. Werner, L.E. Mansoor, T. Gengiah, S. Sidhoo, Q. Abdool Karim. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial? Late Breaker Platform Presentation TUSS0503 in Special Session: Safety and effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial. XVIII International AIDS Conference. Vienna, Austria. 18 – 23 July 2010,
126. Patterson, KB, HA Prince, N White, R Wang, A Jones, and **ADM Kashuba**. Pharmacokinetics (PK) of Raltegravir (RAL) in the Blood Plasma (BP) and Genital Tract (GT) in HIV+ and HIV- Women. Late Breaker Poster XVIII International AIDS Conference. Vienna, Austria. 18 – 23 July 2010,
127. KB Patterson, HA Prince, E Kraft, A Jones, S Paul, NJ Shaheen, M Spacek, PE Heidt, S Reddy, J Rooney, MS Cohen, and **ADM Kashuba**. Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single of fixed-dose TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP) Abstr # **THBS0305** (oral Presentation). XVIII International AIDS Conference, Vienna, Austria July 18-23 2010.
128. Winters M, van Rompay K, **Kashuba ADM**, Shulman N. Maternal-fetal pharmacokinetics of a single intrapartum dose of maraviroc in rhesus macaques Abstr # 7756 (poster). XVIII International AIDS Conference, Vienna, Austria July 18-23 2010.
129. David Wohl, Julie Dumond, Suzanne Blevins, Donna Pittard, David Ragan, Ruili Wang, Kelley Carpenter, Michelle Floris-Moore, Joseph Eron, and **Angela Kashuba**. Raltegravir Pharmacokinetics (PK) in Treatment Nave Patients is Not Influenced by

Race: PK Results from the Early Therapy in African-Americans (AA) Living with HIV (REAL) Study. Abstr 16042 (poster). XVIII International AIDS Conference, Vienna, Austria July 18-23 2010.

130. Patterson K, Prince H, White N, Wang R, Jones A, **Kashuba ADM**. Pharmacokinetics of Raltegravir in the blood plasma and genital tract in HIV+ and HIV- women. Abstract O17. 5th International Workshop on HIV Transmission - Principles of Intervention. July 15-16 2010. Vienna, Austria. 5th Reviews in Antiviral Therapy & Infectious Diseases 2010;7:16.
131. Kwara A, Tashima K, Dumond J, Poethke P, Kurpewski J, **Kashuba ADM**, Court MH, Greenblatt DJ. Effect Of Rifampin On Efavirenz Pharmacokinetics. 39th Annual Meeting of the American College of Clinical Pharmacology. Abstract 066; Poster 15. Baltimore, MD. September 2010.
132. Nuttall J, **Kashuba A**, Wang R, White N, Allen P, Roberts J, Romano R. The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques. Abstr #40. Microbicides 2010 Conference, Pittsburgh, PA, May 21-25, 2010.
133. Kevin Brown, K Patterson, S Malone, N Shaheen, H Prince, J Dumond, M Spacek, P Heidt, M Cohen, and **A Kashuba**. Antiretrovirals (ARV) for Prevention: Maraviroc (MVC) Exposure in the Semen (SE) and Rectal Tissue (RT) of Healthy Male Volunteers after Single and Multiple Dosing. Abstr # 85 (platform pation). 17th Annual Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. February 16-19, 2010.
134. Kristine Patterson, Naser Rezk, Steven Jennings, Ronald Falcon, Joseph Mrus, **Angela Kashuba**. Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) Pharmacokinetics (PK) in the Cervicovaginal Fluid (CVF) and Blood Plasma (BP) of HIV-Infected Women Enrolled in the GRACE Study. Session 052-HIV, Poster 270. Infectious Disease Society of America 47th Annual Meeting. Philadelphia, PA, Oct 29-Nov 1, 2009.
135. Cohen-Wolkowicz M, Smith PB, Piper L, Moran C, Liu P, **Kashuba A**, Capparelli E, Walsh TJ, Hope WW, Benjamin DK Jr. Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 12-15 2009.
136. Nuttall J, **Kashuba A**, Wang R, White N, Allen P, Roberts J, Romano R. The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques. Abstr #1050. 2009 National HIV Prevention Conference. Atlanta, Georgia, August 23-26, 2009.
137. Schwartz J, Rountree R, **Kashuba A**, Brache V, Creinin M, Poindexter A , Kearney, B. A Multi-Compartment, Single And Multiple Dose Pharmacokinetic Study Of The Candidate Vaginal Microbicide 1% Tenofovir Gel. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, SA, July 20-22, 2009.
138. A Jones, J Talameh, N Rezk, H Prince, K Patterson, and **A Kashuba**. First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Uninfected Women. Platform Presentation. 10th Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, April 2009.

139. S Farr, J Nelson, T Ng'ombe, A Kashuba, C Chasela, A Kourtis, J Johnson, G Tegha, J Wiener, and Charles Van der Horst. Addition of 7 Days of Zidovudine + Lamivudine to Peripartum Single-dose Nevirapine Effectively Reduces Nevirapine Resistance at 2 and 6 Weeks Post-partum in HIV-infected Mothers: Lilongwe, Malawi. 958b. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. February 8-11, 2009.
140. Corbett AH, Martinson F, Rezk N, **Kashuba ADM**, Jameison D, Chasela C, Kayira D, Tegha G, Kamwendo D, van der Horst C. Lopinavir/Ritonavir Concentrations in Breast Milk and Breast-feeding Infants. T-139. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. February 8-11, 2009.
141. Kwara A, Lartey M, Boamah I, Rezk N, Oliver-Commey J, Kenu E, **Kashuba ADM**, Court MH. *Variability in the Pharmacokinetics of NRTI in TB/HIV Co-infected Ghanaian Patients*. N-141. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. February 8-11, 2009.
142. Brown KC, Hosseinipour MC, Hoskins JM, Rezk NL, Tien HC, Kazembe P, Weigel R, McLeod H, **Kashuba ADM**, Corbett AH. *Correlations Between Drug Metabolizing Enzyme and Drug Transporter Genotypes and Nevirapine Exposure in HIV-infected Malawian Adults and Children*. 9th International Clinical Pharmacology Workshop on HIV Therapy. New Orleans, LA, April 5-9, 2008.
143. Ilic K, Hogeland G, Rezk, N, White N, Lamba, J, Lee, C, **Kashuba AD**, Schuetz EG, Lindley CM, Chen ML, Hawke RL. The Influence Of Sex, Race/Ethnicity And CYP 2B6 Genotype On Bupropion Metabolism. PIII-30. American Society for Clinical Pharmacology and Therapeutics, Orlando, Fla, April 2-5 2008.
144. Schwartz J, **Kashuba A**, Rezk N, Nasution M, Choi SO, Kim JS, Brache V, Poindexter A, Creinin M, Ju S, Cochon L, Taylor D, Mauck C. Preliminary Results From A Pharmacokinetic Study Of The Candidate Vaginal Microbicide Agent 1% Tenofovir Gel. Abstr. 610.(Platform Presentation). Microbicides 2008, Delhi, India, February 25-29, 2008.
145. Dumond J, Patterson K, Pecha A, Werner R, Andrews E, Damle B, Tressler R, Worsley J, Boggess K, **Kashuba ADM**. Maraviroc (MVC) Pharmacokinetics (PK) in Blood Plasma (BP), Genital Tract (GT) Fluid and Tissue in Healthy Female Volunteers Late Breaker Abstract 135LB. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA. Feb 3-7, 2008.
146. Corbett A, **Kashuba A**, Rezk N, Jamieson D, Chasela C, Hyde L, Tegha G, Joaki G, Kamwendo D, van der Horst C, and BAN Study Team. Antiretroviral Drug Concentrations in Breast Milk and Breastfeeding Infants. Abstr 648. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA. Feb 3-7, 2008.
147. Schrieber, SJ, Wen, Z, Dumas, TE, Vourvahis, M, Smith, PC, **Kashuba, ADM**, Fried, MW, Hawke, RL. Silymarin Pharmacokinetics (PK) is Altered in Patients with Chronic Hepatitis C Virus (HCV) and Nonalcoholic Fatty Liver Disease (NAFLD) and Correlates with Caspase-3/7 Activity. The Liver Meeting 2007, American Association for the Study of Liver Disease. Boston, MA, Nov 2007. HEPATOLOGY 46 (4): 392A-392A 341 Suppl. S OCT 2007
148. Yeh RF, Hammill HA, Fiscus SA, Rezk NL, Miguel B, **Kashuba ADM**, Mayberry C, Nemecek J, Lipman BA, Norton M, Fath M, Gathe Jr. JC. Single Agent Therapy (SAT)

with Lopinavir/ritonavir (LPV/r) Controls HIV-1 Viral Replication in the Female Genital Tract. Poster 7.7/02; 11th European AIDS Conference (EACS). Madrid, Spain, October 24-27, 2007.

149. Vourvahis, M, Dumond J, Patterson K, Rezk N, Tien H, Li J, Choi SO, Drulak M, Sabo J, Castles M, MacGregor T, **Kashuba A**. Effects of Tipranavir/ritonavir on the Activity of Cytochrome P450 Enzymes 1A2, 2C9, and 2D6 in Healthy Volunteers. Abstr. 52 (Platform Presentation). 8th International Workshop on Clinical Pharmacology in HIV Therapy. Budapest, Hungary, April 2007.
150. Schrieber SJ, Wen Z, Dumas TE, Vourvahis MV, Smith PC, **Kashuba ADM**, Fried MW, Hawke RL. Pharmacokinetics Of Silymarin In Healthy Volunteers And Patients With Viral Hepatitis C. Abstract PIII-40. Clinical Pharmacology and Therapeutics 2007;81;S97.
151. Cao Y, Parsons T, Bakshi RP, Fuchs EJ, Guidos AM, Martinez E, **Kashuba ADM**, Hendrix CW. A Novel Method Demonstrating Protein Unbound Indinavir Concentration In Seminal Plasma. Abstract PIII-45. Clinical Pharmacology and Therapeutics 2007;81;S99.
152. Vourvahis, M, Dumond J, Patterson K, Rezk N, White N, Jennings S, Tien H, Sabo J, MacGregor T, **Kashuba A**. Effects of Tipranavir/ritonavir on the Activity of Hepatic and Intestinal Cytochrome P450 3A4/5 and P-glycoprotein: Implications for Drug Interaction. Abstr L-150. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA, Feb 2007.
153. **Kashuba ADM**. Phenotyping for Drug Interactions: Cocktails Anyone? Invited Presentation. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA, Feb 2007.
154. Cu-Uvin S, DeLong A, Rezk N, Jogan J, Burtwell H, Chapman S, Moreira C, Kurpewski J, Ingersoll J, Caliendo A, **Kashuba A**. Antiretroviral Drug Concentrations in the Genital tract of HIV-Infected Women. Poster # 778. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA, Feb 2007
155. Yeh RF, Patterson KB, Dumond JB, Tappouni HL, Chen Y, Vourvahis M, Boggess KA, Horton AL, Fiscus AS, **Kashuba ADM**. *Genital Tract, Cord Blood, and Amniotic Fluid Exposures of 6 Antiretroviral Drugs During Pregnancy and Postpartum*. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 2006. Abstract # A-0378.
156. Wohl D, Menezes P., Torres R., Vollmer K., Taiwo B., Golin C., Tien H.-C., Avots M., Haley D., Rublein J., Klein C., Stephenson B., **Kashuba A**. *Lopinavir Concentrations Do Not Differ Between African-Americans And Caucasians Administered Once Daily HIV Therapy*. Abstract no. TUPE0096. XVI International AIDS Conference, Toronto, Ontario, Canada, Aug 2006.
157. Dumond J, Yeh R, Patterson K, Corbett A, Jung BH, Rezk N, Bridges A, Dempsey E, Cohen M, **Kashuba ADM**. *First Dose and Steady-State Genital Tract Pharmacokinetics of Ten Antiretroviral Drugs in HIV-Infected Women: Implications for Pre- and Post-Exposure Prophylaxis* 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, Feb 2006

158. Vourvahis M, Tappouni H, Patterson K, Chen YC, Rezk N, Fiscus S, Kearney BP, Rooney JF, Cohen MS, **Kashuba ADM**. *A Pharmacologic Basis for the Use of Tenofovir In Pre- and Post-Exposure Prophylaxis: Intra and Extracellular Genital Tract Pharmacokinetics and Pharmacodynamics from First Dose to Steady State in HIV-1 Infected Men and Women* 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, Feb 2006
159. Corbett A, Mosseinipour M, Nyirenda J, Kanyama C, Mshali I, Chinyama S, Lyke A, Rezk N, Tien H, Hoffman I, **Kashuba A**, Mwansambo C, Weigel R, Kazembe P. *Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian Children*. 2005 Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract #H-1106
160. Wohl DA, Menezes P, Torres R, Vollmer K, Taiwo B, Avots M, Haley D, Golin C, Theodore D, Stephenson B, Rublein J, **Kashuba A**. *Early safety, tolerability, efficacy, and pharmacokinetics of once daily lopinavir/r + tenofovir + lamivudine among HIV-infected African-American men and women naïve to HIV therapy – the AAQD Study*. International AIDS Society Meeting, Poster WePe12.2C06. Rio de Janeiro, Brazil, July 2005.
161. Yeh RF, Gaver VE, Park JJ, Patterson KB, Rezk N, Baxter-Meheux F, White N, Eron JJ, Klein CE, Rublein J, **Kashuba ADM**. *Lopinavir/ritonavir inhibits intestinal CYP3A Activity to a Greater Extent than Hepatic CYP3A activity Using Midazolam as a Biomarker in Healthy Human Volunteers*. 6th International Workshop on Clinical Pharmacology in HIV Therapy. Quebec City, Quebec, April 2005.
162. Collier AC, Tierney C, Downey GF, Eshleman S, **Kashuba A**, Klingman K, Vergis E, Pakes GE, Rooney J, Rinehart A, Mellors J for the Adult AIDS Clinical Trials Group Protocol 5143 Team. *Randomized Study of Twice-Daily Lopinavir/ritonavir (LPV/r) or Fosamprenavir (908) + Ritonavir (908 + r) versus LPV/r + 908 (with Tenofovir DF [TDF] and Nucleosides [NRTIs]) as Rescue Therapy*. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005.
163. Hosseinipour M, Corbett A, Kanyama C, Mshali I, Chinyama S, Phakati S, Rezk N, White S, Van der Horst C, **Kashuba ADM**. *Pharmacokinetic Comparison of Generic and Trade Formulations of Lamivudine, Stavudine and Nevirapine in 12 HIV-Infected Malawian Subjects*. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005.
164. McRae MP, Bourdet DL, Kim RB, Brouwer KLR, **Kashuba ADM**. *The Antiretrovirals Ritonavir, Saquinavir And Efavirenz, But Not Nevirapine, Inhibit Taurocholate Uptake In Ntcp-Injected Oocytes*. The American Association of Pharmaceutical Sciences Annual Meeting, Baltimore, MD, November 2004.
165. Lima AM, Brito LFB, Leite RD, Lima NL, **Kashuba ADM**, Rezk NL, Bushen OY, Dillingham RD, Gurrant R. *Glutamine and alanyl-glutamine enhance absorptive function in malnourished children and HIV patients*. 42nd Annual Meeting Infectious Disease Society of America. Boston, MA. September 2004.
166. McRae MP, Brouwer KLR, **Kashuba ADM**. *Effects of ritonavir and nevirapine on hepatic transport and the biliary excretion index of taurocholate in both sandwich-cultured human and rat hepatocytes*. Annual International Society on the Study of Xenobiotics. Vancouver, Canada, October 2004.

167. Chen YC, Patterson K, Boggess K, Marder A, **Kashuba ADM**. *The Impact of Pregnancy on the Disposition of Antiretroviral Agents in Blood and Cervicovaginal Secretions*. 7th Annual International Trends in Infectious Diseases Pharmacotherapy Conference MAD, Phoenix, Arizona, May 2004.
168. Yeh RF, Gaver VE, Park JJ, Patterson KB, Baxter-Meheux FA, Bertz RJ, Eron JJ, **Kashuba ADM**. *Lopinavir/Ritonavir Induces CYP2C9 and 2C19 Activity, as Measured By Warfarin and Omeprazole Biomarkers in Healthy Human Volunteers*. 5th International Workshop on Clinical Pharmacology in HIV. Rome, Italy April 2004.
169. Ma JD, Bertino Jr JS, Gaedigk A, **Kashuba ADM**, Streetman DS, Nafziger AN. *Inter- and intraindividual variability of urinary dextromethorphan/dextrorphan (DM/DX) ratios in CYP2D6 extensive metabolizers (EMS) with one or two active alleles*. Clinical Pharmacology and Therapeutics 2004;75(2):P18
170. Corbett AH, Davidson L, Park JJ, Patterson K, Eron JJ, Ngo L, Lim ML, Shelton M, Wire MB, and **Kashuba ADM**. *Dose Separation Strategies to Overcome the Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir Lopinavir, and Ritonavir*. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2004.
171. Hitti J, S Rosenkranz S, Cohn S, Kamemoto L, **Kashuba A**, Caten E, Aweeka F. *Sex and Weight as Covariates in the Pharmacokinetics of Efavirenz, Indinavir, and Nelfinavir*. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2004.
172. **Kashuba ADM**, Tierney C, Downey G, Vergis EN, Klingman K, Mellors J, Eschelman S, Brothers CH, Collier AC and the A5143 Team. *Combining GW433908 (Fosamprenavir) With Lopinavir/Ritonavir In HIV-1 Infected Adults Results In Substantial Reductions In Amprenavir And Lopinavir Concentrations: Pharmacokinetic Results From Adult ACTG Protocol A5143*. 43rd Annual ICAAC, Chicago, IL, 2003.
173. Rublein JC, Donovan BJ, Hollowell SB, Min SS, Theodore D, Raasch RH, **Kashuba ADM**. *Effect Of Omeprazole On The Plasma Concentrations Of Indinavir In HIV-Negative Subjects*. 43rd Annual ICAAC, Chicago, IL, 2003.
174. van der Horst C, Fiscus S, Piwoz E, Corneli A, Moses A, Jones D, Adair L, Bentley M, Hoffman I, **Kashuba ADM**, Shugars D, Bangdiwala K, Tien H. *Prevention Of Mother To Infant Transmission Of HIV Through Breastfeeding And Reduction Of Morbidity And Mortality Of The Breastfeeding Mothers: A Study In Malawi*. International AIDS Society Meeting, Paris, 2003.
175. **Kashuba ADM**, Min SS, Corbett AH, Rezk N, Cohen MS. *Comparison of Protease Inhibitor and Non-Nucleoside Reverse Transcriptase Inhibitor Concentrations in the Male and Female Genital Tract*. Journal of Investigative Medicine 2003;51 (2).
176. Kim M, LaCourse J, Nafziger AN, Wallace AL, **Kashuba ADM**, Rowland, E, Gaedigk A, Bertino, JS Jr. *Effect Of Cigarette Smoking On CYP2C9 Activity*. Clin Pharmacol Ther 2003;73(2):P148.
177. Shelepova T, Nafziger AN, Victori J, **Kashuba ADM**, Rowland E, Zhang Y, Sellers E, Kearns GL, Leeder S, Gaedigk A, Bertino JS Jr. *Effect Of Oral Contraceptives (OCs)*

On Drug Metabolizing Enzymes (DMEs) As Measured By The Validated Cooperstown 5+1 Cocktail (5+1). Clin Pharmacol Ther 2003;73(2):PI49.

178. Ma JD, Nafziger AN, **Kashuba ADM**, Rowland E, Gaedigk A, Kim JS, Kim M, Bertino JS Jr. *Use Of Limited Sampling Strategy (Lss) Of S-Warfarin (S-W) Concentrations Or Warfarin (W) S/R Ratios As A Biomarker For CYP2C9 Activity.* Clin Pharmacol Ther 2003;73(2):PI50.
179. Lyke AC, Nelsen AC, Paine MF, Rowland EE, **Kashuba ADM**, Lindley C, Clarke MJ, Hawke RL. *Correlation Of Intrinsic Clearance Estimates For Erythromycin N-Demethylation (ERMND) And Midazolam 1'-Hydroxylation (MDZOH) With CYP3A4 And CYP3A5 Content Using Human Liver Microsomes (HLM).* Clin Pharmacol Ther 2003;73(2):PI67.
180. M.L. Lim, S.S. Min, J.J. Eron, R. Bertz, M. Robinson, A. Gaedigk, **A.D.M. Kashuba**. *A Two-Way Drug Interaction Between Lopinavir/Ritonavir (Lpv/R) And Phenytoin (Pht).* 10th Conference On Retroviruses And Opportunistic Infections. Boston, Ma, February 2003.
181. S Reddy, L Troiani, J Kim, J Rodriguez, S Fiscus, van Kempen A, M. Cohen, **A Kashuba**. *Differential Phosphorylation of Zidovudine and Lamivudine (ZDV/3TC) Between Semen and Blood Mononuclear Cells (MCs) in HIV-1 Infected Men.* 10th Conference on Retroviruses and Opportunistic Infections. Boston MA, February 2003.
182. Wohl DA, Pilcher CD, Revuelta M, McComsey G, Koletar SL, Evans S, Yijun Y, Zackin R, Alston B, Welch S, Basar M, **Kashuba A**, Kondo P, Quinn J, Wingfield H. *Absence of Sustained Hyperlactatemia Among HIV-infected Patients with Risk Factors for Mitochondrial Toxicity.* 10th Conference On Retroviruses And Opportunistic Infections. Boston, Ma, February 2003.
183. Corbett A, Eron J, Diebold M, Fiscus S, Rezk N, **Kashuba A**. *Short-term Safety and Efficacy of An Amprenavir [APV] /Saquinavir [SQV] /Ritonavir [RTV] Salvage Regimen.* Infectious Diseases Society of America. Chicago, IL, 2002.
184. Reddy S, Troiani L, Pereira A, Kim J, van Kempen A, Cohen M, **Kashuba ADM**. *Zidovudine and Lamivudine (ZDV/3TC) Seminal Plasma:Blood Plasma (SP:BP) Concentration (CONC) Ratios Do Not Predict Total SP Exposure.* World AIDS Conference, Barcelona, Spain 2002.
185. Min SS, Corbett AH, Rezk N, Fiscus SA, Cohen MS, **Kashuba ADM**. *Differential Penetration of Protease Inhibitors [PI] and Non-Nucleoside Reverse Transcriptase Inhibitors [NNRTI] into the Female Genital Tract [GT]* World AIDS Conference, Barcelona, Spain 2002.
186. Corbett A, Eron J, Diebold M, Rezk N, Troiani L, **Kashuba ADM**. *A Triple Protease Inhibitor [PI] Salvage Regimen of Amprenavir[APV] + Saquinavir [SQV] + Ritonavir [RTV]: Steady State [SS] Pharmacokinetics [PK] and Initial RNA and CD₄ Response.* World AIDS Conference, Barcelona, Spain 2002.
187. **Kashuba ADM**, Min SS, Corbett AH, Rezk N, Cohen MS. *Comparison of Protease Inhibitor [PI] and Non-Nucleoside Reverse Transcriptase Inhibitor [NNRTI] Concentrations [CONC] in the Male [M] and Female [F] Genital Tract [GT].* 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington DC 2002.

188. Shainuvati S, Nafziger AN, Leeder J, Gaedigk A, Kearns GL, Sellers E, Zhang Y, **Kashuba ADM**, Rowland E, Bertino JR JS. *Combined phenotypic assessment of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT2, and XO with the "Cooperstown 5+1 Cocktail"*. Clin Pharmacol Ther 2002;71:P101
189. Kearns GL, Lowry J, Khan IS, **Kashuba ADM**, Bertino Jr JS, Nafziger AN, Abdel-Rahman SM, Leeder JS. *Cisapride: A potential model substrate to assess CYP3A4 activity*. Clin Pharmacol Ther 2002;71:P104.
190. **Kashuba ADM**. Beneficial Antimicrobial Drug Interactions: Taking Advantage of New Insights into Clinical Pharmacology. *Metabolism interactions to improve systemic exposure*. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL 2001.
191. **Kashuba ADM**. *How Should Phenotyping Biomarkers Be Validated?* International Society for the Study of Xenobiotics, Munich, Germany, 2001.
192. **Kashuba ADM**, Reddy YS, Paine MF, Schuetz EG, Lamba J, Dhakhwa S, Watkins PB. *Erythromycin Breath Test: A Basis For Sex Differences, And Lack Of Effect Of CYP3A5 Expression And MDR1 Genotypes*. International Society for the Study of Xenobiotics, Munich, Germany, 2001.
193. Chaudry N, Eron JJ, Naderer OJ, Pereira AS, Fiscus SA, Wire MB, **Kashuba ADM**. *Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of HIV-1 infected males*. 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Poster 2.1 Noordwijk, Netherlands, 2001.
194. Torralba KMD, Bertino Jr JS, **Kashuba ADM**, Gaedigk A, Nafziger AN. *Lack of effect of two COX-2 inhibitors on warfarin stereoisomer metabolism in CYP2C9 extensive metabolizers*. Arthritis & Rheumatism 2001;44:S124.
195. **Kashuba ADM**, Hawke RL, Tonkin J, Treadwell FR, LeCluyse EL. *Suppression of CYP3A4 Activity by Interleukin 2 Using a Human Hepatocyte: Kupffer Cell Coculture System*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL 2001.
196. Khan IS, Bertino KS, **Kashuba ADM**, Lowry JA, Leeder JS, Kearns GL, Treadwell FR, Nafziger AN. *Intravenous Midazolam Versus Oral Midazolam For Phenotyping of Hepatic CYP3A*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL 2001.
197. Kennedy MJ, Gotschall RR, **Kashuba ADM**, Scott CS, Scripture CD, Kearns GL. *Assessment of Hepatic Metabolism in Children with Cystic Fibrosis*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL 2001.
198. Torralba KMD, Bertino JS, **Kashuba ADM**, Treadwell FR, Whitaker AM, Nafziger AN. *Effect of Two Cox-2 Inhibitors on Warfarin Metabolism in CYP2C9 Extensive Metabolizers*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL 2001.
199. Rogers JF, Nafziger AN, **Kashuba ADM**, Streetman DS, Kulawy RW, Rocci ML, Choo EF, Wilkinson GR, Bertino JS. *Prediction of Midazolam Clearance Using Minimized Sampling of 1-OHM and 1-OHM/MDZ in Healthy Subjects*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL 2001.

200. Reddy S, Kim J, Eron J, Fiscus S, Gotzkowsky K, Manion D, Fiske W, Cohen M, **Kashuba A**. *Efavirenz (EFV)-Containing Antiretroviral (ARV) Therapy (T) Effectively Reduces HIV RNA in the Seminal Plasma (SP) of HIV-1 Infected Men (M)*. 8th Annual Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 2001.
201. Gotzkowsky SK, Kim J, Tonkin J, Morlan M, Gaedigk A, van der Horst C, **Kashuba ADM**. *Altered Drug Metabolizing Enzyme Activity and Genotype-Phenotype Discordance in HIV Infected Subjects*. Platform Presentation. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 1169:301 Toronto, Ont. Canada 2000.
202. Kim J, Gotzkowsky K, Eron J, Manion D, Fiske W, Cohen M, **Kashuba ADM**. *Penetration of Efavirenz into the Male Genital Tract as Measured by Seminal Plasma to Blood Plasma Concentration and AUC_{24h} Ratios*. Platform Presentation. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 1168:301 Toronto, Ont Canada 2000.
203. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, **Kashuba ADM**. *Genetic Contribution To Variability (Var) In CYP3A4 Activity: A Repeated Drug Administration Method*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Los Angeles, CA 2000.
204. **Kashuba ADM**, Hawke RL, Tonkin J, LeCluyse EL. *Direct Exposure To Interleukins (II)-2, -10, And -12 Does Not Significantly Suppress CYP3A Activity In Human Hepatocytes*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Los Angeles, CA 2000.
205. Streetman DS, Bertino JS Jr., **Kashuba ADM**, Kulawy RW, Rocci M, Nafziger AN. *Use of a midazolam urinary metabolic ratio for CYP3A phenotyping*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Los Angeles, CA 2000.
206. Kim JS, Nafziger AN, Tsunoda SM, Choo EF, Streetman D, **Kashuba ADM**, Wilkinson GR, Greenblatt DJ, Rocci ML, Bertino JS Jr. *Validation of a minimized plasma sampling strategy to calculate AUC of the CYP3A probe midazolam*. American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Los Angeles, CA 2000.
207. **Kashuba ADM**, Gotzkowsky SK, Tonkin J, Weidler JM, Raasch RH, van der Horst CM. *Characterizing Cytochrome P450 Activity in HIV-1 Infected Women*. American College of Clinical Pharmacy Annual Meeting, Kansas City, MO, 1999.
208. Bertino JS Jr., Drusano GL, **Kashuba ADM**, Nafziger AN. *Inability of a Commercially Available Antibiotic Utilization Information and Consultation Program (AUIC) to Predict Outcome (OUT) or Time to Event (TTE) in Gram Negative Nosocomial Pneumonia (GNNP)*. Poster Presentation, Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
209. Gotzkowsky S.K., Weidler J.W., Tonkin J., Raasch R.H., van der Horst C., **Kashuba A.D.M.** *Cytochrome P450 3A4 and 2D6 Activities are Decreased in HIV-Infected Subjects*. Platform Presentation, Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
210. Gotzkowsky S.K., **Kashuba A.D.M.**, Hall W., Kulawy R.W., Beck D.J., Rocci M.L., Nafziger A.N., Bertino J.S. Jr. *Poor Correlation Between 24 hour Urinary 6 β -hydroxy*

Cortisol: Cortisol Molar Ratios and Plasma Midazolam Clearance as Measures of Hepatic CYP3A Activity. Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Antonio, TX, 1999.

211. **Kashuba A.D.M.**, Nafziger A.N., Kearns G.L., Leeder J.S., Gotschall R, Rocci M.L., Kulawy R.W., Beck D.J., Bertino J.S., Jr. *Dextromethorphan N-demethylation does not accurately reflect hepatic CYP3A Phenotype.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Antonio, TX, 1999.
212. Kim JS, **Kashuba A.D.M.**, Nafziger AN, Rocci ML, Kulawy RW, Beck DJ, Bertino JS. *Optimal Plasma Sampling to Predict AUC of the CYP3A Probe Midazolam.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Antonio, TX, 1999.
213. McCune J, **Kashuba A.D.M.**, Decker J, Meadowcroft A, Williamson K, Pieper J, Lindley C. *Influence of Menstrual Cycle on Cytochrome P450 Enzyme Activity: Results of a Pilot Trial.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Antonio, TX, 1999.
214. **Kashuba A.D.M.** *Inflammation, Cytokine Networks, and Drug Metabolism: Experimental and Clinical Findings.* International Pharmaceutical Abstracts 1998;35(21):2310.
215. **Kashuba A.D.M.**, Nafziger A.N., Kearns G.L., Leeder J.S., Gotschall R., Rocci M.L., Kulawy R.W., Beck D.J., Bertino J.S. Jr. *Effect of Fluvoxamine Therapy on the Activities of CYP1A2, CYP2D6, and CYP3A.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, 1998.
216. **Kashuba A.D.M.**, Bertino J.S. Jr., Rocci M.L., Kulawy R.W., Beck D.J., Nafziger A.N. *Influence of Sex and Menstrual Cycle on CYP3A Activity Measured by Phenotyping with Intravenous Midazolam.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, 1998.
217. Nafziger A.N., **Kashuba A.D.M.**, James A, Kearns G.L., Leeder J.S., Gotschall R., Bertino J.S. Jr. *The Influence of Sex and Menstrual Cycle on CYP1A2, NAT2, and Xanthine Oxidase Activity.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, 1998.
218. Bertino J.S. Jr., **Kashuba A.D.M.**, Shirey C., Kearns G.L. Leeder J.S., Gotschall R., Nafziger A.N. *Long-term Intraindividual Variability and the Influence of Sex on CYP2D6 Activity.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, 1998.
219. Lindley C., Decker J., McCune J., **Kashuba A.D.M.**, Meadowcroft A., Hall W., Patterson J.H., Pieper J.A. *Dextromethorphan and Cortisol Metabolic Ratios: Correlates of CYP3A4 Activity.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, 1998.
220. McCune J., Lindley C., Sawyer W., Williamson K., **Kashuba A.D.M.**, Pieper J. *Comparison of 24 Hour and Morning 6 β OH Cortisol:Cortisol ratio in Men; Women on Oral Contraceptives, and Women Not on Oral Contraceptives.* Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, 1998.

221. Nafziger A.N., Goss-Bley A., Bertino J.S. Jr., **Kashuba A.D.M.** *Incidence of Sexual Dysfunction in Normal Volunteers on Fluvoxamine Therapy*, Poster Presentation, American Psychiatric Association 150th Annual Meeting, San Diego, Ca, 1997.
222. **Kashuba A.D.M.**, Bertino J.S. Jr., Nafziger A.N. *Rapid Achievement of Aminoglycoside Pharmacokinetic and Pharmacodynamic Goals to Attain Therapeutic Response in Gram-Negative Pneumonia: Use of Large Loading Doses with Individualized Pharmacokinetic Monitoring*, Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, Ca, 1997.
223. **Kashuba A.D.M.**, Shirey C.S., Bertino J.S. Jr., Kearns G.L., Nafziger A.N. *Effect of Menstrual Cycle Phase on CYP2D6 Activity in Extensive Metabolizers as Measured by Dextromethorphan Phenotyping*, Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, Ca, 1997.
224. **Kashuba A.D.M.**, Nafziger A.N., Drusano, G.L., Bertino J.S. Jr., *Early Optimization of Aminoglycoside Pharmacokinetic Goals Reduces Time to Therapeutic Response in Gram-Negative Pneumonia*, Platform Presentation, Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1996.
225. **Kashuba A.D.M.**, Nafziger A.N., Bertino J.S. Jr., *Predictors of Therapeutic Response to Aminoglycosides in Gram-Negative Pneumonia and Bacteremia*, Poster Presentation, American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, Fla, 1996.
226. **Kashuba A.D.M.**, Ballow C., Forrest A., *Development of a Population Pharmacokinetic Model and Optimal Sampling Strategies for Intravenous Ceftazidime in the Critically Ill*, Poster Presentation, American College of Clinical Pharmacists Annual Meeting, Washington, DC, 1995.
227. **Kashuba A.D.M.**, Law R., Ohlsson A., *Comparison of Two Vancomycin Dosing Guidelines for Use in the Neonatal Intensive Care Unit: A Focus on Serum Concentrations and Cost Effectiveness*. Women's College Hospital Ninth Annual Research Meeting, Toronto, Ontario, 1992

TEACHING ACTIVITIES

COURSE COORDINATOR:

1. Course Number: DPET 806 (PY2/3 Elective)
Course Title: THE PACKAGE INSERT: Drug Development for Clinicians
Dates: 2011 - 2013
2. Course Number: Pharmacy 361
Course Title: Graduate Student/Fellow Seminar Series/Journal Club
Dates: 2000 - 2006
3. Course Number: Pharmacy 193 (post doctoral research fellows)
Course Title: Clinical Research Methods
Dates: 1998-2000
4. Course Number: PHCY 450 (3rd year, spring semester capstone course)
Course Title: Pharmacotherapy VIII: Problems
Dates: 1998-2000 (course developer)

LECTURER:

Semester/Year	Course Number, title, type	Enrollment	Teaching Responsibility
Spring 2019	PHCY 718 The Patient Care Experience 2.0, 2 credit, Required PharmD	150	Weekly small group facilitator, 8 contact hours
Fall 2018	DPOP872; Proposal Writing, 3 credit, Elective, PhD	10	Lecturer; 1 contact hour
Spring 2018	PY2 OSCE	150	Facilitator/Proctor, 4 contact hours
Spring 2018	PHCY 718 The Patient Care Experience, 2 credit, Required PharmD	150	Weekly small group facilitator, 16 contact hours
Spring 2017	PHCY510 Foundations in Clinical Pharmacology, 3 credit, Required PharmD	150	Final exam case author 1 contact hour
Spring 2017	EPID 896, Clinical Research and Professional Development Seminar; Research Fundamentals	42	Group lecturer 10 contact hours
Spring 2017	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours
Spring 2016	PHCY510 Foundations in Clinical Pharmacology, Required PharmD	150	Final exam case author 1 contact hour
Spring 2016	EPID 896, Clinical Research and Professional Development Seminar; Research Fundamentals	42	Group lecturer 10 contact hours
Spring 2016	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours
Fall 2015	EPID 896, Clinical Research and Professional Development Seminar; Research Fundamentals	42	Group lecturer 10 contact hours
Spring 2015	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours

Fall 2014	EPID 896, Clinical Research and Professional Development Seminar; Research Fundamentals	35	Group lecturer 10 contact hours
Spring 2014	PHCY 805 (section 001) Independent Research Study	1	Course coordinator 2.0 credit hours
Spring 2014	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours
Spring 2013	EPID 690, Design of Clinical Research Studies, 3 credit, Required MPH	25	Lecturer 2 lecture hours
Spring 2013	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours
Spring 2013	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	150	Lecturer 2 contact hours
Spring 2012	EPID 690, Design of Clinical Research Studies, 3 credit, Required MPH	20	Lecturer 2 lecture hours
Spring 2012	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours
Spring 2012	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	150	Lecturer 2 contact hours
Spring 2011	EPID 690, Design of Clinical Research Studies, 3 credit, Required MPH	25	Lecturer 2 lecture hours
Spring 2011	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours
Spring 2011	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	150	Lecturer 2 contact hours
Spring 2010	EPID 690, Design of Clinical Research Studies, 3 credit, Required MPH	25	Lecturer 2 lecture hours
Spring 2010	DPET 810, AIDS: Principles, Practices, and Politics, 2 credit, elective PharmD	20	Lecturer 1 lecture hour
Spring 2010	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	150	Group facilitator 40 contact hours
Spring 2010	MS1, Medical Small Group Sessions in Pharmacology, 4 credit, Required MD	140	Group facilitator 3 contact hours
Spring 2010	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	150	Lecturer 2 contact hours
Spring 2009	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	150	Lecturer 2 contact hours
Spring 2009	MS1, Medical Small Group Sessions in Pharmacology, 4 credit, Required MD	140	Group facilitator 3 contact hours
Spring 2009	EPID 690, Design of Clinical Research Studies, 3 credit, Required MPH	25	Lecturer 2 lecture hours
Spring 2009	DPET 810, AIDS: Principles, Practices, and Politics, 2 credit, elective PharmD	20	Lecturer 1 lecture hour
Spring 2009	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	140	Group facilitator and case author 40 contact hours
Spring 2008	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	150	Lecturer 2 contact hours
Spring 2008	DPET 810, AIDS: Principles, Practices, and Politics, 2 credit, elective PharmD	20	Lecturer 1 lecture hour
Spring 2008	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	140	Group facilitator 40 contact hours

Spring 2007	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	140	Lecturer 4 contact hours
Spring 2007	DPET 810, AIDS: Principles, Practices, and Politics, 2 credit, elective PharmD	20	Lecturer 1 lecture hour
Spring 2007	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	140	Group facilitator and case author 40 contact hours
Spring 2007	DPET 832, Introduction to Applied Pharmacogenomics, 3 credit, Elective PharmD	10	Lecturer 1 contact hour
Fall 2006	MOPH 810, Drug Metabolism, 3 credit, Required PhD	15	Lecturer 2 contact hours
Fall 2006	DPET 840, Advanced Pharmacotherapy, 3 credit, Required PhD	10	Lecturer 15 contact hours
Spring 2006	DPET 832, Introduction to Applied Pharmacogenomics, 3 credit, Elective PharmD	10	Lecturer 1 contact hour
Spring 2006	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	120	Group facilitator 40 contact hours
Spring 2006	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	150	Lecturer 4 contact hours
Fall 2005	DPET 840, Advanced Pharmacotherapy, 3 credit, Required PhD	7	Lecturer 15 contact hours
Fall 2005	MOPH 810, Drug Metabolism, 3 credit, Required PhD	15	Lecturer 2 contact hours
Spring 2005	DPET 832, Introduction to Applied Pharmacogenomics, 3 credit, Elective PharmD	10	Lecturer 1 contact hour
Spring 2005	PHCY 450, Problems in Pharmacotherapy, 3 credit, Required PharmD	120	Group facilitator 40 contact hours
Spring 2005	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	120	Lecturer 4 contact hours
Fall 2004	DPET 840, Advanced Pharmacotherapy, 3 credit, Required PhD	6	Lecturer 15 contact hours
Fall 2004	PHCY 449, Pharmacotherapy VII: Infectious Diseases, 3 credit, Required PharmD	120	Lecturer 4 contact hours
Fall 2004	MOPH 810, Drug Metabolism, 3 credit, Required PhD	15	Lecturer 2 contact hours
Spring 2004	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	120	Lecturer 4 contact hours
Spring 2004	DPET 832, Introduction to Applied Pharmacogenomics, 3 credit, Elective PharmD	10	Lecturer 1 contact hour
Fall 2003	PHCY 449, Pharmacotherapy VII: Infectious Diseases, 3 credit, Required PharmD	120	Lecturer 6 contact hours
Fall 2003	DPET 840, Advanced Pharmacotherapy, 3 credit, Required PhD	8	Lecturer 15 contact hours
Fall 2003	MOPH 810, Drug Metabolism, 3 credit, Required PhD	15	Lecturer 2 contact hours
Spring 2003	PHCY 414, Clinical Pharmacokinetics, 3 credit, Required PharmD	120	Lecturer 2 contact hours
Spring 2003	DPET 832, Introduction to Applied Pharmacogenomics, 3 credit, Elective PharmD	10	Lecturer 1 contact hour
Fall 2002	PHCY 449, Pharmacotherapy VII: Infectious Diseases, 3 credit, Required PharmD	120	Lecturer 4 contact hours
Fall 2002	PHCY 193 Clinical Research Methods, 3 credit,	12	Lecturer

	Required Drug Development Fellows		3
Fall 2002	DPET 840, Advanced Pharmacotherapy, 3 credit, Required PhD	7	Lecturer 15 contact hours
Fall 2002	MOPH 810, Drug Metabolism, 3 credit, Required PhD	15	Lecturer 2 contact hours
Spring 2002	DPET 832, Introduction to Applied Pharmacogenomics, 3 credit, Elective PharmD	10	Lecturer 1 contact hour
Spring 2002	PHCY 139, Computer Applications in Clinical Drug Development and Pharmacokinetics, 3 credit, Required Drug Development Fellows	12	Lecturer 3 contact hours
Fall 2001	PHCY 193 Clinical Research Methods, 3 credit, Required Drug Development Fellows	12	Lecturer 3
Fall 2001	MOPH 810, Drug Metabolism, 3 credit, Required PhD	15	Lecturer 2 contact hours
Fall 2001	PHCY 449, Pharmacotherapy VII: Infectious Diseases, 3 credit, Required PharmD	120	Lecturer 4 contact hours
Fall 2001	PHCY 193 Clinical Research Methods, 3 credit, Required Drug Development Fellows	12	Lecturer 3
Spring 2001	PHCY 139, Computer Applications in Clinical Drug Development and Pharmacokinetics, 3 credit, Required Drug Development Fellows	12	Lecturer 3 contact hours
Fall 2000	PHCY 193 Clinical Research Methods, 3 credit, Required Drug Development Fellows	12	Lecturer 3
Fall 2000	PHCY 193 Clinical Research Methods, 3 credit, Required Drug Development Fellows	12	Lecturer 3
Fall 2000	MOPH 810, Drug Metabolism, 3 credit, Required PhD	15	Lecturer 2 contact hours
Fall 2000	PHCY 449, Pharmacotherapy VII: Infectious Diseases, 3 credit, Required PharmD	120	Lecturer 4 contact hours
Spring 2000	PHCY 139, Computer Applications in Clinical Drug Development and Pharmacokinetics, 3 credit, Required Drug Development Fellows	12	Lecturer 3 contact hours

Courses Taught 1997-1999:

PHCY 450 (3rd year, spring semester capstone course)
Pharmacotherapy VIII: Problems in Pharmacotherapy

PHCY 414 (2nd year, spring semester)
Clinical Pharmacokinetics

MOPH 810 (graduate students, fall semester)
Drug Metabolism
Lecturer

PHCY 449 (3rd year, fall semester)
Pharmacotherapy VII: Infectious Diseases

Pharmacy 139 (post-doctoral research fellows)
Computer Applications in Clinical Drug Development and Pharmacokinetics

Pharmacy 193 (post-doctoral research fellows)
Clinical Research Methods

MENTORING:

Graduate Students

2018 – Present	Major Advisor Talisa Kinsale, MS Eshelman Fellowship Awardee
2017 – Present	Major Advisor Aaron Devanathan, PharmD Eshelman Fellowship Awardee
2016 – Present	Major Advisor Erin Burgunder, BS Eshelman Fellowship Awardee Identifying Factors Influencing Antiretroviral Pharmacology and HIV Eradication in Macaque and Human Lymph Nodes Division of Pharmacotherapy and Experimental Therapeutics
2016 – 2017	Summer Rotation Advisor Shane Falcinelli, BS UNC MD/PhD Student
2014 – 2018	Major Advisor Nithya Srinivas, BS UNC PhD Student, UNC Royster's Fellow Distribution of Antiretrovirals Within the Brain Tissue and Relationship with Neurocognitive Impairment Due to HIV Division of Pharmacotherapy and Experimental Therapeutics 2018 – Present: Research Investigator, Incyte Corporation
2012 – 2017	Major Advisor Corbin Thompson, PharmD UNC PhD Student Mechanisms of Mucosal Tissue Drug Distribution Division of Pharmacotherapy and Experimental Therapeutics 2017 – Present: DMPK Scientist, Theravance Biopharma US
2014 – 2016	Committee Member Oranat Palm Chuchuen Duke University PhD Student Development of Raman Spectroscopy-Based Methods for Analysis of Microbicide Transport in Gels and Tissues Department of Biomedical Engineering
2014	External Examiner Brendan Osborne Clinical and Immunological Correlates of Semen HIV-1 RNA Shedding University of Toronto, School of Graduate Studies, Doctor of Philosophy
2009 – 2014	Major Advisor Melanie Nicol, PharmD

UNC PhD Student
 Molecular Pharmacology Applications to HIV Prevention Strategies
 Division of Pharmacotherapy and Experimental Therapeutics
 2014 – Present: Assistant Professor, Department of
 Experimental and Clinical Pharmacology,
 University of Minnesota College of
 Pharmacy

2008 – 2012 UNC Major Advisor
 Micky Cohen-Wolkowicz, MD
 UNC PhD Student
 Pharmacokinetic-Pharmacodynamic Relationships of Antimicrobials
 in Neonates
 Division of Pharmacotherapy and Experimental Therapeutics
 2012 – 2014: Assistant Professor, Department of
 Pediatrics, School of Medicine, Duke
 University
 2014 – 2017: Associate Professor, Department of
 Pediatrics, School of Medicine, Duke
 University
 2017 – Present Professor of Pediatrics, Director, Duke
 Clinical Research Institute

2008 – 2009 Major Advisor
 Sunita Paul, MS
 UNC PhD Student
 Molecular Pharmacology Applications to HIV Prevention Strategies
 Division of Pharmacotherapy and Experimental Therapeutics
 2009 – Present: Senior Site Manager for Global Clinical
 Operations, Janssen Virology, Research
 Pharmaceutical Services

2001 – 2005 Major Advisor
 Mary Peace McRae, Pharm.D, Ph.D.
 PhD in Pharmaceutical Sciences from UNC-CH
 Understanding the Hepatotoxicity of Antiretroviral Drugs in the
 Treatment of HIV/AIDS
 Division of Pharmacotherapy and Experimental Therapeutics
 2006 – 2011: Assistant Professor, Department of
 Pharmacology, Kansas City University of
 Medicine and Biosciences
 2011 – 2012: Associate Professor, Department of
 Pharmacology, Kansas City University of
 Medicine and Biosciences
 2012 – Present: Assistant Professor, Department of
 Pharmacotherapy and Outcomes Sciences,
 Virginia Commonwealth University

2002 – 2007 Major Advisor
 Naser L. Rezk, MS, Ph.D.
 PhD in Bioorganic Chemistry from Tanta University, Egypt
 Simultaneous quantification of antiretroviral medications in human
 breast milk

2007 – 2009: Research Assistant Professor, School of
Pharmacy, UNC Center for AIDS
Research, UNC-CH, Chapel Hill, NC

UNC School of Pharmacy Postdoctoral Research Fellows:

those in **BOLD are 2-3 year academic clinical pharmacology research fellows, program accredited by ACCP*

1997 - 1999	Jodi W. Weidler, Pharm.D., GlaxoWellcome Research Fellow
1998 - 2000	S. Karl Gotzkowsky, Pharm.D., GlaxoWellcome Research Fellow
1999 - 2001	Julie Kim, Pharm.D., GlaxoWellcome Research Fellow
	Mary Jayne Kennedy, Pharm.D., Pediatric Research Fellow
	Naumann Chaudry, Pharm.D., PPD Research Fellow
2000 - 2002	Sunila Reddy, Pharm.D., GlaxoWellcome Research Fellow
2001 - 2003	Amanda Corbett, Pharm.D., HIV Pharmacology Research Fellow
	Michael Lim, Pharm.D., GlaxoSmithKline Research Fellow
2002 – 2004	Jennifer Park, Pharm.D., GlaxoSmithKline Research Fellow
	Leslie Davidson, Pharm.D., Pozen Research Fellow
2003 – 2005	Rosa Yeh, Pharm.D., HIV Pharmacology Research Fellow
	Ya-Chi Chen, Pharm.D., GlaxoSmithKline Research Fellow
	Hiba Tappouni, Pharm.D., GlaxoSmithKline Research Fellow
2005 – 2007	Julie Dumond, Pharm.D., HIV Pharmacology Research Fellow
	Manoli Vourvahis, Pharm.D., GlaxoSmithKline Research Fellow
2006 – 2008	Kan Lu, MS, Pharm.D., GlaxoSmithKline Research Fellow
2007 – 2008	Sunny Paul, MS, HIV Pharmacology Training Program
2007 – 2010	Kevin Brown, Pharm.D., HIV Pharmacology Research Fellow
2008 – 2010	Amanda Jones, Pharm.D., United Therapeutics Research Fellow
2009 – 2011	Racheal Kendrick, Pharm.D., Quintiles Pharmacokinetics Fellow
2010 – 2011	Anne Mattson, Pharm.D., GlaxoSmithKline Research Fellow
2010 – 2012	Jessica Adams, Pharm.D., HIV Pharmacology Research Fellow
2011 – 2013	Ben Greener, Pharm.D., PPD Drug Development Fellow
2012 - 2014	Tanja Hadzic, PhD, Quintiles Research Fellow
2012 – 2015	Mackenzie Cottrell, Pharm.D., M.S., HIV Pharmacology Research Fellow, T32 Clinical Pharmacology Fellow
2013 – 2015	Christine Trezza, Pharm.D., GlaxoSmithKline Research Fellow
2014 – 2016	Elizabeth Andrews, PharmD. PPD Drug Development Fellow
2015 – 2017	Michael Weber, PharmD, United Therapeutics Drug Development Fellow
2015 – 2017	Katy Garrett, Pharm.D., HIV Pharmacology Research Fellow
2016 – 2018	Robert Pope, PharmD, PPD Drug Development Fellow
2017 – 2019	Kristin Moody, PharmD, GSK Medical Affairs Fellow
2018 – 2020	Daijha Anderson, PharmD, GSK Medical Affairs Fellow

International Postdoctoral Fellows

2017 – Present	Adeniyi Olagunju, PhD Wellcome Trust Fellow & Lecturer I Faculty of Pharmacy Obafemi Awolowo University Ile-Ife, Nigeria
----------------	--

International Visiting Scientists

05/2004 – 05/2005	Byung Hwa Jung, PhD, Bioanalysis and Biotransformation Research Center Korea Institute of Science and Technology Seoul, South Korea
-------------------	--

12/2005 – 12/2007 Sun Ok Choi, PhD
 Senior Scientific Officer
 Division of Biopharmaceutics
 National Institute of Toxicological Research
 Korea Food and Drug Administration
 Seoul, South Korea

July 2006 Mohamed F. Abdel Megeed El-Shereif
 Professor of Organic Chemistry
 Chemistry Department
 Faculty of Science
 University of Tanta
 Tanta, Egypt

5/2008 – 12/2008 Li Hou, PhD
 Postdoctoral Research Fellow
 National University of Singapore

UNC Carolina Covenant Scholars

2009-2011 Allison Hastings (UNC biology major)
 UNC Summer Undergraduate Fellowship Awardee
 Graduated with Highest Honors in Biology
 MD from UVA

2016 Lance Snodderly (UNC biology major)
 Laboratory Intern

UNC Roadmap Training Program

2006 Donglei Yu, PhD Candidate, School of Pharmacy

UNC School of Pharmacy Campbell Faculty Mentoring Program:

2018 – Present Aaron Anselmo, PhD
 Assistant Professor
 Division of Pharmacoengineering and Molecular Pharmaceutics

2017 – Present Sachiko Ozawa, PhD, MHS
 Associate Professor,
 Division of Practice Advancement and Clinical Education

2012 – 2017 Christine Uzonna Oramasionwu, Pharm.D., Ph.D., BCPS
 Assistant Professor,
 Division of Pharmaceutical Outcomes and Policy

UNC School of Pharmacy Students:

1999 - 2000	Tamara Watson, Pharm.D. Candidate, Research Honor Student Penetration of Liposome-Encapsulated AZT Diphosphate in Macrophages
2000 - 2002	Melissa Diebold, Pharm.D. Candidate, Research Honor Student Efficacy, Safety, and Pharmacokinetics of An Amprenavir 600mg/Saquinavir 800mg/Ritonavir 100mg BID – Based Antiretroviral Salvage Regimen
2001 - 2003	Ashley Herring, Pharm.D. Candidate, Research Honor Student Correlation of PXR and RXR Receptor Expression with IL-1 and IL-6 Suppression of CYP3A Activity in Human Hepatocytes
2002 – 2004	Stephanie Burge Hollowell, Pharm.D. Candidate, Research Honor Student Effect of Omeprazole on the Pharmacokinetics of Indinavir
2003 – 2004	Vincent Gaver, Pharm.D. Candidate, Research Honor Student Evaluating the Effects of Lopinavir/Ritonavir (Kaletra®) on Cytochrome P450 Activity Using A Biomarker Cocktail in Healthy Human Volunteers
2003 – 2005	Carolina Molina Lowe, Pharm.D. Candidate, Infectious Diseases Scholarly Program Student. Effects of BSEP Activity on The Development of Hepatotoxicity of Antiretroviral Agents
2004 – 2005	Wole Johnson, BS Candidate, Durham Technical Institute, North Carolina Transfer Assistance in the Biomedical Sciences Scholar
2005 - 2006	Christina Sarrubbi, Pharm.D. Candidate, Research Honor Student Comparison of 3 Hour Omeprazole and 5-hydroxyomeprazole Concentration Ratios to 24 Hour AUC Ratios as a Measure of Hepatic CYP2C19 Activity
2005 – 2007	Irene La, Pharm.D. Candidate, Research Honor Student Evaluating the Effects of Tipranavir (with Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers.
2006 - 2007	Amanda Jones, Pharm.D. Candidate, Research Elective Student Erythromycin Breath Test: A basis for sex differences, and lack of effect of CYP3A5 expression and <i>MDR1</i> genotypes
2006 – 2007	Kevin Brown, Pharm.D. Cadidate, Clinical Specialists Program The Relationship Between Drug Metabolizing Enzyme and Drug Transporter Genotypes and Nevirapine Exposure in HIV-Infected Malawian Adults and Children
2007 – 2009	Allison Pecha, Pharm.D. Candidate, Research Honor Student

A Phase I, Open Label, Study in Healthy Female Subjects to Investigate the Extent of Maraviroc Exposure in Blood, Cervicovaginal Fluid, Vaginal Tissue and to Investigate CCR5 Receptor Saturation in Cervicovaginal Mononuclear Cells and Peripheral Blood Mononuclear Cells, Following Single and Multiple Dosing of Maraviroc.

2009 – 2011	Brianna Franklin, Pharm.D. Candidate, Research Honor Student Maraviroc as an Agent for HIV Prevention (MAP). A Phase IV Open-Label Study to Characterize the Relationship Between Single-Dose Maraviroc Concentrations in Cervical and Vaginal Tissues of Women and Their Ability to Inhibit HIV Infection in an Ex-Vivo Explant Culture Model.
2010 – 2013	Maya Wai, PharmD Candidate, Research Honor Student A Phase I, Open Label, Study in Healthy Female Subjects to Describe GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue Following Single and Multiple Dosing of GSK1349572
2014, Spring Semester	Angela Kashyap, PharmD Candidate, Research Elective Mucosal Pharmacokinetics of Tenofovir Alafenamide Fumarate (GS-7340)
2014 – 2016	Amanda Malone, PharmD Candidate, Research Honor Student Mucosal Pharmacokinetics of Tenofovir Alafenamide Fumarate (GS-7340)
2014 – 2017	Ashley Moody, PharmD Candidate, Research Honor Student Antiretroviral Exposure within the Central Nervous System of Preclinical Models of HIV Infection
2015 (summer)	John Jones, PharmD Candidate, SBTDC/ESOP Intern, EDGE Office
2015 - 2019	Ashlyn Norris, PharmD Candidate AFPE Gateway Recipient Antiretroviral Drug Distribution in Nonhuman Primate Testes
2018 - 2019	Ashley Saunders, PharmD Candidate The Use of Mass Spectroscopy Imaging to Measure Drug Adherence in Hair

UNC Eshelman Innovation Institute Young Innovator Program Students

Summer 2018	Suleman Qamar, Panther Creek High School Bryan Yam, Chapel Hill High School
-------------	--

UNC Hospitals Residents:

2000 - 2001	Amanda Corbett, Pharm.D., Infectious Diseases Specialty Resident
2001 – 2002	Brian Donovan, Pharm.D., Infectious Diseases Specialty Resident

UNC School of Medicine Students:

2006 – 2007	Rebecca Werner, BS
-------------	--------------------

UNC School of Medicine Fellows:

2000 – 2003	Sherene Min, M.D., Infectious Diseases Fellow
2002 – 2003	Esam Hamed, M.D., Anesthesiology Fellow

UNC Building Interdisciplinary Research Careers in Women's Health (BIRCWH K12) Scholars:

2003 – 2005	Kristine Patterson, M.D., Assistant Professor, Division of Infectious Diseases, Department of Medicine
-------------	--

UNC Center for AIDS Research Investigators:

1999 - 2000	Jose F. Rodrigues, Ph.D., University of Puerto Rico
2000 - 2002	John Rublein, Pharm.D., UNC Chapel Hill
2002 – 2006	Susan Cu-Uvin, MD, Brown University
2004 – 2005	Amanda Corbett, Pharm.D., UNC Chapel Hill
	Rebecca Dillingham, M.D., University of Virginia
2008 - 2013	Gretchen Stuart, M.D., UNC Chapel Hill

UNC Interdisciplinary Clinical Research Career Development (KL2) Program:

2010 – 2017	Gary Asher, MD, Assistant Professor, UNC Dept of Family Medicine
-------------	--

UNC Research Apprenticeship Program Students

2006	Mahmoud Salameh Junior, Farmville High School, NC
------	--

UNC Postbaccalaureate Research Education Program (PREP):

2017-2018	Bryan Guzman, BS University of Puerto Rico R25 GM089569 (unfunded – lab supported)
2018-2019	Micah Willis, BS North Carolina Central University R25 GM089569 (funded)

Undergraduate Students:

2006 - 2007	Ji Song Kim (UNC biochemistry major) Saed Adwalla (UNC chemistry major)
2007	Janice McMillan (Oberlin chemistry major) Robert Hartley (Oberlin chemistry major)
2008	Sam Alfiler (Oberlin chemistry major)

International Students:

2003	Mwayi Kazembe, Malawi, Africa, UNC Research Apprenticeship Program
2005	Susan Pendame, Malawi, Africa UNC Research Apprenticeship Program

INVESTIGATOR-INITIATED REFEREED GRANTS and CONTRACTS (123):

NEW AWARDS FOR 2018

1. Benhabbour, R, Principle Investigator. **Kashuba, Angela, Co-Investigator**. Innovative 3D Printed Intravaginal Rings: Reengineering Multipurpose Intravaginal Rings for Prevention of HIV, STIs and Unintended Pregnancy. R61 AI136002. 10% effort. \$300,000; 08/08/2018 – 07/31/2020
2. Adimora, A, Principle Investigator. **Kashuba, Angela, Co-Investigator**. UNC MACS/WIHS Combined Cohort Study Clinical Research Site. NIH/NHLBI. 5% effort. \$3,500,946; 1/01/2019 – 12/31/2025
3. Heredia, A. Principle Investigator. **Kashuba, Angela, Co-Investigator**. Impact of Concomitant Chemotherapy on HIV Resistance to cART and Reservoir Size. R01 CA233441 Subaward. 3% effort; \$49,951; 9/01/2018 – 8/31/2023
4. Batchelor, K. Principle Investigator. **Kashuba, Angela, Co-Investigator**. Novel Biguanides to Treat Type 2 Diabetes. R44 DK096803. \$150,000. 4/02/2018 – 3/31/2020

NEW AWARDS 2017

5. Buse, J, Principle Investigator. **Kashuba, Angela, Co-Investigator**. North Carolina Translational & Clinical Sciences Institute (NC TraCS). 1UL1TR001111 (NCATS). 5% Effort. 5/1/2017 – 4/30/22.

NEW AWARDS 2016

6. Sharon Lewin, Principle Investigator, **Kashuba ADM Co-Investigator**. Long term persistence of HIV in the liver and the clinical impact on HIV-HBV co-infection. National Health and Medical Research Council. \$70,173.00. 10/1/2017 – 9/30/2020.
7. Margolis D, Principle Investigator. **Kashuba ADM Co-investigator**. QURA - Project 1 - Round 2 - Discovery, Development and Testing of Latency Reversing Agents. Qura Therapeutics LLC. \$192,173.94. 1/1/2017 – 12/31/2017.
8. Hightow L, Principle Investigator, **Kashuba ADM Co-Investigator**. The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuum. U19 (Adolescent Trials Network) (NIAID). \$19,000,000. 7/1/2016 – 6/30/2021.
9. **Kashuba ADM, Principle Investigator**. Brigham and Women's Hospital subcontract for the AIDS Clinical Trial Group (ACTG) UM1 AI068636 (NIAID). \$16,000. 2016-2017.
10. Margolis, D Principle Investigator, **Kashuba ADM, Co-I**. Collaboratory of AIDS Researchers for Eradication (CARE). UM1 AI126619 (NIAID). 7/14/2016 – 7/13/2021. **\$17,271,300** (direct).
11. **Kashuba, ADM Principle Investigator**, Rosen E, Co-PI. Novel Mass Spectrometry Imaging Methods to Quantify Antiretroviral Adherence. \$5,395,638 (direct) R01 AI122319. January 2016 – December 2020
12. Swanstrom R, Principal Investigator, **Kashuba ADM, Co-Investigator**. *UNC Center for AIDS Research (CFAR), Director, Pharmacology Core*. P30-HD37260, 6/2016 - 6/2020.\$5,500,000.00 (Core receives \$320,000 per year direct costs)

NEW AWARDS 2015

13. Boggess, C, Principle Investigator (UNC), **Kashuba ADM**, Co-PI. UNC Building Interdisciplinary Research Careers in Women's Health. \$1,524,694 (direct) K12 HD001441. September 2015 – July 2020.
14. Apetrei, C, Principle Investigator (University of Pittsburgh), **Kashuba ADM, Co-Investigator**. Animal Model of Testing SIV Latency Reversal Strategies. \$390,499 (direct) R01 AI119346. Aug 2015 – Jan 2020.
15. Wira C, Principle Investigator (Dartmouth College), **Kashuba ADM, Co-Investigator**. Chemical Contraceptive Control of Microbicides in the Female Reproductive Tract. \$256,468 (direct) R01 AI117739. Feb 2015 – Jan 2019.
16. **Kashuba ADM, Principle Investigator**. Dose Proportionality of TFV-DP in Mucosal Tissue, and Endogenous Nucleotide Quantification, After a Single Dose of GS-7430 in Women. \$866,691 (direct). Gilead. March 2015 – September 2016.
17. Ambrose, Z, Principle Investigator (University of Pittsburgh), **Kashuba ADM, Co-Investigator**. Visualization of in vivo HIV-1 vaginal transmission in the presence and absence of PrEP. \$100,000 (direct). R01 AI116276. 2015-2016.

NEW AWARDS 2014

18. **Kashuba ADM, Principle Investigator**. A Phase IV, Open-Label Study to Compare Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Men and Women. \$316,377 (direct). Merck. October 2014 – September 2015.
19. **Kashuba ADM, Principle Investigator**. Multi-Species Mechanisms of Drug Bio-distribution in HIV Tissue Reservoirs. R01 AI111891 \$4,400,000 (direct). March 15, 2014 – February 28 2019.
20. **Kashuba ADM**. Lab service for In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products, Protocol A11-118. CONRAD. 06/01/2014 – 05/31/2015. \$73,151 (direct).
21. **Kashuba, ADM, Co-Investigator**. Lab service for assessing the effect of contraception and the menstrual cycle on pharmacokinetics, pharmacodynamics and vaginal safety in tenofovir vaginal gel users. USAID. 1/1/2014 – 08/30/2014. \$160,538 (direct).
22. **Kashuba ADM**, Principle Investigator. Lab service for A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine, Protocol A11-117. 1/1/2014 – 8/31/2014. \$321,084.00 (direct)
23. **Kashuba ADM**, Co-Investigator. (PI: Z Ambrose, University of Pittsburgh) Visualization of in vivo HIV- vaginal transmission in the presence and absence of PrEP. R01 AI116276
24. **Kashuba ADM**, Co-Investigator. (PI: H Reese, Wits reproductive Health and HIV institution) FACTS001 SLA – A phase III multi-center, randomized controlled trial to assess the safety and effectiveness of the vaginal microbicide 1% tenofovir gel in the prevention of HIV-1 infection in young women. 7/1/14 – 6/30/16. \$71,497 (direct).
25. **Kashuba ADM**, Co-Investigator. (PI: J Passmore, Doris Duke Medical Research Institute) Inflammation and HIV risk; understanding partial tenofovir efficacy in CAPRISA004. R01 AI111936. 7/10/14-5/31/16. \$50,000 (direct).

26. **Kashuba ADM**, Co-Investigator. (PI: B Jackson, JHU). Johns Hopkins Purchase Agreement for IMPAACT Study. UM1 AI068632. 1/1/14-11/30/14. \$35,550 (direct).

NEW AWARDS 2013

27. Doncel, G. Principle Investigator (EVMS), **Kashuba ADM, Co-Investigator**. Influence of female reproductive cycle and menopause on cervicovaginal tissue susceptibility to HIV-1 infection and tenofovir gel activity. R01 HD072705. Supplement \$43,977.00 (direct).
28. Garcia-Martinez JV, Principal Investigator, **Kashuba ADM and Mumper R, Co-Investigators**. Next Generation Pre-exposure Prophylaxis. R01 AI096138 (NIAID). Supplement 7/01/2013 – 6/30/2015. \$121,912 (direct).
29. **Kashuba ADM**. UNC Center for AIDS Research Supplement to Purchase Imaging Mass Spectrometer. Supplement to 5P30 AI0504108/1/2013-7/31/2014 \$450,000.00 (direct)
30. Kapito-Tembo, A, Principle Investigator (UNC Project Malawi). **Kashuba ADM, Co-Investigator**. Pharmacovigilance of infants exposed to antiretroviral drugs given to HIV-infected mothers during breastfeeding in Malawi. International AIDS Society Collaborative Initiative for Pediatric HIV Education and Research. 8/2013 – 7/2015. \$150,000.00 (total)
31. Bose, C, Principle Investigator (UNC-CH). **Kashuba ADM, Consultant**. A Strategy to Reduce Stunting of Growth in Early Infancy: A Global Network Study. U10 HD076465 (NICHD). 5/3/2013 - 4/30/2018. \$3,204,360.00 (total)
32. Herrera, C, Principle Investigator (Univ of London Imperial College). **Kashuba ADM, Co-Investigator**. Mucosal tissue explants as surrogates for in vivo efficacy of microbicides. R21 AI094515 (NIAID) 2/2013 – 6-2014. \$ 166,539 (direct).

NEW AWARDS 2012

33. Adimora, A, Principle Investigator (UNC-CH). **Kashuba ADM, Co-Investigator**. University of North Carolina Women's Interagency HIV Study UNC WIHS. NIAID U01 AI103390. 1/1/2013 – 12/31/2017. \$11,877,470 (direct).
34. Hernandez, M, Principle Investigator (UNC-CH). **Kashuba ADM, Co-Mentor**. K23 ES021745 Down-regulation of Oxidant-Induced Airway Inflammation Through Modulation of NRF2. 8/2012 – 7/2017. \$1,033,004
35. **Kashuba ADM, Principle Investigator**. Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues. U01 AI095031 (NIAID) Administrative Supplement 8/2012 – 7/2013. \$254,000 (direct).
36. Akkina, R, Principle Investigator (Colorado State University). **Kashuba ADM, Co-Investigator**. R01 AI100845 Modeling Next Generation HIV PrEP in Humanized Mice 6/1/2012 – 5/31/2015 \$2,066,745 (direct).
37. **Kashuba ADM, Principle Investigator**. ULPC-MS/MS to Support Preclinical and Clinical Pharmacology Studies in HIV Treatment and Prevention". Institutional Development Grant Program. North Carolina Biotechnology Center. \$200,000.00 (direct).

38. Katz, D, Principle Investigator (Duke University), **Kashuba ADM, Co-Investigator**. R01 HD072702 Novel Determination of Microbicide Pharmacokinetics In Women's Reproductive Health. 7/1/2012 – 6/30/17 \$2,313,000 (direct).
39. **Margolis, D**. Principle Investigator (UNC). Kashuba ADM, Co-Investigator. A Phase I/II Investigation of the Effect of Vorinostat (VOR) in HIV Infection. U01 AI095052. 4/1/2012 – 3/31/2016 \$576,704 (direct).
40. Schwartz, J, Principle Investigator (EVMS), **Kashuba, ADM, Co-Investigator**. Assessing the effect of contraception and the menstrual cycle on pharmacokinetics, pharmacodynamics and vaginal safety in tenofovir vaginal gel users. USAID. 1/1/2012 – 08/30/2014. \$160,538 (direct).
41. Doncel, G Principle Investigator (EVMS), **Kashuba, ADM, Co-Investigator**. Enhancing protective activity of topical tenofovir against HIV-1 infection . NIAID U19 . 12/1/2012 – 11/30/2017 \$409,644.00 (direct, subcontract)
42. Doncel, G. Principle Investigator (EVMS), **Kashuba ADM, Co-Investigator**. Differential HIV Infection and Tenofovir Activity in Pre and Postmenopausal women. R01 HD072705. \$409,644.00 (direct, subcontract).
43. Stuart, G. Principle Investigator (UNC-CH). **Kashuba ADM, Co-Investigator**. Pharmacokinetics, pharmacodynamics, and genital tract viral shedding in HIV+ women using combined oral contraceptives and raltegravir. Merck COC-ARV 012012. Merck, Sharp, and Dohme. 5/30/2012 – 5/29/2015. \$387,748.91 (direct).
44. **Kashuba ADM, Principle Investigator** Lab service for A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine, Protocol A11-117. 9/1/2012 – 8/31/2014. \$321,084.00 (direct)

NEW AWARDS 2011

45. **Kashuba ADM, Principle Investigator**. Truvada For Prevention of HIV In Women (FemPrEP). 0437.0158/805273. FHI360. 7/2011 – 06/2013. \$417,020 (direct)
46. **Kashuba ADMK, Principle Investigator**. HIV Vaccine Trials Network Laboratory Program. Fred Hutchinson Cancer Research Center. 8/18/2011 – 8/17/2013. \$295,200.
47. **Kashuba ADM, Principle Investigator**. Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues. U01 AI095031 (NIAID) 8/2011 – 7/2014. 1,479,082 (direct).
48. **Kashuba ADM, Principle Investigator**. UPLC-MS/MS to Support Preclinical and Clinical Antiretroviral Pharmacology Studies. S10 RR026581 (NCRR) 8/2011 \$402,500 (direct).
49. Ju, S, Principle Investigator (EVMS), **Kashuba, ADM, Co-Investigator**. PPC-11-119: Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Using the BAT 24 Regimen Versus Daily and Pericoital Dosing. Eastern Virginia Medical School. 8/3/2011 – 8/2 2013 \$305,893 (direct).
50. Schwartz, J, Principle Investigator (CONRAD), **Kashuba ADM, Co-Investigator**. Influence of female reproductive cycle and menopause on cervicovaginal tissue

susceptibility to HIV-1 infection and tenofovir gel activity. CONRAD. 8/4/2011 – 8/3/2013. \$166,193 (direct)

51. Swanstrom R, Principle Investigator, **Kashuba ADM Co-Investigator**. HIV Tropism, Persistence, Inflammation, and Neurocognition in Therapy Initiation. P01 MH094177. \$5,000,000 NIMH 8/22/2011 – 5/31/2016
52. **Kashuba ADM, Principle Investigator**. CO-US-106-0104 Phase IIb Trial to assess the safety and effectiveness of the vaginal microbicide 1% tenofovir gel for the prevention of HIV infection in women in South Africa. Gilead Sciences. 8/12/2011 – 8/11/2012. \$168,000
53. Margolis D, Principal Investigator, **Kashuba ADM Co-Investigator and Clinical Pharmacology Core Director**. Martin Delaney Collaboratory to Eradicate HIV-1 Infection. U19 AI096113 (NIAID). 7/01/2011 – 6/30/2016. **\$24,590,259** (direct) (Core receives \$300,000 per year direct costs).
54. Garcia-Martinez JV, Principal Investigator, **Kashuba ADM and Mumper R, Co-Investigators**. Next Generation Pre-exposure Prophylaxis. R01 AI096138 (NIAID). 7/01/2011 – 6/30/2015. \$1,999,036 (direct).
55. **Kashuba ADM, Principal Investigator**, Patterson KB, Co-Investigator. A Phase I, Open Label, Study in Healthy Male Subjects to Describe GSK1349572 Exposure in Blood, Semen, and Rectal Tissue Following Single and Multiple Dosing of GSK1349572. Investigator-initiated research grant. GlaxoSmithKline. 01/2011 – 09-2013. \$368,000
56. **Kashuba ADM, Principal Investigator**, Patterson KB, Co-Investigator. A Phase I, Open Label, Study in Healthy Female Subjects to Describe GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue Following Single and Multiple Dosing of GSK1349572. Investigator-initiated research grant. GlaxoSmithKline. 05/2011 – 04-2013. \$300,000
57. Swanstrom R, Principal Investigator, **Kashuba ADM, Co-Investigator**. *UNC Center for AIDS Research (CFAR), Director, Pharmacology Core*. P30-HD37260, 6/2011 - 6/2016. \$5,500,000.00 (Core receives \$320,000 per year direct costs)
58. **Kashuba, ADM, Principle Investigator**. Duke Acyclovir Subcontract for Contract No HHSN275201000003I under Task Order No HHSN27500005 funded by NIH NICHD. \$48,634.
59. Dumond, JD, Principal Investigator; **Kashuba ADM Mentor and Co-Investigator** Optimizing Antiretroviral Use In Aging: Pharmacokinetics, Response, And Toxicity. K23AI093156 (NIAID). March 2011- February 2016 \$540,595 (direct).
60. Brouwer KL, Watkins PB, Benjamin DK, Principal Investigators. **Kashuba ADM Co-Investigator (Co-Director, Clinical Pharmacology Fellowship)** UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program. T32 GM086330 (NIGMS). July 2011 – June 2016. \$2,043,611

NEW AWARDS 2010

61. **Kashuba ADM**. Principal Investigator. Antiretroviral Drug Exposure in Phase III Clinical Studies of a Novel Compound to Reduce HIV-Associated Diarrhea. Salix Master Services Agreement. 10/2010 - 9/2011. \$125,740.00

62. **Kashuba ADM**. Principal Investigator, Subcontract from NICHD (D Benjamin, PI). Intestinal Meropenem Metabolism and Disposition in Young Infants (<91 DAYS). 6/2010 - 9/2010. \$314,890.00
63. Patterson KB, **Kashuba ADM Co-Investigators**. HPTN 066: Dose-Proportionality And Intra-Individual Variability Of Intracellular Tenofovir Diphosphate And Emtricitabine Triphosphate In Healthy Volunteers (DAIDS ID: 10851). A Study of the HIV Prevention Trials Network. January 2010 – August 2011. \$425,000.
64. Cohen-Wolkowicz M, Principal Investigator. **Kashuba ADM Co-Mentor**. Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants. K23HD064814. 8/15/2010 – 7/31/2015. \$577,370 (direct)
65. Kashuba ADM. Co-Investigator. (PI: M Cohen UNC). HIV in semen – effects of STDs and antiviral therapy. R37 DK049381. 5/1/10 – 4/30/15. \$2,125,00.
66. **Kashuba ADM**. Principal Investigator. The Mucosal Tissue Model for HIV Infection and Antiretroviral Protection. CFAR Supplement. NIAID 09/2010 – 09/2011. \$200,000.
67. **Kashuba ADM**, Patterson KB Co-Principal Investigators. A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers. Investigator-initiated research grant. Merck Inc. 09/2010 – 09-2012. \$410,000
68. **Kashuba ADM**, Patterson KB Co-Principal Investigators. Raltegravir pharmacokinetics in the 2nd and 3rd trimesters of pregnancy. Investigator-initiated research grant. Merck Inc. 09/2010 – 09-2011. \$140,000
69. Dumond, JB, Principal Investigator, **Kashuba ADM Co-Investigator**. Atripla Pharmacokinetics in the Aging HIV-Infected Population. UNC TraCS Grant 3/2010-2/2011. \$50,000.00.

NEW AWARDS 2009

70. **Kashuba ADM**. Principal Investigator, Subcontract from NICHD (D Benjamin, PI). Development of a Pharmacokinetic Algorithm to Improve Outcomes in Neonates. 9/2009 – 6/2010. \$110,000.00
71. **Kashuba ADM, Principal Investigator**. Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues. R34 AI087065 (NIAID). December 2009- November 2010. \$111,000.00
72. Dumond, JB, Principal Investigator, **Kashuba ADM Co-Investigator**. Atripla Pharmacokinetics in the Aging HIV-Infected Population. Society of Infectious Diseases Pharmacists. 9/2009-0/2010. \$10,000.00.
73. Cohen, MS, Principal Investigator, **Kashuba ADM Co-Investigator**. HIV in Semen: Effects of Antiviral Agents. NIDDK R37 DK049381 Supplement. 9/2009 – 9/2010. \$100,000.00.

NEW AWARDS 2008

74. Floris-Moore M Principle Investigator, **Kashuba ADM Co-Investigator**. Antiretroviral Activity and Tolerability of TMC-125 in Treatment-Naive Adults with HIV-1 Infection. Tibotec Pharmaceuticals (Investigator-initiated research). 11/05/2008 - 12/31/2009. \$786,648.96

75. **Kashuba ADM**, Patterson KB, Co-Principal Investigators. First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV-Infected and HIV Uninfected Women. Merck (Investigator-initiated research). 4/2008 – 4/2009. \$196,420.00.
76. **Kashuba ADM**, Patterson KB Co-Principal Investigators. A phase IV open-label study to characterize extracellular and intracellular tenofovir/emtricitabine residues in multiple biological matrices after a single dose: implications for pre-exposure HIV prophylaxis dosing of Truvada®. Gilead (Investigator-initiated research). 3/2008 – 3/2009. \$259,913.00
77. **Kashuba ADM**, Patterson KB Co-Principal Investigators. A phase IV, open label study in healthy male subjects to investigate the extent of darunavir/ritonavir exposure in blood, seminal fluid, and rectal mucosal tissue, following single and multiple dosing of darunavir/ritonavir and TMC 125 in treatment and prevention settings. Tibotec (Investigator-initiated research). 3/2008 – 3/2009. \$300,000.00
78. **Kashuba ADM**, Patterson KB Co-Principal Investigators. A phase IV, open label study in healthy male subjects to investigate the extent of maraviroc exposure in blood, saliva, seminal fluid, and rectal mucosal tissue following single and multiple dosing. Pfizer Inc (Investigator-Initiated Research). 3/2008 – 3/2009. \$293,789.00
79. Patterson KB, Principal Investigator, **Kashuba ADM** and Eron JJ **Co-Mentors**. Sex, Aging, and Antiretroviral Pharmacology. NIAID K23 AI077355. 2/2008 – 1/2013.
80. Shulman, N, Principal Investigator, **Kashuba ADM Co-Investigator**. Feasibility of CCR5 Inhibitors in Preventing Maternal to Infant SIV Transmission. NIAID. R03 AI074465. 1/2008 – 12/2009.

NEW AWARDS 2007

81. **Kashuba ADM**, Patterson KB, Co-Principal Investigators. Comparison of Darunavir/Ritonavir and Etravirine Exposure in the Genital Tract of Pre- and Post-menopausal Women, to Exposure in Blood Plasma. Tibotec Virco, Inc. (Investigator-Initiated) 1/2007 – 1/2009. \$95,000.00
82. **Kashuba ADM**, Patterson KB, Co-Principal Investigators. The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet: A Longitudinal Investigation in the Second and Third Trimesters Including Empiric Dosage Adjustment. Abbott, Inc. (Investigator-Initiated Research) 1/2007 – 1/2010. \$187,000.00
83. **Kashuba ADM, Principal Investigator**. A Phase I, Open Label, Study in Healthy Female Subjects to Investigate the Extent of Maraviroc Exposure in Blood, Cervicovaginal Fluid, Vaginal Tissue and to Investigate CCR5 Receptor Saturation in Cervicovaginal Mononuclear Cells and Peripheral Blood Mononuclear Cells, Following Single and Multiple Dosing of Maraviroc. Pfizer Inc. (Investigator-Initiated Research) 1/2007 – 1/2009. \$349,000.00.

NEW AWARDS 2006

84. **Kashuba ADM, Principal Investigator**. A Phase I Pharmacokinetic Evaluation of Single and Multiple Doses of Tenofovir 1% Gel in Blood Plasma, Cervicovaginal Secretions, and Vaginal Tissue in Healthy Volunteers. CONRAD. 12/2006 – 1/2009. \$140,000.00
85. **Kashuba ADM, Principal Investigator** (Alan Forrest, mentor). American College of Clinical Pharmacy Infectious Disease Practice Research Network Minisabbatical. 2006-2007. \$3,500.00

86. **Kashuba ADM, Principal Investigator.** The Effect Of Tipranavir/Ritonavir On Steady-State Concentrations Of Omeprazole And Its Metabolites. Boehringer Ingelheim Pharmaceuticals, Inc. 12/2006 – 2/2007. \$51,100.00
87. Fried, M, Principal Investigator, **Kashuba ADM Co-Investigator.** Effect of Silymarin on Fibrosis in Patients with Hepatic Disease (NCAM 1U01-AT003560) 2006 – 2010. \$2,500,00.00
88. **Kashuba ADM, Principal Investigator.** Ortho-McNeil Infectious Diseases Academic Fellowship. American College of Clinical Pharmacy. 2006 – 2007 \$42,000.00.
89. Swanstrom R, Principal Investigator, **Kashuba ADM, Co-Investigator.** *UNC Center for AIDS Research (CFAR), Director, Pharmacology Core.* P30-HD37260, 6/2006 - 6/2011.\$5,500,000.00 (Core received \$298,000 per year direct costs)
90. **Kashuba ADM, Principal Investigator,** Evaluating the Effects of Tipranavir (with Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers. Boehringer Ingelheim Pharmaceuticals, Inc. (Investigator-Initiated Research) 2/2006 – 2/2007. \$1,668,280.00

NEW AWARDS 2005

91. **Kashuba ADM, Principal Investigator,** Shimadzu LC/MS Grant for Academic Institutions. 07/2005. \$65,000.00

NEW AWARDS 2004

92. **Kashuba ADM, Principal Investigator,** Society for Infectious Diseases Pharmacists Research Fellowship (for Rosa Yeh, Pharm.D. HIV Pharmacology Fellow) 09/2004 – 09/2005. \$25,000.00
93. **Kashuba ADM. Principal investigator.** University of North Carolina ACTU Pharmacology Support Laboratory. Adult AIDS Clinical Trials Group. DAIDS (NIH). 1/2004-12/2005. \$560,000.00

NEW AWARDS 2003

94. **Kashuba ADM. Principal investigator.** Rate and extent of tenofovir (TDF:Viread) exposure in the female and male genital tract; implications for sexual post-exposure prophylaxis of HIV-1. Gilead (Investigator-Initiated Research), 2003-2004. \$175,420.00.
95. **Kashuba ADM, Principal Investigator.** Evaluating the Effects of Lopinavir/Ritonavir (Kaletra) on Cytochrome P450 Activity Using A Biomarker Cocktail in Healthy Human Volunteers. Abbott (Investigator-Initiated Research), 2003-2004. \$60,495.00
96. **Kashuba ADM, Principal Investigator.** Antiretroviral Pharmacology In The Genital Tract, \$767,262.00. K23 AI54980 4/1/03 – 3/31/08.

NEW AWARDS 2002

97. **Kashuba, ADM, Principal Investigator.** Antiretroviral Pharmacology in the Genital Tract: Can We Affect HIV Transmission? Center for AIDS Research Supplemental Funding. 2002 – 2003 \$49,757.00.
98. Cu-Uvin S, Principal Investigator, **Kashuba ADM, Co-Investigator.** Antiviral Therapy and HIV in the Genital Tract of Women. NIAID (AI40350) 2003 – 2008 \$2,491,114.00
99. **Kashuba, ADM, Principal Investigator.** The Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir, Lopinavir and Ritonavir in

Healthy Volunteers. GlaxoSmithKline (Investigator Initiated Research), 2002-2003.
\$59,000.00

100. **Kashuba ADM, Principal Investigator.** Quantifying the 2-Way Drug Interaction Between Lopinavir/Ritonavir (Kaletra®) and Phenytoin Under Steady-State Conditions in Healthy Human Volunteers. Abbott Laboratories (Investigator Initiated Research), 2002 – 2003. \$162,660.00
101. Tidwell, R, Principal Investigator, **Kashuba ADM, Co-Investigator.** *API 3000 LCMS/MS System.* NCRR Shared Instrumentation Grant. 2002. \$430,830.00
102. Hawke R, Principal Investigator, **Kashuba ADM Co-Investigator.** Pharmacogenetics in the Elderly II: Investigation of Major CYP3A Polymorphisms on the Regulation of CYP3A Activity in Elderly African American Women. UNC Center on Minority Aging, 2002. \$16,090.64
103. **Kashuba ADM, Principal Investigator.** Ortho-McNeil Infectious Diseases Academic Fellowship. American College of Clinical Pharmacy. 2002 – 2003 \$20,000.00.

NEW AWARDS 2001

104. Swanstrom R, Principal Investigator, **Kashuba ADM, Co-Investigator.** *UNC Center for AIDS Research (CFAR), Pharmacology Core.* P30-HD37260, 6/2001 - 6/2006.\$5,500,000.00 (Core awarded \$200,000 directs per year)
105. van der Horst C, Principal Investigator, **Kashuba ADM, Co-Investigator.** *Postnatal Health Practices and Alternatives for HIV Infected Mothers and Their Infants.* CDC Special Interest Project. 2001-2003; \$2,700,000.00.
106. **Kashuba ADM, Principal Investigator,** Eron J, Co-Investigator. *Efficacy, Safety, and Pharmacokinetics of An Amprenavir 600mg/Saquinavir 800mg/Ritonavir 100mg BID – Based Antiretroviral Salvage Regimen.* GlaxoSmithKline (investigator-initiated research), 2001-2002; \$22,000.00
107. Hawke R, Principal Investigator, **Kashuba ADM Co-Investigator.** *Pharmacogenetics in the Elderly: Understanding the Effects of Age and Major Genetic Polymorphisms on the Regulation of CYP3A Activity in African American Women,* UNC Center on Minority Aging, 2001. \$29,999.65

NEW AWARDS 2000

108. Cohen, MS, Principal Investigator, **Kashuba ADM, Co-Investigator.** *HIV in Semen: Implications for Transmission.* R01 49381-2, 3/31/00-3/30/05.\$3,200,000.00

NEW AWARDS 1999

109. **Kashuba ADM, Principal Investigator,** *Penetration and Activity of Amprenavir in the Male Genital Tract: comparison of GW433908 and amprenavir.* Glaxo Wellcome (investigator-initiated research), 1999-2000; \$17,000.00
110. Campbell, WH, Principal Investigator, **Kashuba ADM, Co-Investigator.** *Rational Therapeutics for the Pediatric Population,* Agency for Health Care Policy and Research (AHCPR), Grant #: 1-U18-HS10397, 9/30/99 - 9/29/02; \$1,984,255.
111. **Kashuba ADM, Principal Investigator,** *Predicting Interleukin-2 Drug Interactions with a Human Kupffer Cell: Hepatocyte Coculture System.* Society for Infectious Diseases Pharmacists, October 1999 - October 2000; \$38,145.00

112. Scott CS, Principal Investigator, **Kashuba ADM, Co-Investigator**, *Pilot Study to Assess Activity of CYP1A2, CYP2D6, and CYP3A4 in Children with Cystic Fibrosis as Compared to Age and Gender Matched Controls*. UNC School of Pharmacy Seed Grant, June 1999 - June 2000; \$6,000.00.
113. **Kashuba ADM, Principal Investigator**, *Development of a population pharmacokinetic-pharmacodynamic (PK-PD) model and optimal sampling strategies for efavirenz in blood and seminal plasma*, DuPont Pharma Grant (Investigator-Initiated Research), October 1999 - October 2000; \$60,000.00

NEW AWARDS 1998

114. Swanstrom R, Principal Investigator, **Kashuba ADM, Co-Investigator**. *UNC Center for AIDS Research (CFAR), Pharmacology Core*. P30-HD37260, 6/1998 - 6/2001.\$5,500,000.00 (Core received \$197,000 direct costs per year)
115. **Kashuba ADM, Principal Investigator**, *Penetration of Liposome-Encapsulated AZT Diphosphate in Macrophages*, UNC Center for AIDS Research (CFAR) Grant, Oct 1998 - Oct 1999; \$10,000
116. **Kashuba ADM, Principal Investigator**, *Effect of IL-2, IL-10, and IL-12 on CYP3A Activity as Measured in the Human Hepatocyte Cell Culture Model*, UNC Junior Faculty Development Grant, Oct 1998 - Oct 1999; \$5,000
117. **Kashuba ADM, Principal Investigator**, *Effect of IL-2, IL-10, and IL-12 on CYP3A Activity as Measured in the Human Hepatocyte Cell Culture Model*, UNC School of Pharmacy Seed Grant, Oct 1998 - Oct 1999; \$5,200
118. **Kashuba A.D.M, Principal Investigator**, *Characterizing Cytochrome P450 Activity in HIV-1 Infected Women*, UNC Women's Health Task Force Grant, June 1998 - June 1999; \$10,000.00
119. **Kashuba A.D.M, Principal Investigator**, *Cytochrome P450 Activity in HIV-1 Infected Women*. Research Institute of the American College of Clinical Pharmacy, Bayer Infectious Disease Research Award, July 1998 - June 1999; \$10,000
120. **Kashuba A.D.M, Principal Investigator**, *Intra- and Interindividual Variability in the Activities of Cytochrome P450 1A2, 1D6, and 3A4, and NAT-2 and Xanthine Oxidase as Measured by Phenotyping in Women Infected with HIV-1*, UNC Research Council Award, April 1998 - April 1999; \$2,850.00
121. **Kashuba A.D.M, Principal Investigator**, *Intra- and Interindividual Variability in the Activities of Cytochrome P450 1A2, 1D6, and 3A4, and NAT-2 and Xanthine Oxidase as Measured by Phenotyping in Women Infected with HIV-1*, UNC Pharmacy Foundation Seed Grant, April 1998 - April 1999; \$7,312.00

NEW AWARDS 1997

122. **Kashuba A.D.M, Principal Investigator**, *Intra- and Interindividual Variability in the Activities of Cytochrome P450 1A2, 1D6, and 3A4, and NAT-2 and Xanthine Oxidase as Measured by Phenotyping in Patients who are Infected with HIV-1*, UNC Pharmacy Foundation Seed Grant, November 1997 - November 1998; \$3,300.
123. **Kashuba A.D.M., Bertino J.S. Jr., Co-Principal Investigators**, *The Effect of Menstrual Cycle on Cytochrome P450 Activity*, Research Institute of the American College of

Clinical Pharmacy, Wyeth-Ayerst Laboratories Women's Healthcare Research Award,
July 1997 - June 1998; \$10,000.

MULTICENTER INDUSTRY-SPONSORED RESEARCH:

Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjects

Phase IV Trial

Sponsor: Bristol-Myers Squibb

Role: Site Principal Investigator

Dates: October 2006 – October 2007

Contract: \$250,000

Precose: Resolution of Optimal Titration to Enhance Current Therapies

Phase IV Dose Titration Trial

Sponsor: Bayer Corporation

Role: Site Principal Investigator

Dates: September 1995-September 1996

PROFESSIONAL SERVICE:

Adult AIDS Clinical Trials Group (AACTG)

2004 – 2006	Member, Experimental Therapeutics Research Agenda Committee
2004 – 2006	Vice-Chair, AACTG Pharmacology Committee
2004 – 2006	Member, HIV Research Agenda Committee Tipranavir Working Group
2004 – 2006	Director, UNC ACTG Pharmacology Support Laboratory
2002 – 2006	Member, Pharmacology Committee Gender Issues Working Group
2002 – 2004	Chair, Drug Interactions Working Group
2001 – 2002	Vice-Chair, Drug Interactions Working Group
2001 – 2004	Member, Women's Health Committee
1999 – 2006	Member, Pharmacology Subcommittee
1999 – 2002	Member, Pharmacogenetics Working Group

American College of Clinical Pharmacy (ACCP)

2003	Member, ACCP Research Fellowship Review Committee
2002	Member, ACCP Research Institute Fellowship Task Force
1999 – 2000	Secretary Treasurer, PK/PD PRN
2018	Member, Precision Medicine Task Force
1999 – Present	Abstract Reviewer for winter and Spring Annual Meetings

American Society for Clinical Pharmacology and Therapeutics (ASCPT)

2008 – 2011	Member, Publications Committee
2003 – 2005	Chair, Infectious Diseases and Antimicrobial Agents Scientific Section
2003 – 2004	Co-Chair, ASCPT Educational Symposium "When Does Sex Matter: A Clinical Pharmacology Symposium on Women's Health"
2003 – 2004	Member, Scientific Awards Committee
2002 – 2003	Member, Nominations Committee
2000 - 2003	Vice-Chair, Infectious Diseases and Antimicrobial Agents Scientific Section

American Pharmaceutical Association (APhA)

2002 – 2006	Section Advisor, HIV Care, APhA DrugInfoLine
-------------	--

Centers for Disease Control and Prevention

2011 – 2014	Member, CDC/DHAP Expert Consultation Panel Recommendations for Non-Occupational Post-Exposure HIV Prophylaxis Guidelines Update
-------------	---

Conference on Retroviruses and Opportunistic Infections

2018 – Present	Member, Organizing Committee Pharmacology Lead
----------------	---

Contagion

2005	Member, Editorial Board
------	-------------------------

Doris Duke Charitable Foundation

2004 – 2018	Grant Reviewer
-------------	----------------

Foundation for the Treatment and Management of HIV Infection in the United States

2006 – 2009	Member, Scientific Organizing Committee American Conference for the Treatment of HIV (ACTHIV)
-------------	--

HIV Research for Prevention

2014 – 2018 Member, Scientific Organizing Committee

HIV Prevention Trials Network

2014 – Present Member, Women at Risk Committee
Member, HPTN 066 Protocol Team
Member, HPTN 069 Protocol Team

iMedOptions.com

2002 – 2013 Faculty Member

International AIDS Foundation

2011 - 2012 Member, IAS-ILF Organizing Committee
ARV Pharmacology in Children and Women
March 5th, 2012, Seattle, Washington

**International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs
(Formerly International Workshop on Clinical Pharmacology of HIV Therapy)**

2008 – 2009 Chair, 10th International Workshop, Amsterdam, The Netherlands
2006 – 2007 Chair, 8th International Workshop, Budapest, Hungary
2016 – 2017 Chair, 19th International Workshop, Chicago, Illinois
2006 – 2018 Member, Organizing Committee
2018 – Present Member, Academic Advisory Board

International Workshop on Women's Health in HIV

2012 – 2013 Chair, 3rd International Workshop, Washington, DC
2011 – 2012 Chair, 2nd International Workshop, Washington, DC
2010 – 2011 Chair, 1st International Workshop, Washington, DC
2009 – 2018 Member, Organizing Committee
2018 – Present Member, Scientific Committee

Medscape.com

2001 - 2005 Faculty Member, HIV Ask-The-Experts

Microbicide Trial Network

2009 – 2017 Member, M2010 Scientific Program Committee
Member, M2012 Scientific Program Committee
Member MTN 006 Protocol Team

National Institutes of Health (NIH)

2013 – Present Member, Microbicides Planning Group, NIH Office of AIDS Research
2012 – 2017 Invited Member, Advisory Committee on Research on Women's
Health, NIH Office of Research on Women's Health
2011 – 2018 Chair, Clinical Pharmacology Best Practices Working Group
2010 – 2014 Member, NIAID AARR-3 Study Section
2004 – Present Member, NIH/OAR Planning Committee: FY2007 – FY2019 Plan for
HIV-Related Research on Women and Girls
2004 – 2011 Ad-Hoc Study Section Reviewer NIAID AADD
2002 – 2004 Ad-Hoc Study Section Reviewer NIAID AARR-3
2017 – 2018 Ad-Hoc Study Section Reviewer NIAID AIDSRR
2018 – 2019 NIAID K23 Review Spring 2018

Rho Chi

2017 – 2018 Scholarship/Fellowship Committee

Society for Infectious Diseases Pharmacists (SIDP)

2006 – 2007	Member, Strategic Planning Committee
2005 – 2006	Member, Professional Affairs/Public Policy Committee
2001 – 2003	Board Member at Large
1998 – 2001	Chair, Publications Committee

University of North Carolina at Chapel Hill

2017 – 2018	Member, Vice Chancellor Committee on Precision Health and Society
2016 – 2017	Faculty Mentor, Carolina Covenant Scholar Program (15/year)
2015 – Present	Chair, BIRCWH Resource Laboratory Network
2012 – 2013	Member, Search Committee
	Director, Office of Clinical Trials
2009 – 2011	Member, Committee on Post-Baccalaureate Teaching Awards

UNC Center for Infectious Diseases

2008 – 2013	Member, Editorial Board This Week in Public Health
-------------	---

UNC School of Pharmacy

2018-2019	Chair, Executive Vice Dean and COO Search Committee
2018-2019	Member, School of Pharmacy Reaccreditation Standards 5-9 Subcommittee
2018 – Present	Member, Space Planning Taskforce
2015 – Present	Member, Executive Committee
2012 – Present	Member, Full Professors Committee
2015	Chair, School of Pharmacy Graduate Program Governance Document Committee
2013 – 2016	Member, Scholarship Committee 2010 – 2013 Member, Assessment Committee
2010 - 2011	Chair, Curricular Assessment Subcommittee
2010 – 2011	Faculty Representative, Business Cluster Committee
2009 – 2010	Chapel Hill Drug Conference 2010 Planning Committee
2008 – 2010	Member, Scholarship Committee
2007 – 2008	Member, UNC SOP Graduate Program Self-Study Committee
2005 – 2008	Member, Laboratory Instrumentation Committee
1999 – 2008	Laboratory Safety Committee
2004 – 2007	Member, Infectious Disease Student Training Group
2004 – 2006	Member, Graduate Education Committee
2003 – 2004	Research Space Planning Committee
2002 – 2006	Honor Student Committee
1997 – 2000, 2003	Ferguson Lecturer Committee

UNC AIDS Clinical Trials Unit (ACTU)

1999 – 2006	Pharmacologist
-------------	----------------

Women's Day Magazine

2000	Consultant, Dangerous Drug Interactions
------	---

Women's HIV Interagency Study (NIH)

2014 – Present	Member, UNC Scientific Committee Member, Pharmacology Committee
----------------	--

JOURNAL REVIEWER

1. Trends in Pharmacologic Sciences (2009-2011)
2. Antiviral Therapy (2006 – Present)
3. Sexually Transmitted Diseases (2006-2011)
4. Journal of Acquired Immune Deficiency Syndrome (2005 – Present)
5. Drugs (2002 – 2010)
6. Antimicrobial Agents and Chemotherapy (2002-Present)
7. Journal of Infectious Diseases (2002-Present)
8. Clinical Infectious Diseases (2002-Present)
9. Clinical Pharmacology and Therapeutics (2002-Present)
10. Journal of Pharmaceutical Sciences (2000-Present)
11. Journal of Clinical Psychopharmacology (2000-2005)
12. AIDS (1999-Present)
13. Pharmaceutical Research (1999-2011)
14. Clinical Pharmacokinetics (1998-Present)
15. The Annals of Pharmacotherapy (1997-Present)
16. American Journal of Health-System Pharmacy (1995-2012)
17. Science Translational Medicine (2010 – Present)
18. Nature (2012 – Present)
19. Lancet (2013 – Present)

PROFESSIONAL AFFILIATIONS

1. American Society for Clinical Pharmacology and Therapeutics (1995 - Present)
2. American Society for Microbiology (1995 - Present)
3. Society of Infectious Diseases Pharmacists (1995 - Present)
4. The Alliance for the Prudent Use of Antibiotics (1999 - Present)
5. The American College of Clinical Pharmacy (1995 - Present)
6. Rho Chi Pharmaceutical Honor Society (1995 - Present)
7. The Ontario College of Pharmacists (1990 - Present)
8. The American Society of Health System Pharmacists (1995 - 2011)
9. The International Society for the Study of Xenobiotics (2001 – 2010)
10. The American Association of Colleges of Pharmacy (1997 - 2010)
11. American Society for Human Genetics (2002 – 2006)
12. The Canadian Society of Hospital Pharmacists (1990 - 1997)

Mail Ballot
Board of Trustees
June 6, 2019

Interim Chancellor Kevin Guskiewicz submits for your review and approval the terms of appointment and compensation for Angela Kashuba as Dean of the Eshelman School of Pharmacy. This mail ballot will be approved as part of the consent agenda at the Full Board meeting on Thursday, August 1, 2019.

The undersigned votes as follows with recommendation to these proposed actions as presented by the Chancellor.

	Approve	Disapprove
Appointment and compensation for Angela Kashuba as Dean of the Eshelman School of Pharmacy	<input type="checkbox"/>	<input type="checkbox"/>
Signature_____		
Printed Name_____		
Date_____		

Please fax to TJ Scott at (919) 962-1647 or email at tj_scott@unc.edu

This mail ballot was approved by majority vote on June 6, 2019 by the following: Haywood Cochrane, Chuck Duckett, Lowry Caudill, Allie Ray McCullen, Ed McMahan, Hari Nath, Richard Stevens, and Dwight Stone.



MEMORANDUM

TO: Members of the Board of Trustees

FROM: Kevin M. Guskiewicz

RE: Mail Ballot

DATE: August 13, 2019

You have authorized me to poll you by mail ballot concerning personnel matters which require the immediate attention of the Board.

I am seeking approval to appoint Charles Marshall as the next Vice Chancellor and General Counsel. The appointment is effective September 16, 2019. Attached is the formal offer letter and a copy of Mr. Marshall's CV.

Please complete the attached mail ballot and return to Clayton Somers at your earliest convenience.



**OFFICE OF
THE CHANCELLOR**

KEVIN M. GUSKIEWICZ
INTERIM CHANCELLOR

chancellor@unc.edu
O 919-962-1365 | F 919-962-1647

**THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
OFFICE OF THE CHANCELLOR**

South Building | Suite 103 | Campus Box 9100
200 East Cameron Avenue | Chapel Hill, NC 27599-9100
chancellor.unc.edu

August 2, 2019

Mr. Charles F. Marshall
3037 Rothgeb Drive
Raleigh, North Carolina 27609

Dear Charles,

It is with pleasure that I extend to you this offer of employment at The University of North Carolina at Chapel Hill ("UNC-Chapel Hill"). UNC-Chapel Hill, the nation's first public university, is a global higher education leader known for innovative teaching, research and public service. Carolina's vibrant people and programs attest to the University's long-standing place among leaders in higher education since it was chartered in 1789 and opened its doors for students in 1795. We embrace an unwavering commitment to excellence as one of the world's great research universities.

You are being offered the position of Vice Chancellor and General Counsel at the University of North Carolina at Chapel Hill, subject to approval of The University's Board of Trustees. As a vice chancellor, you will be classified as a Tier I Senior Academic and Administrative Officer and subject to all of the relevant human resources policies for employees in this category. The following outlines the specific details of your appointment:

Employment effective date:

16 *gm* *KMG*
September 3, 2019 (negotiable)

Employment status:

At-will; subject to continuation or discontinuation at any time at the discretion of the Chancellor.

Compensation:

\$400,000 per year based on a full-time (1.0 FTE) work schedule and subject to annual review. The Office of the Chancellor is responsible for initiating any changes in salary, subject to compensation policies adopted by the Board of Governors and/or Board of Trustees.

Leave Accrual:

26 days (208 hours) per year of annual (vacation) leave and 12 days (96 hours) per year of sick leave for full-time service. Up to 30 days (240 hours) of annual leave may be carried forward each calendar year with any excess balance converted to sick leave at year end. Sick leave does not have a maximum accrual rate.

Leave Payout at Appointment End: Up to 30 days (240 hours) of annual leave; unused sick leave is not eligible for payout.

University Vehicle: An annual stipend of \$7,500 will be provided to cover costs, incurred by you while using your personal vehicle to conduct University business. This stipend will be disbursed at a rate of \$625.00 per month and is included in your annual W2 statement as taxable income.

Moving Allowance: You are eligible to receive customary and reasonable expenses related to moving household goods to a maximum amount of \$15,000. Because personal moving expense payments are now considered taxable wages under the 2017 Tax Cuts and Jobs Act, the total amount of the expenses submitted for reimbursement will be increased by 30 percent to assist with the tax impact up to a maximum amount of \$19,500. Reimbursement of the mover should occur within 6 months of the first date of employment in accordance with the following policy: *Policy on Employee Moving Expense Reimbursement*

House Hunting Trips: You are eligible to receive up to \$3,000 of reasonable travel and lodging expenses for up to two (2) house hunting trips to Chapel Hill, North Carolina.

Temporary Housing Allowance: You are eligible to receive up to \$3,000 per month for a period of up to twelve (12) months in reimbursement of rent, utilities, and other expenses related to temporary housing following relocation. All reimbursements require documentation of actual expenses and must be submitted in a timely manner to be eligible for payment.

Athletic Event Tickets: You will be provided two tickets to UNC Men's basketball and football games. Please note that you may decline the tickets, pay for them entirely, or receive them at no cost. If you receive the tickets at no cost, the value of the tickets will be reported as taxable income.

Background Check: Your appointment is conditional on satisfactory completion of the University's required criminal conviction and credentials checking processes and may be rescinded based on the results of the background check.

Employee Parking: Employee parking is governed by the University's parking regulations and specific parking space allocations made to individual University departments. Employees pay the cost of parking and specific details can be obtained from your

appointment Department's HR Representative and also by consulting the UNC Department of Transportation and Parking at: <https://move.unc.edu/>

Employment Policies:

Your appointment will be subject to the *Employment Policies for Tier I Senior Academic and Administrative Officers of the University of North Carolina at Chapel Hill* as presently defined and as they may be periodically revised. A copy of the policies currently in effect is enclosed with this letter and is also available at any time by consulting the University's Office of Human Resources web site at <http://hr.unc.edu>.


In addition, your employment is contingent on your acceptance of the terms and conditions stated in this offer letter and as set out in the "Conditions of Employment" form, which is attached. You must complete and return these signed documents to me by the deadline stated below. After receiving these signed documents and assuming your background check is satisfactory, a human resources representative in the Office of the Chancellor will contact you to establish an official start date.

Also accompanying this offer of employment are "Equal Opportunity Employment Data Forms" which request information regarding gender and race/ethnicity information, Protected Veteran status and Individuals with Disability information. The University of North Carolina at Chapel Hill is an Equal Opportunity Employer. Collection of this information is in accordance with Federal laws and regulations, executive orders, and applicable State laws and regulations. The information that you submit will remain confidential and will be used by the UNC-Chapel Hill Equal Opportunity and Compliance Office only for statistical and required reporting purposes, or as otherwise required or authorized by law. Completion of these forms is voluntary; failure to provide this information will not adversely affect your candidacy or employment.

In order to accept this offer, you must return signed and dated copies of the enclosed: (1) offer letter and (2) Conditions of Employment form to my office no later than seven days after receipt of this letter. A failure to return these signed documents within the indicated timeline may result in rescission of your offer.

I look forward with great enthusiasm to our working together and in your leadership as the University's new Vice Chancellor and General Counsel. Welcome you to The University of North Carolina at Chapel Hill.

Sincerely,



Kevin M. Guskiewicz
Interim Chancellor

Enclosure: Employment Policies for EHRA Non-Faculty Employees
Conditions of Employment Permanent Employee Appointment
Equal Opportunity Employment Data Forms

Acknowledgment and Acceptance by Appointee:

Charles Mahelp
(Signature)

Date: 8/9/2019

cc: Departmental Personnel File
EHRA Non-Faculty Human Resources

CHARLES F. MARSHALL
3037 Rothgeb Drive, Raleigh, North Carolina, 27609
919-621-2977 – charles.marshall@gmail.com

PROFESSIONAL EXPERIENCE

Partner, Brooks, Pierce, McLendon, Humphrey & Leonard, LLP, January 2003-present.

- Appear as lead counsel in federal and state trial and appellate courts; advocate for clients in the U.S. Congress, the North Carolina General Assembly, and regulatory agencies; represent clients in internal and governmental investigations.
- Outside General Counsel, North Carolina Association of Broadcasters, 2017-present.
- Advise companies, governmental bodies, and trade associations in various legal and policy matters, including constitutional law, communications law, data privacy, and ethics and election law.
- Member of firm's Management Committee (2017-present); Chair, Client Development Committee (2015-2017); Co-Chair, Recruiting Committee (2009-2014).
- Recognized in *The Best Lawyers in America* (Government Relations and Commercial Litigation, 2012-present), *North Carolina Super Lawyers* (Business Litigation, 2013-present); profiled in 2016 *North Carolina Super Lawyers* publication.

Office of United States Senator Mitch McConnell, Washington, DC, Legislative Assistant, 2001-2002.

- Policy advisor to Senator on issues relating to appropriations, financial services, tort reform, telecommunications, energy, and the environment.
- Drafted speeches for floor debates and prepared Senator for regular media appearances.

United States Department of Justice, Appellate Section, Tax Division, Washington, DC, 1997-2000.

- Argued and briefed cases before the United States Court of Appeals throughout the country.

Law Clerk to the Honorable John D. Butzner, Jr., Senior United States Circuit Judge, United States Court of Appeals for the Fourth Circuit, Richmond, VA, 1996-1997.

EDUCATION

The University of North Carolina at Chapel Hill

School of Law, J.D. with Honors, 1996; Member, *North Carolina Journal of International Law and Commercial Regulation*, 1994-1996.

College of Arts and Sciences, B.A. with Distinction in History and Political Science, 1992; Phi Beta Kappa, Assistant Student Attorney General, 1991-1992.

COMMUNITY

UNC-Chapel Hill Board of Visitors, 2013-2016; Chair, Government Affairs Committee.

Justice Matters, Board of Directors, Durham, North Carolina, 2015-2018.

Z. Smith Reynolds Foundation, Board of Advisors, 2006-2008.

Government Affairs Liaison, Business Law Section, North Carolina Bar Association, 2015-present.

Salvation Army of Wake County, Youth Flag Football Coach.

Mail Ballot
Board of Trustees
August 13, 2019

Interim Chancellor Kevin Guskiewicz submits for your review and approval the terms of appointment and compensation for Charles Marshall as Vice Chancellor and General Counsel. This mail ballot will be approved as part of the consent agenda at the Full Board meeting on Thursday, September 26, 2019.

The undersigned votes as follows with recommendation to these proposed actions as presented by the Chancellor.

	Approve	Disapprove
Appointment and compensation for Charles Marshall as Vice Chancellor and General Counsel	<input type="checkbox"/>	<input type="checkbox"/>

Signature_____

Printed Name_____

Date_____

Please fax to Clayton Somers at (919) 962-1647 or email at clayton@unc.edu

This mail ballot was approved by majority vote on August 13, 2019 by the following: Teresa Artis Neal, David Boliek, Jeff Brown, Haywood Cochrane, Gene Davis, Chuck Duckett, Kelly Hopkins, Allie Ray McCullen, Ralph Meekins, John Preyer, Richard Stevens, and Dwight Stone.



**OFFICE OF
THE CHANCELLOR**

KEVIN M. GUSKIEWICZ
INTERIM CHANCELLOR

chancellor@unc.edu
O 919-962-1365 | F 919-962-1647

**THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
OFFICE OF THE CHANCELLOR**

South Building | Suite 103 | Campus Box 9100
200 East Cameron Avenue | Chapel Hill, NC 27599-9100
chancellor.unc.edu

MEMORANDUM

TO: Members of the Board of Trustees

FROM: Kevin M. Guskiewicz *KMG*

RE: Mail Ballot

DATE: September 12, 2019

You have authorized my office to poll you by mail concerning personnel matters that require attention by the Board. Accordingly, we are transmitting to you herewith personnel actions as follows:

EHRA Faculty Compensation & Tenure Actions

Attachment A

Please mark and return the enclosed mail ballot indicating whether you approve or disapprove with the action proposed. Thank you.

The University of North Carolina at Chapel Hill
EXECUTIVE SUMMARY
Board of Trustees
August 2019

Appendix A

No.	College/Division	Name	Dept./School	Current Rank	New Rank	Tenure Request Reason	Effective Date	Salary
Personnel Actions								
New Appointments without Tenure								
1	Health Affairs	Marc Bjurlin	Urology	Nominated Associate Professor	Associate Professor		9/27/2019	\$265,000.00
2	Health Affairs	Emily Ray	Medicine	Nominated Clinical Assistant Professor	Assistant Professor		10/1/2019	\$190,000.00
Addition of Joint Appointment without Tenure								
0								
Promotion to Full Professor								
1	Academic Affairs	David Adalsteinsson	Mathematics	Associate Professor	Professor		1/1/2020	\$102,404.00
2	Health Affairs	Wolfgang Bergmeier - RETURNING	Biochemistry & Biophysics	Associate Professor	Professor		8/2/2019	\$185,250.00
3	Academic Affairs	Amy Oldenburg	Physics & Astronomy	Associate Professor	Professor		1/1/2020	\$120,986.00
4	Health Affairs	Alison Stuebe	OB-BYN/Maternal & Child Health	Associate Professor	Professor		8/2/2019	\$340,000.00
5	Academic Affairs	Brian Sturm	SILS	Associate Professor	Professor		1/1/2020	\$93,365.00
6	Health Affairs	Justin Trogdon	Health Policy & Management	Associate Professor	Professor		10/1/2019	\$150,650.00
Reappointments to the same Rank								
0								
Designation/Reappointments to Departmental Chair								
1	Academic Affairs	Kenneth Andrews	Sociology	Chair	Chair		7/1/2019	\$164,080.00
2	Academic Affairs	Navin Bapat	Peace, War & Defense	Professor/Adjunct Professor	Chair		7/1/2019	\$109,328.00
3	Health Affairs	Ronald Falk	Pathology & Laboratory Medicine	Professor	Interim Department Chair		7/1/2019	\$506,374.00
4	Health Affairs	Gary Gala	Psychiatry	Clinical Associate Professor	Interim Department Chair		7/1/2019	\$217,500.00
5	Academic Affairs	Kevin Jeffay	Computer Science	Chair	Chair		7/1/2019	\$204,256.00
6	Academic Affairs	Arne Kalleberg	Global Studies	Professor	Chair		7/1/2019	\$234,900.00
7	Academic Affairs	Paul Leslie	Environment, Ecology & Energy	Distinguished Professor	Chair		7/1/2019	\$150,020.00
8	Academic Affairs	Benjamin Waterhouse	History	Associate Professor	Acting Chair		5/30/2019	\$88,780.00
9	Health Affairs	Jennifer Wu	OB-GYN	Professor	Interim Department Chair		7/1/2019	\$328,500.00
Designation/Reappointments to Distinguished Professorship								
1	Academic Affairs	Paul Lanier III	Social Work	Associate Professor	Wallace Kuralt Early Career Distinguished Scholar		9/1/2019	\$95,000.00
2	Health Affairs	Rafal Pawlinski	Medicine	Research Professor	Lenvil Lee Rothrock Professorship		10/1/2019	\$150,000.00
3	Academic Affairs	Andrew Perrin	Sociology	Professor	Ruel W Tyson Distinguished Professorship		7/1/2019	\$110,305.00
4	Health Affairs	Ronald Swanson	Biochemistry & Biophysics	James Postelle Distinguished Term Professor	James Postelle Distinguished Term Professorship		9/27/2019	\$220,907.00
5	Academic Affairs	Waleed Ziad	Religious Studies	N/A	Dr Ali Jarrahi Fellow in Persian Studies		7/1/2019	\$72,000.00
Actions Conferring Tenure								
Promotion Conferring Tenure								
1	Health Affairs	Jennifer Flythe	Medicine	Assistant Professor	Associate Professor	Promotion based on excellence in research	10/1/2019	\$169,862.00
2	Health Affairs	Saame Shaikh	Nutrition	Associate Professor	Associate Professor	Promotion based on excellence in research	11/1/2019	\$153,000.00
New Appointments Conferring Tenure								
1	Health Affairs	James Hagood	Pediatrics	Nominated Professor	Professor	Appointment based on excellence in research	9/27/2019	\$287,273.00
2	Academic Affairs	Nicole Else-Quest	Women's & Gender Studies	Nominated Associate Professor	Associate Professor	Appointment based on research and teaching	1/1/2020	\$87,500.00
3	Health Affairs	David Wright	Family Medicine	Nominated Research Associate Professor	Associate Professor	Appointment based on excellence in research	9/27/2019	\$140,000.00
Addition of Joint Appointment Conferring Tenure								
0								

The University of North Carolina at Chapel Hill
EXECUTIVE SUMMARY
Board of Trustees
August 2019

Appendix A

No.	College/Division	Name	Dept./School	Current Rank	New Rank	Tenure Request Reason	Effective Date	Salary
Corrections								
0								

EXECUTIVE SUMMARY

Board of Trustees

August 2019

No.	College/Division	Name	School	Department	Rank	Reason	Requested Amount of Increase **	Percent of Increase **	June 30 Salary	Current Salary	New Salary *	Effective Date
Compensation Actions							** Based on cumulative increase(s) to 6/30 salary					
*Available funding for each action has been confirmed by the appropriate Department and School/Division management officials to support the proposed salary increase. Upon implementation, specific funding sources are reviewed and approved at the Department level, as well as by the applicable University Central financial offices, including the University Budget Office and the Office of Sponsored Research for grant-funded salaries.												
1	Health Affairs	Berry, Diane	Nursing		Professor/Distinguished Term Professor	Increase due to preemptive retention, as Dr. Berry is being actively recruited by Columbia and Virginia Commonwealth University	\$20,000	11.94%	\$167,568	\$167,568	\$187,568	8/1/2019
2	Health Affairs	Brinkley-Rubenstein, Lauren	Medicine	Social Medicine	Assistant Professor	Increase due to preemptive retention as Dr. Brinkley-Rubenstein is being actively recruited by Johns Hopkins University	\$22,000	21.20%	\$103,767	\$103,767	\$125,767	7/1/2019
3	Academic Affairs	Brooker, John	Law		Clinical Assistant Professor	Increase due to merit as Professor Brooker has exceeded expectations since his hire last year	\$10,000	10.00%	\$100,000	\$100,000	\$110,000	8/1/2019
4	Academic Affairs	Chavis, Larry	Business	Strategy & Entrepreneurship	Clinical Associate Professor/Interim Director	Increase due to moving from Interim Director to Director of the American Indian Center	\$36,000	17.04%	\$221,249	\$221,249	\$247,249	8/1/2019
5	Academic Affairs	Clemens, J Christopher	Arts & Sciences	Physics & Astronomy	Distinguished Professor/Senior Associate Dean	Increase due to preemptive retention, as Professor Clemens is being recruited by Ohio State, George Washington University, and UCLA-Irvine	\$32,714	15.41%	\$212,286	\$218,942	\$245,000	6/24/2019
6	Health Affairs	Hairston, Essence	Medicine	OB/GYN	Social Work Practitioner	Increase due to new faculty appointment as Clinical Instructor via external competitive event	\$15,674	39.86%	\$39,326	\$39,326	\$55,000	10/1/2019
7	Health Affairs	Halladay, Jacqueline	Medicine	Family Medicine	Research Professor	Increase due to new administrative appointment as Chair of Research for UNC Health Sciences at Mountain Area Health Education Center	\$52,000	37.77%	\$137,687	\$137,687	\$189,687	9/1/2019
8	Health Affairs	Ho, James	Medicine	Neurology	Clinical Fellow	Increase due to new faculty appointment as Clinical Assistant Professor via external competitive event	\$123,327	184.97%	\$66,673	\$66,673	\$190,000	9/16/2019
9	Academic Affairs	Lanier, Paul	Social Work		Associate Professor	Increase due to being recipient of the Wallace Kuralt Early Career Distinguished Scholar	\$14,642	16.68%	\$87,758	\$95,000	\$102,400	9/1/2019
10	Health Affairs	Matthews, Nigel	Dentistry	Oral Surgery	Clinical Associate Professor/Director	Increase due to change in Terms and Conditions of contract	\$20,000	6.02%	\$331,981	\$331,981	\$351,981	7/1/2019
11	Academic Affairs	Mosley, Maria Lanya	Arts & Sciences	Political Science	Professor	Increase due to counteroffer retention as Professor Mosely has received an offer from Dartmouth	\$50,352	37.40%	\$134,648	\$134,648	\$185,000	7/1/2019
12	Health Affairs	Parr, Jonathan	Medicine	Medicine	Clinical Assistant Professor	Increase due to new faculty appointment as Assistant Professor via external competitive event	\$20,000	16.67%	\$120,000	\$120,000	\$140,000	9/1/2019
13	Health Affairs	Stoudemire, William	Medicine	Pediatrics	Clinical Fellow	Increase due to new faculty appointment as Clinical Assistant Professor via external competitive event	\$75,767	117.50%	\$64,483	\$64,483	\$140,250	9/16/2019
14	Academic Affairs	Tisdale, Judy	Business	Management & Corporate Communication	Clinical Professor/Chair	Increase due to internal equity re secondary administrative appointment stipend	\$7,500	5.50%	\$136,468	\$136,468	\$143,968	8/1/2019
15	Academic Affairs	Venataraman, Sriraman	Business	Marketing	Associate Professor	Increase due to retention counteroffer, as Dr. Venataraman has received an offer from Cornell	\$54,542	24.74%	\$220,458	\$220,458	\$275,000	8/1/2019
16	Health Affairs	Wahl, Angie	Medicine	Medicine	Research Assistant Professor	Increase due to new faculty appointment as Assistant Professor via external competitive event	\$19,699	23.65%	\$83,301	\$83,301	\$103,000	9/1/2019
17	Academic Affairs	Waters, Marcey	Arts & Sciences	Chemistry	Distinguished Professor	Increase due to preemptive retention as Dr. Waters is being actively recruited by the National Institute of Health Chemical Biology Lab	\$15,320	9.90%	\$154,741	\$154,741	\$170,061	7/1/2019
18												
19												
20												

The University of North Carolina at Chapel Hill
EXECUTIVE SUMMARY
Board of Trustees
August 2019

No.	College/Division Name	Department/School	Rank	Description
For Information				
0	N/A	N/A	N/A	N/A

Mail Ballot
Board of Trustees
September 12, 2019

Interim Chancellor Kevin Guskiewicz submits for your review and approval the EHRA faculty compensation and tenure actions as recommended for August 2019. This mail ballot will be approved as part of the consent agenda at the Full Board meeting on Thursday, September 26, 2019.

The undersigned votes as follows with recommendation to these proposed actions as presented by the Chancellor.

	Approve	Disapprove
EHRA Faculty Compensation and Tenure Actions	<input type="checkbox"/>	<input type="checkbox"/>

Signature_____

Printed Name_____

Date_____

Please fax to TJ Scott at (919) 962-1647 or email at tj_scott@unc.edu

This mail ballot was approved by majority vote on September 17, 2019 by the following: Teresa Artis Neal, Jeff Brown, Haywood Cochrane, Gene Davis, Chuck Duckett, Ralph Meekins, and Richard Stevens. Allie Ray McCullen voted to disapprove.

Environment, Ecology, and Energy Program (E3P)



UNC

**COLLEGE OF
ARTS AND SCIENCES**

MISSION

A habitable planet for a changing world

VISION

1. Be the model for interdisciplinary social and natural science research and education at UNC
2. Lead NC in local-to-global environmental research
3. Leverage proximity of RTP and other universities to build partnerships in innovation and economic development

VALUES

Interdisciplinary Research Challenges
Experiential Education
Reimagining Environment at UNC


Strategy Statements



Student-Focused, Solutions-Oriented



Growth in Demand for Systems-Level Approaches




Environmental Dual Degrees with Professional Schools

BS/BA Environmental Sciences – MA Mass Communication


BS/BA Environmental Sciences – MS Information Sciences

BS/BA Environmental Sciences – Masters in Public Administration


BS Environmental Sciences – Masters in Public Health



College of Arts & Sciences
Synergy Unleashed



Drawing on Faculty from Across Campus



Campus as a Living Lab

Ecostudio Internship Program

Campus internships (e.g. Energy Services, Stormwater Management, Campus Arborist)

Private Sector (e.g., Pfizer)

City and State Government

Include structured time in professional development and networking

Developing partnership with English and Comparative Literature in Environmental Humanities

Located on the ground floor of Murray Hall next to Kenan Science Library



Campus as a Living Lab

Environmental Capstone Program

Town of Hillsborough Stormwater Management Plan


Jordan Lake Bathymetry (NCPC)

Jordan Lake Nitrogen Budget

Pfizer Corporation Water Use Strategies


Research Triangle Clean Tech Cluster Smart Cities Inventory

UNC Stormwater Management and Demonstration Plan



E3P Faculty Cluster Hires

- Energy and Energy Analytics
Paige Weber, Economics and Energy Finance
Noah Kittner, Energy and Engineering
- Water Resources and Hydrology
Antonia Sebastian, Floodplain Modeling
- Cities and Critical Infrastructure
Miyuki Hino, Cities and Climate Adaptation Planning
- Inequality and the Environment
Caela O'Connell, Food Security and Communities
- Public Policy and Development
Angel Hsu, Climate Policy and Data Science



NSF rapid grant: Monitoring for water safety after Hurricane Florence



Jill Stewart
Professor, Environmental Sciences and Engineering
Associate Director, Center for Galapagos Studies
E3P Executive Advisory Committee



NCPC - Retreat or Rebuild: Are floodplain buyouts a smart investment for local governments?




Todd BenDor
Professor, City and Regional Planning
Director, The Odum Institute
E3P Affiliated Faculty



PRIORITIES

1. High-impact research
2. Interdisciplinary and experiential education
3. Translating research to society through service and solving problems

Research Supported by the NC Policy Collaboratory



Update on the State of the Collaboratory

Jeffrey Warren, PhD
Acting Executive Director



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

UNC Chapel Hill Board of Trustees
September 26, 2019



@NCCollaboratory

Session Law 2016-94 (Section 11.8) effective July 14, 2016

Collaboratory Legislative Mandate

- Facilitate dissemination of policy & research expertise of The UNC System for practical use by State & local govt.
- Conduct research on natural resources mgmt, including, but not limited to:
 1. Enviro & economic components of natural resource mgmt.
 2. New technologies for habitat, environmental, and water quality improvement
- Develop and disseminate 'best practices', lead or participate in projects, and make recommendations to the General Assembly.





Unique Research Funding Model


Efficient and Timely Research

- No indirect costs / overhead (F&A) taken out of our research funds (100% of our grants go directly to research) – this is essentially a ‘doubling’ effect
- We can enter into funding agreements directly with a PI or their home department (outside of OSR)
- The average time it takes us to execute a scope of work to transfer funds is one week – we’ve done it in less
- Some non-reverting dollars (from Challenge Grant) allow us to fund across fiscal years and do multi-year projects (Rapid Response Research Reserve)
- With only one full-time employee, we keep operating costs at a minimum to maximize research funding



How We Do It


Organizational Structure



Where We Are

17 campuses in the UNC System

- Campus with project(s) (9)
- No project(s) to date (6)
- Future project(s) FY 19-20 (2)




Where We Are

Current Research Portfolio


Total Projects to date 138*

(59 complete, 59 active, 20 coming online in FY 19-20)

**Many icons represent broad subject areas and multiple projects; not all projects shown*



Total Legislative Funding



Financials (FY 16-17 through FY 19-20)

Total Revenue > \$18 M


(NCGA approps of ~\$17.7M & donations of ~\$400k)

Donations to date:

2017-18: \$130,650













2018-19: \$280,871.50

Total of ~\$16.7M to research with ~\$1.3M for operations (i.e., ~92% going to research)



NCGA Mandated Studies

Current and Past Research

	STUDY	2016	2017	2018	2019	2020	2021	2022	2023
 	Jordan Falls	July 13			Dec 31 July 1				Dec 31
 	Oysters	July 14		Dec 31					
	Data Mgmt		June 28	March 1					
 * 	Energy Storage		July 27	Dec 1					
 	PFAS			June 12	Dec 1	*Dec 1?			
	Cancer				June 19	April 30			
 	Flood Resilience				Sept 19	Dec 1			



NCGA has/is providing ~\$10.16M in funding for four of the seven assigned projects (\$1.5M for Jordan, \$1.5M for Falls, \$150k for oysters, ~\$82k* for energy storage, \$5.013M for PFAS, and \$2M for flood resilience).

*NCGA Challenge Grant match for non-State donations

Strategic Partnerships

North Carolina Executive Branch







Team 1:
PFAS Sampling
and Analysis



Team 2:
Private Well
Risk Modeling



Team 3:
PFAS Removal
Performance
Testing



Team 4:
Air Emissions
and
Atmospheric
Deposition




Team 5:
Applied
Research
*lab experiments
animal studies
human samples*




Team 6:
Risk
Communication



Team 7:
Data Science
and
Management



Program Management Team & Synthetic Chemist



ncpfastnetwork.com



Policy
Collaboratory



collaboratory.unc.edu

collaboratory@unc.edu



[@NCCollaboratory](https://twitter.com/NCCollaboratory)